

File copy

Davis 10/646348

02/17/2006

=> file registry

FILE 'REGISTRY' ENTERED AT 11:32:03 ON 17 FEB 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 15 FEB 2006 HIGHEST RN 874326-73-5

DICTIONARY FILE UPDATES: 15 FEB 2006 HIGHEST RN 874326-73-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

```
*****
*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added,   *
* effective March 20, 2005. A new display format, IDERL, is now     *
* available and contains the CA role and document type information. *
*
*****
```

Structure search iteration limits have been increased. See HELP SLIMITS for details.




REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>



=> d stat que L19

L1 STR




C 77 N 78






Page 1-A





Page 1-B




Page 2-A



Page 2-B



Page 3-A



Page 3-B

VAR G1=5/11/17/23

VAR G2=77/78

VAR G3=33/39/45/51/61

NODE ATTRIBUTES:

NSPEC	IS R	AT	1
NSPEC	IS R	AT	2
NSPEC	IS R	AT	3
NSPEC	IS R	AT	4
NSPEC	IS R	AT	5
NSPEC	IS R	AT	6
NSPEC	IS R	AT	7
NSPEC	IS R	AT	8
NSPEC	IS R	AT	9
NSPEC	IS R	AT	10
NSPEC	IS R	AT	11
NSPEC	IS R	AT	12
NSPEC	IS R	AT	13
NSPEC	IS R	AT	14
NSPEC	IS R	AT	15
NSPEC	IS R	AT	16
NSPEC	IS R	AT	17
NSPEC	IS R	AT	18
NSPEC	IS R	AT	19
NSPEC	IS R	AT	20
NSPEC	IS R	AT	21
NSPEC	IS R	AT	22
NSPEC	IS R	AT	23
NSPEC	IS R	AT	24
NSPEC	IS C	AT	25
NSPEC	IS R	AT	26
NSPEC	IS R	AT	27
NSPEC	IS R	AT	28
NSPEC	IS R	AT	29
NSPEC	IS R	AT	30
NSPEC	IS R	AT	31
NSPEC	IS R	AT	32
NSPEC	IS R	AT	33
NSPEC	IS R	AT	34



NSPEC	IS	R	AT	35	
NSPEC	IS	R	AT	36	
NSPEC	IS	R	AT	37	
NSPEC	IS	R	AT	38	
NSPEC	IS	R	AT	39	
NSPEC	IS	R	AT	40	
NSPEC	IS	R	AT	41	
NSPEC	IS	R	AT	42	
NSPEC	IS	R	AT	43	
NSPEC	IS	R	AT	44	
NSPEC	IS	R	AT	45	
NSPEC	IS	R	AT	46	
NSPEC	IS	R	AT	47	
NSPEC	IS	R	AT	48	
NSPEC	IS	R	AT	49	
NSPEC	IS	R	AT	50	
NSPEC	IS	R	AT	51	
NSPEC	IS	R	AT	52	
NSPEC	IS	R	AT	53	
NSPEC	IS	R	AT	54	
NSPEC	IS	C	AT	55	
NSPEC	IS	C	AT	56	
NSPEC	IS	C	AT	57	
NSPEC	IS	C	AT	58	
NSPEC	IS	R	AT	59	
NSPEC	IS	R	AT	60	
NSPEC	IS	R	AT	61	
NSPEC	IS	R	AT	62	
NSPEC	IS	R	AT	63	
NSPEC	IS	R	AT	64	
NSPEC	IS	C	AT	65	
NSPEC	IS	C	AT	66	
NSPEC	IS	C	AT	67	
NSPEC	IS	C	AT	68	
NSPEC	IS	C	AT	69	
NSPEC	IS	C	AT	70	
NSPEC	IS	C	AT	71	
NSPEC	IS	C	AT	72	
NSPEC	IS	C	AT	73	
NSPEC	IS	C	AT	74	
NSPEC	IS	C	AT	75	
NSPEC	IS	C	AT	76	
CONNECT	IS	E3	RC	AT	66
CONNECT	IS	E3	RC	AT	67
CONNECT	IS	E3	RC	AT	68
CONNECT	IS	E3	RC	AT	69
CONNECT	IS	E3	RC	AT	70
CONNECT	IS	E1	RC	AT	71
CONNECT	IS	E1	RC	AT	72
CONNECT	IS	E1	RC	AT	73
CONNECT	IS	E1	RC	AT	74
CONNECT	IS	E1	RC	AT	75
DEFAULT MLEVEL IS ATOM					
MLEVEL	IS	CLASS	AT	55 56 57 58 65 66 67 68 69 70 71 72 73 74 75	
DEFAULT ECLEVEL IS LIMITED					

## GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 78


STEREO ATTRIBUTES: NONE

L2 ( 4356201)SEA FILE=REGISTRY ABB=ON PLU=ON NC5/ESS



L3 281 SEA FILE=REGISTRY SUB=L2 SSS FUL L1

L10 STR


C 107N 108




Page 1-A






Page 1-B




Page 2-A



Page 2-B



Page 3-A



Page 3-B

VAR G1=5/11/17/23

VAR G2=107/108

VAR G3=32/38/44/50/60

VAR G4=27/78/90

NODE ATTRIBUTES:

NSPEC	IS	R	AT	1
NSPEC	IS	R	AT	2
NSPEC	IS	R	AT	3
NSPEC	IS	R	AT	4
NSPEC	IS	R	AT	5
NSPEC	IS	R	AT	6
NSPEC	IS	R	AT	7
NSPEC	IS	R	AT	8
NSPEC	IS	R	AT	9
NSPEC	IS	R	AT	10
NSPEC	IS	R	AT	11
NSPEC	IS	R	AT	12
NSPEC	IS	R	AT	13
NSPEC	IS	R	AT	14
NSPEC	IS	R	AT	15
NSPEC	IS	R	AT	16
NSPEC	IS	R	AT	17
NSPEC	IS	R	AT	18
NSPEC	IS	R	AT	19
NSPEC	IS	R	AT	20
NSPEC	IS	R	AT	21
NSPEC	IS	R	AT	22
NSPEC	IS	R	AT	23
NSPEC	IS	R	AT	24
NSPEC	IS	R	AT	25
NSPEC	IS	R	AT	26
NSPEC	IS	R	AT	27
NSPEC	IS	R	AT	28
NSPEC	IS	R	AT	29
NSPEC	IS	R	AT	30

NSPEC	IS R	AT	31
NSPEC	IS R	AT	32
NSPEC	IS R	AT	33
NSPEC	IS R	AT	34
NSPEC	IS R	AT	35
NSPEC	IS R	AT	36
NSPEC	IS R	AT	37
NSPEC	IS R	AT	38
NSPEC	IS R	AT	39
NSPEC	IS R	AT	40
NSPEC	IS R	AT	41
NSPEC	IS R	AT	42
NSPEC	IS R	AT	43
NSPEC	IS R	AT	44
NSPEC	IS R	AT	45
NSPEC	IS R	AT	46
NSPEC	IS R	AT	47
NSPEC	IS R	AT	48
NSPEC	IS R	AT	49
NSPEC	IS R	AT	50
NSPEC	IS R	AT	51
NSPEC	IS R	AT	52
NSPEC	IS R	AT	53
NSPEC	IS C	AT	54
NSPEC	IS C	AT	55
NSPEC	IS C	AT	56
NSPEC	IS C	AT	57
NSPEC	IS R	AT	58
NSPEC	IS R	AT	59
NSPEC	IS R	AT	60
NSPEC	IS R	AT	61
NSPEC	IS R	AT	62
NSPEC	IS R	AT	63
NSPEC	IS C	AT	64
NSPEC	IS C	AT	65
NSPEC	IS C	AT	66
NSPEC	IS C	AT	67
NSPEC	IS C	AT	68
NSPEC	IS C	AT	69
NSPEC	IS C	AT	70
NSPEC	IS C	AT	71
NSPEC	IS C	AT	72
NSPEC	IS C	AT	73
NSPEC	IS C	AT	74
NSPEC	IS C	AT	75
NSPEC	IS R	AT	76
NSPEC	IS R	AT	77
NSPEC	IS R	AT	78
NSPEC	IS R	AT	79
NSPEC	IS R	AT	80
NSPEC	IS R	AT	81
NSPEC	IS R	AT	82
NSPEC	IS R	AT	83
NSPEC	IS R	AT	84
NSPEC	IS R	AT	85
NSPEC	IS C	AT	86
NSPEC	IS C	AT	87
NSPEC	IS R	AT	88
NSPEC	IS R	AT	89
NSPEC	IS R	AT	90

NSPEC IS R AT 91  
NSPEC IS R AT 92  
NSPEC IS R AT 93  
NSPEC IS R AT 94  
NSPEC IS R AT 95  
NSPEC IS R AT 96  
NSPEC IS R AT 97  
NSPEC IS R AT 98  
NSPEC IS R AT 99  
NSPEC IS R AT 100  
NSPEC IS R AT 101  
NSPEC IS R AT 102  
NSPEC IS R AT 103  
NSPEC IS R AT 104  
NSPEC IS R AT 105  
NSPEC IS C AT 106  
CONNECT IS E3 RC AT 65  
CONNECT IS E3 RC AT 66  
CONNECT IS E3 RC AT 67  
CONNECT IS E3 RC AT 68  
CONNECT IS E3 RC AT 69  
CONNECT IS E1 RC AT 70  
CONNECT IS E1 RC AT 71  
CONNECT IS E1 RC AT 72  
CONNECT IS E1 RC AT 73  
CONNECT IS E1 RC AT 74  
CONNECT IS E2 RC AT 100  
CONNECT IS E2 RC AT 102  
DEFAULT MLEVEL IS ATOM  
MLEVEL IS CLASS AT 54 55 56 57 64 65 66 67 68 69 70 71 72 73 74  
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:  
RING(S) ARE ISOLATED OR EMBEDDED  
NUMBER OF NODES IS 108

STEREO ATTRIBUTES: NONE

L12 180 SEA FILE=REGISTRY SUB=L3 SSS FUL L10  
L13 1 SEA FILE=REGISTRY ABB=ON PLU=ON "CARBAMIC ACID, (3-(5-(3,4-BIS(PHENYLMETHOXY)PHENYL)-1-(2-PYRIDINYL)-1H-PYRAZOL-3-YL)PHENYL)-, PHENYLMETHYL ESTER"/CN  
L14 1 SEA FILE=REGISTRY ABB=ON PLU=ON "BENZAMIDE, N-(4-(2-(2-CHLOROPHENYL)-4-(3-METHYLPHENYL)-5-THIAZOLYL)-2-PYRIDINYL)-"/CN  
L15 1 SEA FILE=REGISTRY ABB=ON PLU=ON "BENZENEACETAMIDE, N-(4-(2-(2-CHLOROPHENYL)-4-(3-METHYLPHENYL)-5-THIAZOLYL)-2-PYRIDINYL)-"/CN  
L16 1 SEA FILE=REGISTRY ABB=ON PLU=ON "BENZENEPROPANAMIDE, N-(4-(2-(2-CHLOROPHENYL)-4-(3-METHYLPHENYL)-5-THIAZOLYL)-2-PYRIDINYL)-"/CN  
L17 4 SEA FILE=REGISTRY ABB=ON PLU=ON (L13 OR L14 OR L15 OR L16)  
L18 101 SEA FILE=REGISTRY ABB=ON PLU=ON L3 ~~AND~~ L12  
L19 105 SEA FILE=REGISTRY ABB=ON PLU=ON L18 OR L17 STRUCTURE QUERY L#

these 4  
(out of  
the 180  
"not"  
structures  
are still  
good

=> file caplus

FILE 'CAPLUS' ENTERED AT 11:32:05 ON 17 FEB 2006  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

AUTHOR  
SEARCH

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 17 Feb 2006 VOL 144 ISS 9  
FILE LAST UPDATED: 16 Feb 2006 (20060216/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>  
'OBI' IS DEFAULT SEARCH FIELD FOR 'CAPLUS' FILE

=> d que nos L27

L24	10289	SEA	FILE=CAPLUS	ABB=ON	PLU=ON	SINGH R?/AU
L25	208	SEA	FILE=CAPLUS	ABB=ON	PLU=ON	GOFF D?/AU
L26	396	SEA	FILE=CAPLUS	ABB=ON	PLU=ON	PARTRIDGE J?/AU
L27	5	SEA	FILE=CAPLUS	ABB=ON	PLU=ON	L24 AND L25 AND L26

=> d que nos L28

L24	10289	SEA	FILE=CAPLUS	ABB=ON	PLU=ON	SINGH R?/AU
L25	208	SEA	FILE=CAPLUS	ABB=ON	PLU=ON	GOFF D?/AU
L26	396	SEA	FILE=CAPLUS	ABB=ON	PLU=ON	PARTRIDGE J?/AU
L28	9	SEA	FILE=CAPLUS	ABB=ON	PLU=ON	L24 AND (L25 OR L26)

=> d que nos L29

L25	208	SEA	FILE=CAPLUS	ABB=ON	PLU=ON	GOFF D?/AU
L26	396	SEA	FILE=CAPLUS	ABB=ON	PLU=ON	PARTRIDGE J?/AU
L29	5	SEA	FILE=CAPLUS	ABB=ON	PLU=ON	L25 AND L26

=> d que nos L46

L1		STR				
L2	( 4356201)	SEA	FILE=REGISTRY	ABB=ON	PLU=ON	NC5/ESS
L3	281	SEA	FILE=REGISTRY	SUB=L2	SSS	FUL L1
L10		STR				
L12	180	SEA	FILE=REGISTRY	SUB=L3	SSS	FUL L10
L13	1	SEA	FILE=REGISTRY	ABB=ON	PLU=ON	"CARBAMIC ACID, (3-(5-(3,4-BI S(PHENYLMETHOXY) PHENYL) -1-(2-PYRIDINYL) -1H-PYRAZOL-3-YL) PHENYL) -, PHENYLMETHYL ESTER"/CN
L14	1	SEA	FILE=REGISTRY	ABB=ON	PLU=ON	"BENZAMIDE, N-(4-(2-(2-CHLORO PHENYL) -4-(3-METHYLPHENYL) -5-THIAZOLYL) -2-PYRIDINYL) -"/CN
L15	1	SEA	FILE=REGISTRY	ABB=ON	PLU=ON	"BENZENEACETAMIDE, N-(4-(2-(2 -CHLOROPHENYL) -4-(3-METHYLPHENYL) -5-THIAZOLYL) -2-PYRIDINYL) -"/C N
L16	1	SEA	FILE=REGISTRY	ABB=ON	PLU=ON	"BENZENEPROPANAMIDE,

N-(4-(2-(2-CHLOROPHENYL)-4-(3-METHYLPHENYL)-5-THIAZOLYL)-2-PYRIDINYL)-"/CN

L17 4 SEA FILE=REGISTRY ABB=ON PLU=ON (L13 OR L14 OR L15 OR L16)  
 L18 101 SEA FILE=REGISTRY ABB=ON PLU=ON L3 NOT L12  
 L19 105 SEA FILE=REGISTRY ABB=ON PLU=ON L18 OR L17  
 L20 14 SEA FILE=CAPLUS ABB=ON PLU=ON L19  
 L24 10289 SEA FILE=CAPLUS ABB=ON PLU=ON SINGH R?/AU  
 L25 208 SEA FILE=CAPLUS ABB=ON PLU=ON GOFF D?/AU  
 L26 396 SEA FILE=CAPLUS ABB=ON PLU=ON PARTRIDGE J?/AU  
 L46 2 SEA FILE=CAPLUS ABB=ON PLU=ON (L24 OR L25 OR L26) AND L20

*(author search results that were also structure search results)*

=> s L27-L29 or L46

L47 9 (L27 OR L28 OR L29) OR L46

=> file uspatfull

FILE 'USPATFULL' ENTERED AT 11:32:09 ON 17 FEB 2006  
 CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 16 Feb 2006 (20060216/PD)  
 FILE LAST UPDATED: 16 Feb 2006 (20060216/ED)  
 HIGHEST GRANTED PATENT NUMBER: US7000250  
 HIGHEST APPLICATION PUBLICATION NUMBER: US2006037120  
 CA INDEXING IS CURRENT THROUGH 14 Feb 2006 (20060214/UPCA)  
 ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 16 Feb 2006 (20060216/PD)  
 REVISED CLASS FIELDS (/NCL) LAST RELOADED: Dec 2005  
 USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Dec 2005

=> d que nos L33

L30 565 SEA FILE=USPATFULL ABB=ON PLU=ON SINGH R?/AU  
 L31 73 SEA FILE=USPATFULL ABB=ON PLU=ON GOFF D?/AU  
 L32 83 SEA FILE=USPATFULL ABB=ON PLU=ON PARTRIDGE J?/AU  
 L33 5 SEA FILE=USPATFULL ABB=ON PLU=ON L30 AND L31 AND L32

=> d que nos L34

L30 565 SEA FILE=USPATFULL ABB=ON PLU=ON SINGH R?/AU  
 L31 73 SEA FILE=USPATFULL ABB=ON PLU=ON GOFF D?/AU  
 L32 83 SEA FILE=USPATFULL ABB=ON PLU=ON PARTRIDGE J?/AU  
 L34 7 SEA FILE=USPATFULL ABB=ON PLU=ON L30 AND (L31 OR L32)

=> d que nos L35

L31 73 SEA FILE=USPATFULL ABB=ON PLU=ON GOFF D?/AU  
 L32 83 SEA FILE=USPATFULL ABB=ON PLU=ON PARTRIDGE J?/AU  
 L35 5 SEA FILE=USPATFULL ABB=ON PLU=ON L31 AND L32

=> d que nos L43

L1 STR  
 L2 ( 4356201) SEA FILE=REGISTRY ABB=ON PLU=ON NC5/ESS  
 L3 281 SEA FILE=REGISTRY SUB=L2 SSS FUL L1  
 L10 STR



L12 180 SEA FILE=REGISTRY SUB=L3 SSS FUL L10  
 L13 1 SEA FILE=REGISTRY ABB=ON PLU=ON "CARBAMIC ACID, (3-(5-(3,4-BIS(PHENYLMETHOXY)PHENYL)-1-(2-PYRIDINYL)-1H-PYRAZOL-3-YL)PHENYL)-, PHENYLMETHYL ESTER"/CN  
 L14 1 SEA FILE=REGISTRY ABB=ON PLU=ON "BENZAMIDE, N-(4-(2-(2-CHLOROPHENYL)-4-(3-METHYLPHENYL)-5-THIAZOLYL)-2-PYRIDINYL)-"/CN  
 L15 1 SEA FILE=REGISTRY ABB=ON PLU=ON "BENZENEACETAMIDE, N-(4-(2-(2-CHLOROPHENYL)-4-(3-METHYLPHENYL)-5-THIAZOLYL)-2-PYRIDINYL)-"/CN  
 L16 1 SEA FILE=REGISTRY ABB=ON PLU=ON "BENZENEPROPANAMIDE, N-(4-(2-(2-CHLOROPHENYL)-4-(3-METHYLPHENYL)-5-THIAZOLYL)-2-PYRIDINYL)-"/CN  
 L17 4 SEA FILE=REGISTRY ABB=ON PLU=ON (L13 OR L14 OR L15 OR L16)  
 L18 101 SEA FILE=REGISTRY ABB=ON PLU=ON L3 NOT L12  
 L19 105 SEA FILE=REGISTRY ABB=ON PLU=ON L18 OR L17  
 L22 13 SEA FILE=USPATFULL ABB=ON PLU=ON L19  
 L30 565 SEA FILE=USPATFULL ABB=ON PLU=ON SINGH R?/AU  
 L31 73 SEA FILE=USPATFULL ABB=ON PLU=ON GOFF D?/AU  
 L32 83 SEA FILE=USPATFULL ABB=ON PLU=ON PARTRIDGE J?/AU  
 L33 5 SEA FILE=USPATFULL ABB=ON PLU=ON L30 AND L31 AND L32  
 L34 7 SEA FILE=USPATFULL ABB=ON PLU=ON L30 AND (L31 OR L32)  
 L35 5 SEA FILE=USPATFULL ABB=ON PLU=ON L31 AND L32

~~L43 2 SEA FILE=USPATFULL ABB=ON PLU=ON (L33 OR L34 OR L35) AND L22~~

=> d que nos L44

L1 STR  
 L2 ( 4356201)SEA FILE=REGISTRY ABB=ON PLU=ON NC5/ESS  
 L3 281 SEA FILE=REGISTRY SUB=L2 SSS FUL L1  
 L10 STR  
 L12 180 SEA FILE=REGISTRY SUB=L3 SSS FUL L10  
 L13 1 SEA FILE=REGISTRY ABB=ON PLU=ON "CARBAMIC ACID, (3-(5-(3,4-BIS(PHENYLMETHOXY)PHENYL)-1-(2-PYRIDINYL)-1H-PYRAZOL-3-YL)PHENYL)-, PHENYLMETHYL ESTER"/CN  
 L14 1 SEA FILE=REGISTRY ABB=ON PLU=ON "BENZAMIDE, N-(4-(2-(2-CHLOROPHENYL)-4-(3-METHYLPHENYL)-5-THIAZOLYL)-2-PYRIDINYL)-"/CN  
 L15 1 SEA FILE=REGISTRY ABB=ON PLU=ON "BENZENEACETAMIDE, N-(4-(2-(2-CHLOROPHENYL)-4-(3-METHYLPHENYL)-5-THIAZOLYL)-2-PYRIDINYL)-"/CN  
 L16 1 SEA FILE=REGISTRY ABB=ON PLU=ON "BENZENEPROPANAMIDE, N-(4-(2-(2-CHLOROPHENYL)-4-(3-METHYLPHENYL)-5-THIAZOLYL)-2-PYRIDINYL)-"/CN  
 L17 4 SEA FILE=REGISTRY ABB=ON PLU=ON (L13 OR L14 OR L15 OR L16)  
 L18 101 SEA FILE=REGISTRY ABB=ON PLU=ON L3 NOT L12  
 L19 105 SEA FILE=REGISTRY ABB=ON PLU=ON L18 OR L17  
 L22 13 SEA FILE=USPATFULL ABB=ON PLU=ON L19  
 L30 565 SEA FILE=USPATFULL ABB=ON PLU=ON SINGH R?/AU  
 L31 73 SEA FILE=USPATFULL ABB=ON PLU=ON GOFF D?/AU  
 L32 83 SEA FILE=USPATFULL ABB=ON PLU=ON PARTRIDGE J?/AU

~~L44 2 SEA FILE=USPATFULL ABB=ON PLU=ON (L30 OR L31 OR L32) AND L22~~

*(author search results that were also structure search results)*

=> s L33-L35 or L43-L44

~~L48 7 (L33 OR L34 OR L35) OR (L43 OR L44)~~

=> file toxcenter

FILE 'TOXCENTER' ENTERED AT 11:32:13 ON 17 FEB 2006  
COPYRIGHT (C) 2006 ACS

FILE COVERS 1907 TO 14 Feb 2006 (20060214/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TOXCENTER has been enhanced with new files segments and search fields.  
See HELP CONTENT for more information.

TOXCENTER thesauri in the /CN, /CT, and /MN fields incorporate the MeSH 2006 vocabulary.

See <http://www.nlm.nih.gov/mesh/>  
[http://www.nlm.nih.gov/pubs/techbull/nd05/nd05\\_med\\_data\\_changes.html](http://www.nlm.nih.gov/pubs/techbull/nd05/nd05_med_data_changes.html)  
[http://www.nlm.nih.gov/pubs/techbull/nd05/nd05\\_2006\\_MeSH.html](http://www.nlm.nih.gov/pubs/techbull/nd05/nd05_2006_MeSH.html)  
for a description of changes.

=> d que nos L39

L36	2326	SEA	FILE=TOXCENTER	ABB=ON	PLU=ON	SINGH R?/AU
L37	171	SEA	FILE=TOXCENTER	ABB=ON	PLU=ON	GOFF D?/AU
L38	101	SEA	FILE=TOXCENTER	ABB=ON	PLU=ON	PARTRIDGE J?/AU
L39	1	SEA	FILE=TOXCENTER	ABB=ON	PLU=ON	L36 AND L37 AND L38

=> d que nos L40

L36	2326	SEA	FILE=TOXCENTER	ABB=ON	PLU=ON	SINGH R?/AU
L37	171	SEA	FILE=TOXCENTER	ABB=ON	PLU=ON	GOFF D?/AU
L38	101	SEA	FILE=TOXCENTER	ABB=ON	PLU=ON	PARTRIDGE J?/AU
L40	2	SEA	FILE=TOXCENTER	ABB=ON	PLU=ON	L36 AND (L37 OR L38)

=> d que nos L41

L37	171	SEA	FILE=TOXCENTER	ABB=ON	PLU=ON	GOFF D?/AU
L38	101	SEA	FILE=TOXCENTER	ABB=ON	PLU=ON	PARTRIDGE J?/AU
L41	1	SEA	FILE=TOXCENTER	ABB=ON	PLU=ON	L37 AND L38

=> d que nos L42

L1		STR				
L2	( 4356201)	SEA	FILE=REGISTRY	ABB=ON	PLU=ON	NC5/ESS
L3	281	SEA	FILE=REGISTRY	SUB=L2	SSS	FUL L1
L10		STR				
L12	180	SEA	FILE=REGISTRY	SUB=L3	SSS	FUL L10
L13	1	SEA	FILE=REGISTRY	ABB=ON	PLU=ON	"CARBAMIC ACID, (3-(5-(3,4-BIS(PHENYLMETHOXY)PHENYL)-1-(2-PYRIDINYL)-1H-PYRAZOL-3-YL)PHENYL)-, PHENYLMETHYL ESTER"/CN
L14	1	SEA	FILE=REGISTRY	ABB=ON	PLU=ON	"BENZAMIDE, N-(4-(2-(2-CHLORO PHENYL)-4-(3-METHYLPHENYL)-5-THIAZOLYL)-2-PYRIDINYL)-"/CN
L15	1	SEA	FILE=REGISTRY	ABB=ON	PLU=ON	"BENZENEACETAMIDE, N-(4-(2-(2-CHLOROPHENYL)-4-(3-METHYLPHENYL)-5-THIAZOLYL)-2-PYRIDINYL)-"/CN

L16 1 SEA FILE=REGISTRY ABB=ON PLU=ON "BENZENEPROPANAMIDE,  
N- (4- (2- (2-CHLOROPHENYL) -4- (3-METHYLPHENYL) -5-THIAZOLYL) -2-PYRI  
DINYL) -"/CN

L17 4 SEA FILE=REGISTRY ABB=ON PLU=ON (L13 OR L14 OR L15 OR L16)

L18 101 SEA FILE=REGISTRY ABB=ON PLU=ON L3 NOT L12

L19 105 SEA FILE=REGISTRY ABB=ON PLU=ON L18 OR L17

L23 4 SEA FILE=TOXCENTER ABB=ON PLU=ON L19

L36 2326 SEA FILE=TOXCENTER ABB=ON PLU=ON SINGH R?/AU

L37 171 SEA FILE=TOXCENTER ABB=ON PLU=ON GOFF D?/AU

L38 101 SEA FILE=TOXCENTER ABB=ON PLU=ON PARTRIDGE J?/AU

L39 1 SEA FILE=TOXCENTER ABB=ON PLU=ON L36 AND L37 AND L38

L40 2 SEA FILE=TOXCENTER ABB=ON PLU=ON L36 AND (L37 OR L38)

L41 1 SEA FILE=TOXCENTER ABB=ON PLU=ON L37 AND L38

L42 1 SEA FILE=TOXCENTER ABB=ON PLU=ON (L39 OR L40 OR L41) AND L23

=> d que nos L45

L1 STR

L2 ( 4356201) SEA FILE=REGISTRY ABB=ON PLU=ON NC5/ESS

L3 281 SEA FILE=REGISTRY SUB=L2 SSS FUL L1

L10 STR

L12 180 SEA FILE=REGISTRY SUB=L3 SSS FUL L10

L13 1 SEA FILE=REGISTRY ABB=ON PLU=ON "CARBAMIC ACID, (3- (5- (3,4-BI  
S(PHENYLMETHOXY) PHENYL) -1- (2-PYRIDINYL) -1H-PYRAZOL-3-YL) PHENYL)  
-, PHENYLMETHYL ESTER"/CN

L14 1 SEA FILE=REGISTRY ABB=ON PLU=ON "BENZAMIDE, N- (4- (2- (2-CHLORO  
PHENYL) -4- (3-METHYLPHENYL) -5-THIAZOLYL) -2-PYRIDINYL) -"/CN

L15 1 SEA FILE=REGISTRY ABB=ON PLU=ON "BENZENEACETAMIDE, N- (4- (2- (2-  
-CHLOROPHENYL) -4- (3-METHYLPHENYL) -5-THIAZOLYL) -2-PYRIDINYL) -"/C  
N

L16 1 SEA FILE=REGISTRY ABB=ON PLU=ON "BENZENEPROPANAMIDE,  
N- (4- (2- (2-CHLOROPHENYL) -4- (3-METHYLPHENYL) -5-THIAZOLYL) -2-PYRI  
DINYL) -"/CN

L17 4 SEA FILE=REGISTRY ABB=ON PLU=ON (L13 OR L14 OR L15 OR L16)

L18 101 SEA FILE=REGISTRY ABB=ON PLU=ON L3 NOT L12

L19 105 SEA FILE=REGISTRY ABB=ON PLU=ON L18 OR L17

L23 4 SEA FILE=TOXCENTER ABB=ON PLU=ON L19

L36 2326 SEA FILE=TOXCENTER ABB=ON PLU=ON SINGH R?/AU

L37 171 SEA FILE=TOXCENTER ABB=ON PLU=ON GOFF D?/AU

L38 101 SEA FILE=TOXCENTER ABB=ON PLU=ON PARTRIDGE J?/AU

L45 1 SEA FILE=TOXCENTER ABB=ON PLU=ON (L36 OR L37 OR L38) AND L23

*author search results that were also structure  
search result*

=> s L39-L42 or L45

L49 2 (L39 OR L40 OR L41 OR L42) OR L45

=> => dup rem L47 L48 L49

FILE 'CAPLUS' ENTERED AT 11:33:37 ON 17 FEB 2006  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 11:33:37 ON 17 FEB 2006  
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'TOXCENTER' ENTERED AT 11:33:37 ON 17 FEB 2006

COPYRIGHT (C) 2006 ACS

PROCESSING COMPLETED FOR L47

PROCESSING COMPLETED FOR L48

PROCESSING COMPLETED FOR L49

L50 15 DUP REM L47 L48 L49 (3 DUPLICATES REMOVED)

ANSWERS '1-9' FROM FILE CAPLUS

ANSWERS '10-15' FROM FILE USPATFULL

=&gt; d ibib abs hitind hitstr L50 1-9; d ibib abs hitstr L50 10-15

L50 ANSWER 1 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 1

ACCESSION NUMBER: 2004:430800 CAPLUS

DOCUMENT NUMBER: 140:423667

TITLE: A preparation of rhodanine derivatives, useful as inhibitors of ubiquitination

INVENTOR(S): Singh, Rajinder; Ramesh, Usha V.; Goff, Dane; Laidig, Guy; Issakani, Sarkiz D.; Huang, Jianing; Payan, Donald G.

PATENT ASSIGNEE(S): Rigel Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 71 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004043955	A1	20040527	WO 2003-US36747	20031113
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1597255	A1	20051123	EP 2003-783609	20031113
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
PRIORITY APPLN. INFO.:			US 2002-426280P	P 20021113
			US 2003-514951P	P 20031028
			WO 2003-US36747	W 20031113
OTHER SOURCE(S):			MARPAT 140:423667	
GI				

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB This invention describes rhodanine derivs. of formula I [wherein: A is (hetero)aryl; B is C1-6alkyl or C2-6alkenyl; X is S, O, etc.; Y is S, O, S(O), or SO<sub>2</sub>, etc.; R<sub>1</sub> = H, NH<sub>2</sub>, C1-6alkyl, or C1-2alkenyl, etc.; R<sub>2</sub> = H, halogen, C1-6alkyl, C0-6alkyl-(hetero)aryl, or NO<sub>2</sub>, etc.; R<sub>3</sub> = H, C1-6alkyl, or C2-6alkenyl; or R<sub>3</sub> and B together with the carbon atom to which they are attached form an alkenyl or a spirocyclic ring], useful as inhibitors of ubiquitination. The compds. and compns. of the invention

are useful as inhibitors of the biochem. pathways of organisms in which ubiquitination is involved. The invention compds. were screened in MDM2 assay (measuring the attachment of ubiquitin to p53) and APC-11/APC-2 ligase assay (auto-ubiquitination). In particular, the compds. and compns. are useful for treating cell proliferative diseases such as cancers. For instance, rhodanine derivative II was prepared via addition of Et thioglycolate to benzyl isothiocyanate, intramol. heterocyclization of the obtained carboxylate III, and condensation of furan derivative IV with the obtained thiazolone V (example 1).

IC ICM C07D417-06

ICS C07D417-14; A61K031-427; A61P035-00

CC 28-7 (Heterocyclic Compounds (More Than One Hetero Atom))

Section cross-reference(s): 1, 63

REFERENCE COUNT: 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L50 ANSWER 2 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 2

ACCESSION NUMBER: 2004:182875 CAPLUS

DOCUMENT NUMBER: 140:235699

TITLE: Preparation of pyridyl substituted heterocycles useful for treating or preventing HCV infection

INVENTOR(S): Singh, Rajinder; Goff, Dane; Partridge, John

PATENT ASSIGNEE(S): Rigel Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 158 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004018463	A2	20040304	WO 2003-US26478	20030822
WO 2004018463	A3	20040506		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2494164	AA	20040304	CA 2003-2494164	20030822
US 2004127497	A1	20040701	US 2003-646348	20030822
EP 1530569	A2	20050518	EP 2003-793349	20030822
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
BR 2003013755	A	20050621	BR 2003-13755	20030822
JP 2006501312	T2	20060112	JP 2005-501778	20030822
NO 2005001404	A	20050510	NO 2005-1404	20050317
PRIORITY APPLN. INFO.:			US 2002-405467P	P 20020823
			US 2002-417837P	P 20021011
			US 2003-471373P	P 20030515
			US 2003-646348	A 20030822
			WO 2003-US26478	W 20030822

OTHER SOURCE(S): MARPAT 140:235699


GI



I



II



III

AB The present invention relates to the preparation of pyridyl substituted heterocycles I and II [B ring is aromatic or nonarom. ring that includes 1-4 heteroatoms, wherein X, Y, and Z independently = C, CH, N, substituted N, S, or O, provided that X and Y are not both O; U and T independently = C, CH, or N; Z = N or CH; A = N or CR2; B = N or CR3; D = N or CR4; E = N or CR5; G = N or CR6; J = N or CR14; K = N or CR8; L = N or CR9; M = N or CR10; R2 and R6 = H, halo, (un)substituted-alkyl, -alkoxy, -carbamoyl, etc.; R3 and R5 = H, halo, (un)substituted-alkyl, -alkylthio, -carbamoyl, etc.; R4 = H, halo, (un)substituted-alkyl, -alkylthio, -alkoxy, -dialkylamino, etc.; R8, R9, R10, R14 = H or halo; R7 = NR11COR12; R11 = H or alkyl; R12 = substituted alkyl or (un)substituted cycloheteroalkyl; with provisions that (i) at least one of A, B, D, E, G, J, K, L or M = n, (ii) no more than one of A, B, D, E or G = N, and (iii) no more than one of J, K, L or M = N] and hydro isomers thereof and pharmaceutical compns. thereof that inhibit replication and/or proliferation of HCV virus. Thus, e.g., III, was prepared by cyclocondensation of 2-ethynyl-4-(dichloromethylcarboxamido)pyridine (preparation given) with the chlorooxime of 2-fluoro-6-trifluoromethylbenzaldehyde. The inhibitory activity of I was confirmed using an HCV replicon assay with numerous compds. possessing IC50 values of less than 10  $\mu$ M. The present invention also relates to the use of the pyridyl heterocycles and hydro isomers thereof and/or pharmaceutical compns. comprising the compds. to treat or prevent HCV infections.

IC ICM C07D413-14

ICS C07D401-14; C07D417-14; C07D413-04; C07D417-04; C07D401-04; A61K031-4439; A61P031-12

CC 28-6 (Heterocyclic Compounds (More Than One Hetero Atom))  
Section cross-reference(s): 1, 63

IT 667931-22-8P 667931-24-0P 667931-28-4P  
667931-30-8P 667931-32-0P 667931-34-2P  
667931-36-4P 667931-38-6P 667931-40-0P  
667931-42-2P 667931-44-4P 667931-46-6P

667931-48-8P 667931-50-2P 667931-52-4P  
 667931-60-4P 667931-62-6P 667931-64-8P  
 667931-68-2P 667931-80-8P

RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (drug candidate; prepare and cytotoxicity of pyridylisoxazoles for treatment of hepatitis C virus infections)

IT 667931-26-2P 667931-56-8P 667931-58-0P  
 667931-66-0P 667931-70-6P 667931-72-8P  
 667931-74-0P 667931-76-2P 667931-78-4P  
 667931-82-0P 667931-84-2P 667931-87-5P  
 667931-89-7P 667931-91-1P 667931-92-2P  
 667931-94-4P 667931-96-6P 667931-98-8P  
 667932-00-5P 667932-02-7P 667932-04-9P  
 667932-06-1P 667932-08-3P 667932-10-7P  
 667932-12-9P 667932-14-1P 667932-16-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; prepare and cytotoxicity of pyridylisoxazoles for treatment of hepatitis C virus infections)


IT 667931-22-8P 667931-24-0P 667931-28-4P  
 667931-30-8P 667931-32-0P 667931-34-2P  
 667931-36-4P 667931-38-6P 667931-40-0P  
 667931-42-2P 667931-44-4P 667931-46-6P  
 667931-48-8P 667931-50-2P 667931-52-4P  
 667931-60-4P 667931-62-6P 667931-64-8P  
 667931-68-2P 667931-80-8P

RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; prepare and cytotoxicity of pyridylisoxazoles for treatment of hepatitis C virus infections)


RN 667931-22-8 CAPLUS

CN Acetamide, 2,2-dichloro-N-[2-[3-(2-chloro-6-fluorophenyl)-5-isoxazolyl]-4-pyridinyl]- (9CI) (CA INDEX NAME)




RN 667931-24-0 CAPLUS

CN Acetamide, 2,2-dichloro-N-[2-[3-[2-fluoro-6-(trifluoromethyl)phenyl]-5-isoxazolyl]-4-pyridinyl]- (9CI) (CA INDEX NAME)




RN 667931-28-4 CAPLUS

CN Acetamide, 2,2-dichloro-N-[5-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 667931-30-8 CAPLUS


CN Acetamide, 2,2-dichloro-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]- (9CI) (CA INDEX NAME)



RN 667931-32-0 CAPLUS


CN Acetamide, 2,2-dichloro-N-[3-[3-(3,5-dichloro-4-pyridinyl)-5-isoxazolyl]phenyl]- (9CI) (CA INDEX NAME)






RN 667931-34-2 CAPLUS

CN Acetamide, 2,2-dichloro-N-[5-[3-(2-chloro-6-fluorophenyl)-5-isoxazolyl]-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 667931-36-4 CAPLUS

CN Acetamide, 2,2-dichloro-N-[5-[3-(2-fluoro-6-methoxyphenyl)-5-isoxazolyl]-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 667931-38-6 CAPLUS

CN Acetamide, 2,2-dichloro-N-[2-[3-(2,6-dimethylphenyl)-5-isoxazolyl]-4-pyridinyl]- (9CI) (CA INDEX NAME)




RN 667931-40-0 CAPLUS

CN Acetamide, 2,2-dichloro-N-[5-[3-(2,6-dimethylphenyl)-5-isoxazolyl]-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 667931-42-2 CAPLUS

CN Acetamide, 2,2-dichloro-N-[5-[3-(2,6-difluorophenyl)-5-isoxazolyl]-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 667931-44-4 CAPLUS

CN Acetamide, 2,2-dichloro-N-[5-[3-(2,3-dichlorophenyl)-5-isoxazolyl]-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 667931-46-6 CAPLUS

CN Acetamide, 2,2-dichloro-N-[2-[3-[2-(4-morpholinyl)-6-(trifluoromethyl)phenyl]-5-isoxazolyl]-4-pyridinyl]- (9CI) (CA INDEX NAME)




RN 667931-48-8 CAPLUS

CN Acetamide, 2,2-dichloro-N-[3-[3-(3-methyl-2-pyridinyl)-5-isoxazolyl]phenyl]- (9CI) (CA INDEX NAME)




RN 667931-50-2 CAPLUS

CN Acetamide, 2,2-dichloro-N-[6-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 667931-52-4 CAPLUS

CN Acetamide, 2,2-dichloro-N-[5-[3-[2-fluoro-6-(trifluoromethyl)phenyl]-5-isoxazolyl]-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 667931-60-4 CAPLUS

CN Acetamide, 2,2-dichloro-N-[2-[3-[2-fluoro-6-(4-morpholinylsulfonyl)phenyl]-5-isoxazolyl]-4-pyridinyl]- (9CI) (CA INDEX NAME)




RN 667931-62-6 CAPLUS

CN Acetamide, 2,2-dichloro-N-[2-[3-[2-methoxy-6-(trifluoromethyl)phenyl]-5-isoxazolyl]-4-pyridinyl]- (9CI) (CA INDEX NAME)




RN 667931-64-8 CAPLUS

CN Acetamide, 2,2-dichloro-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 667931-68-2 CAPLUS

CN Acetamide, 2,2-dichloro-N-[5-[3-[2-methoxy-6-(trifluoromethyl)phenyl]-5-isoxazolyl]-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 667931-80-8 CAPLUS

CN Acetamide, 2,2-dichloro-N-[5-[3-[2-chloro-6-[4-(2-pyridinyl)-1-piperazinyl]phenyl]-5-isoxazolyl]-3-pyridinyl]- (9CI) (CA INDEX NAME)




IT 667931-26-2P 667931-56-8P 667931-58-0P  
 667931-66-0P 667931-70-6P 667931-72-8P  
 667931-74-0P 667931-78-4P 667931-82-0P  
 667931-84-2P 667931-87-5P 667931-89-7P  
 667931-91-1P 667931-92-2P 667931-94-4P  
 667931-96-6P 667931-98-8P 667932-00-5P  
 667932-02-7P 667932-04-9P 667932-06-1P  
 667932-08-3P 667932-10-7P 667932-12-9P  
 667932-14-1P 667932-16-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; prepare and cytotoxicity of pyridylisoxazoles for treatment of hepatitis C virus infections)


RN 667931-26-2 CAPLUS

CN Acetamide, 2,2-dichloro-N-[2-[3-(2-fluoro-6-methoxyphenyl)-5-isoxazolyl]-4-pyridinyl]- (9CI) (CA INDEX NAME)




RN 667931-56-8 CAPLUS

CN Acetamide, 2,2-dichloro-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-1-oxido-4-pyridinyl]- (9CI) (CA INDEX NAME)




RN 667931-58-0 CAPLUS

CN 3-Pyridinecarboxylic acid, 2-[5-[3-[(dichloroacetyl)amino]phenyl]-3-isoxazolyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 667931-66-0 CAPLUS


CN Acetamide, 2,2-dichloro-N-[2-[3-[2-chloro-6-[4-(2-pyridinyl)-1-piperazinyl]phenyl]-5-isoxazolyl]-4-pyridinyl]- (9CI) (CA INDEX NAME)



RN 667931-70-6 CAPLUS


CN Acetamide, 2,2-dichloro-N-[5-[3-[2-[4-(2-pyridinyl)-1-piperazinyl]-6-chlorophenyl]-3-isoxazolyl]-4-pyridinyl]- (9CI) (CA INDEX NAME)

(trifluoromethyl)phenyl]-5-isoxazolyl]-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 667931-72-8 CAPLUS


CN Acetamide, N-[5-[3-[2-(4-acetyl-1-piperazinyl)-6-chlorophenyl]-5-isoxazolyl]-3-pyridinyl]-2,2-dichloro- (9CI) (CA INDEX NAME)



RN 667931-74-0 CAPLUS


CN Acetamide, 2,2-dichloro-N-[5-[3-[2-chloro-6-(4-ethyl-1-piperazinyl)phenyl]-5-isoxazolyl]-3-pyridinyl]- (9CI) (CA INDEX NAME)






RN 667931-78-4 CAPLUS

CN Acetamide, 2,2-dichloro-N-[5-[3-[2-(trifluoromethyl)phenyl]-5-isoxazolyl]-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 667931-82-0 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[3-chloro-2-[5-[5-[(dichloroacetyl)amino]-3-pyridinyl]-3-isoxazolyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 667931-84-2 CAPLUS

CN Acetamide, 2,2-dichloro-N-[5-[3-[2-chloro-6-(1-piperazinyl)phenyl]-5-isoxazolyl]-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 667931-87-5 CAPLUS

CN Acetamide, 2,2-dichloro-N-[5-[3-[2-chloro-6-[[[1,1-dimethylethyl]dimethylsilyl]oxy]phenyl]-5-isoxazolyl]-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 667931-89-7 CAPLUS

CN Acetamide, 2,2-dichloro-N-[5-[3-(2-chloro-6-hydroxyphenyl)-5-isoxazolyl]-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 667931-91-1 CAPLUS

CN Carbamic acid, ethyl-, 3-chloro-2-[5-[5-[(dichloroacetyl)amino]-3-pyridinyl]-3-isoxazolyl]phenyl ester (9CI) (CA INDEX NAME)




RN 667931-92-2 CAPLUS

CN 1-Piperazinecarboxamide, 4-[3-chloro-2-[5-[5-[(dichloroacetyl)amino]-3-pyridinyl]-3-isoxazolyl]phenyl]-N-ethyl- (9CI) (CA INDEX NAME)




RN 667931-94-4 CAPLUS

CN Acetamide, 2,2-dichloro-N-[2-[3-[2-chloro-6-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]phenyl]-5-isoxazolyl]-4-pyridinyl]- (9CI) (CA INDEX NAME)




RN 667931-96-6 CAPLUS

CN Carbamic acid, propyl-, 3-chloro-2-[5-[4-[(dichloroacetyl)amino]-2-pyridinyl]-3-isoxazolyl]phenyl ester (9CI) (CA INDEX NAME)




RN 667931-98-8 CAPLUS

CN Acetamide, 2,2-dichloro-N-[2-[3-[2-chloro-6-(methoxymethoxy)phenyl]-5-isoxazolyl]-4-pyridinyl]- (9CI) (CA INDEX NAME)




RN 667932-00-5 CAPLUS

CN Acetamide, 2,2-dichloro-N-[2-[3-(2-chloro-6-hydroxyphenyl)-5-isoxazolyl]-4-pyridinyl]- (9CI) (CA INDEX NAME)




RN 667932-02-7 CAPLUS

CN Acetamide, 2,2-dichloro-N-[3-[3-[4-chloro-2-(dimethylamino)-3-pyridinyl]-5-isoxazolyl]phenyl]- (9CI) (CA INDEX NAME)




RN 667932-04-9 CAPLUS

CN Acetamide, 2,2-dichloro-N-[3-[3-(2,4-dichloro-3-pyridinyl)-5-isoxazolyl]phenyl]- (9CI) (CA INDEX NAME)




RN 667932-06-1 CAPLUS

CN Acetamide, 2,2-dichloro-N-[3-[3-[2-chloro-4-(4-morpholinyl)-3-pyridinyl]-5-isoxazolyl]phenyl]- (9CI) (CA INDEX NAME)




RN 667932-08-3 CAPLUS

CN Acetamide, N-[3-[3-(6-bromo-2-pyridinyl)-5-isoxazolyl]phenyl]-2,2-dichloro- (9CI) (CA INDEX NAME)



RN 667932-10-7 CAPLUS

CN Acetamide, 2,2-dichloro-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 667932-12-9 CAPLUS

CN Acetamide, 2,2-dichloro-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]-, mono(4-methylbenzenesulfonate) (9CI) (CA INDEX NAME)

CM 1

CRN 667931-30-8


CMF C16 H9 Cl4 N3 O2



CM 2

CRN 104-15-4

CMF C7 H8 O3 S




RN 667932-14-1 CAPLUS

CN Ethanesulfonic acid, compd. with 2,2-dichloro-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]acetamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 667931-30-8

CMF C16 H9 Cl4 N3 O2




CM 2

CRN 594-45-6

CMF C2 H6 O3 S






RN 667932-16-3 CAPLUS  
 CN Acetamide, 2,2-dichloro-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]-, mononitrate (9CI) (CA INDEX NAME)


CM 1

CRN 667931-30-8  
 CMF C16 H9 Cl4 N3 O2



CM 2

CRN 7697-37-2  
 CMF H N O3



L50 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 3  
 ACCESSION NUMBER: 2004:589255 CAPLUS  
 DOCUMENT NUMBER: 141:140418  
 TITLE: Preparation of diphenylazoles for treatment of hepatitis C infection  
 INVENTOR(S): Singh, Rajinder; Goff, Dane; Partridge, John  
 PATENT ASSIGNEE(S): USA  
 SOURCE: U.S. Pat. Appl. Publ., 92 pp.  
 CODEN: USXXCO  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

```

-----
US 2004142985      A1      20040722      US 2003-440349      20030515
WO 2004103366      A1      20041202      WO 2004-US14520     20040510
W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
    CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
    GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
    LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
    NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
    TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW,
RW:  BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
    AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
    EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
    SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
    SN, TD, TG

```

PRIORITY APPLN. INFO.:


US 2003-440349

A 20030515

OTHER SOURCE(S):

MARPAT 141:140418

GI



I

AB Title compds. [I; X, Y, Z = C, CH, N, NR16, NR18, S, O; U, T = C, CH, N; R2-R6, R8-R10, R13 = H, OH, SH, cyano, NO2, N3, F, Cl, Br, iodo, (substituted) alkyl, heteroalkyl, cycloalkyl, haloalkyl, alkoxy, aryl, aryloxy, PhO, aralkyl, etc.; R11 = H, alkyl; R12 = mono- or dihalomethyl; R16, R18 = H, (substituted) alkyl, heteroalkyl, cycloheteroalkyl, aralkoxy, aryl, aryloxy, PhO, carbamoyl, etc.; with provisos], were prepared Thus, 3-(3-aminophenyl)-5-(2,6-dichlorophenyl)isoxazole (preparation given) in THF was treated with Et3N and then with dichloroacetyl chloride under ice cooling to give 2,2-dichloro-N-[3-[5-(2,6-dichlorophenyl)-3-isoxazolyl]phenyl]acetamide. Some I inhibited HCV replication with IC50 values in the nanomolar range.

IC ICM A61K031-4245

ICS A61K031-4196; C07D271-12; C07D249-14

INCL 514364000; 514383000; 548131000; 548264800

CC 28-6 (Heterocyclic Compounds (More Than One Hetero Atom))

Section cross-reference(s): 1

L50 ANSWER 4 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:1126672 CAPLUS

DOCUMENT NUMBER: 143:405897

TITLE: Heterocyclic anti-viral compounds comprising metabolizable moieties and their uses as inhibitors of hepatitis C virus replication and/or proliferation for treatment of hepatitis C infection

INVENTOR(S): Singh, Rajinder; Goff, Dane; Kolluri, Rao S. S.; Darwish, Ihab S.; Partridge, John; Cooper, Robin; Lu, Henry H.; Park, Gary

PATENT ASSIGNEE(S): Rigel Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 149 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005097760	A1	20051020	WO 2005-US9909	20050325
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2005239751	A1	20051027	US 2005-90823	20050325
PRIORITY APPLN. INFO.:			US 2004-556625P	P 20040326
			US 2004-582903P	P 20040624

OTHER SOURCE(S): MARPAT 143:405897

AB The invention is related to substituted diphenyl-, diheteroaryl- and mixed Ph heteroaryl substituted 5-membered heterocycle compds. of formula A-B-D-(CO)<sub>n</sub>-N(R<sub>11</sub>)-CO-CX<sub>2</sub>-R<sub>12</sub> (I) [A = substituted Ph, 6-membered heteroaryl, provided that at least one of the substituents is located in the ortho position; B = (un)saturated, aromatic heteroat. ring having from 1

to 3

annular heteroatoms, with proviso; D = Ph, heteroaryl with provisos; n = 0-1; R<sub>11</sub> = H, lower alkyl, aryloxy, 5-substituted 2-oxo-1,3-dioxol-4-yl, etc.; R<sub>12</sub> = H, OCO-alkyl, aryloxycarbonyl, alkylcarbonyl, PO<sub>3</sub>H<sub>2</sub> and derivs., etc.; X = H, halo, provided both X are not H; including pharmaceutically acceptable salts, hydrates, solvates, and N-oxides], prodrugs and compns. thereof useful for treating or preventing Hepatitis C virus (HCV) infections. The invention is particularly related to di-Ph and Ph pyridinyl isoxazoles of formula I. For example, a 3-step synthesis, starting from 3-ethynylaniline and 2,2-dichloro-2-(diethoxyphosphonyl)acetyl chloride (preparation given), was given for 2,2-Dichloro-2-(dihydroxyphosphonyl)-N-[3-[3-(2,6-dichlorophenyl)-5-isoxazolyl]phenyl]acetamide. The invention is also related to the use of compds. and compns. to inhibit HCV replication and/or proliferation and to treat or prevent HCV infections in humans and animals. Selected I inhibited HCV translation or replication with IC<sub>50</sub>'s < 10 μM in a replicon and/or Western blot assay.

IC ICM C07D261-08

ICS C07D413-04; A61K031-4439; A61P031-12

CC 28-6 (Heterocyclic Compounds (More Than One Hetero Atom))

Section cross-reference(s): 1, 63

IT 867215-83-6P, 2,2-Dichloro-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridyl]-N-[(5-tert-butyl-2-oxo-1,3-dioxol-4-yl)methyl]acetamide

RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of substituted heterocyclic prodrugs for treating HCV infection)

IT 867215-36-9P 867215-95-0P, tert-Butyl 4-[3-[2,2-Dichloro-N-[2-[3-

(2,6-dichlorophenyl)isoxazol-5-yl]pyridin-4-yl]acetamido]propanoyl]benzoate 867216-30-6P, tert-Butyl 2-[3-[[2-[3-(2,6-Dichlorophenyl)isoxazol-5-yl]pyridin-4-yl]amino]propanoyl]pyrrolidine-1-carboxylate 867216-39-5P, tert-Butyl 4-[3-Chloro-2-[5-[3-[2,2-dichloro-N-[(5-isopropyl-2-oxo-1,3-dioxol-4-yl)methyl]acetamido]phenyl]isoxazol-3-yl]phenoxy]piperidine-1-carboxylate **867216-46-4P**, Di-tert-butyl [[4-[3-[2,2-Dichloro-N-[2-[3-(2,6-dichlorophenyl)isoxazol-5-yl]pyridin-4-yl]acetamido]propyl]phenyl]methyl]phosphonate

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(drug candidate; preparation of substituted heterocyclic prodrugs for treating HCV infection)

IT **667931-30-8P** 867215-38-1P, 2,2-Dichloro-2-(dihydroxyphosphonyl)-N-[3-[3-(2,6-dichlorophenyl)-5-isoxazolyl]phenyl]acetamide 867215-39-2P, 2-Chloro-2-(diethoxyphosphonyl)-N-[3-[3-(2,6-dichlorophenyl)-5-isoxazolyl]phenyl]acetamide 867215-40-5P, 2-Chloro-2-(diethoxyphosphonyl)-2-fluoro-N-[3-[3-(2,6-dichlorophenyl)-5-isoxazolyl]phenyl]acetamide 867215-41-6P, 2-(Diethoxyphosphonyl)-2,2-difluoro-N-[3-[3-(2,6-dichlorophenyl)-5-isoxazolyl]phenyl]acetamide 867215-42-7P, 2,2-Dichloro-2-(diisopropoxyphosphonyl)-N-[3-[3-(2,6-dichlorophenyl)-5-isoxazolyl]phenyl]acetamide 867215-43-8P, 2,2-Dichloro-2-(diethoxyphosphonyl)-N-[3-[3-(2-trifluoromethylphenyl)-5-isoxazolyl]phenyl]acetamide 867215-44-9P, 2,2-Dichloro-2-(diethoxyphosphonyl)-N-[3-[3-(2-fluoro-6-trifluoromethylphenyl)-5-isoxazolyl]phenyl]acetamide 867215-45-0P, 2,2-Dichloro-2-(tert-butoxycarbonyl)-N-[3-[3-(2,6-dichlorophenyl)-5-isoxazolyl]phenyl]acetamide 867215-48-3P, 2,2-Dichloro-2-(isopropoxycarbonyl)-N-[3-[3-(2,6-dichlorophenyl)-5-isoxazolyl]phenyl]acetamide 867215-51-8P, 2,2-Dichloro-2-[[[(1S)-ethoxycarbonyl-1-(methyl)methyl]oxy]carbonyl]-N-[3-[3-(2,6-dichlorophenyl)-5-isoxazolyl]phenyl]acetamide 867215-52-9P, 867215-53-0P, 2,2-Dichloro-2-[[[(1-adamantyl)oxy]carbonyl]-N-[3-[3-(2,6-dichlorophenyl)-5-isoxazolyl]phenyl]acetamide 867215-54-1P, 2,2-Dichloro-2-[(1R,2S,5R)-menthyloxycarbonyl]-N-[3-[3-(2,6-dichlorophenyl)-5-isoxazolyl]phenyl]acetamide 867215-55-2P, 2,2-Dichloro-2-(sec-butoxycarbonyl)-N-[3-[3-(2,6-dichlorophenyl)-5-isoxazolyl]phenyl]acetamide 867215-56-3P, 2,2-Dichloro-2-(cyclohexyloxycarbonyl)-N-[3-[3-(2,6-dichlorophenyl)-5-isoxazolyl]phenyl]acetamide 867215-57-4P, 2,2-Dichloro-2-(neopentyloxycarbonyl)-N-[3-[3-(2,6-dichlorophenyl)-5-isoxazolyl]phenyl]acetamide 867215-58-5P, 2,2-Dichloro-2-(benzyloxycarbonyl)-N-[3-[3-(2,6-dichlorophenyl)-5-isoxazolyl]phenyl]acetamide 867215-59-6P, 2,2-Dichloro-2-(methoxycarbonyl)-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]phenyl]acetamide **867215-60-9P**, 2,2-Dichloro-2-(tert-butoxycarbonyl)-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridyl]acetamide 867215-61-0P, 2,2-Dichloro-2-(tert-butoxycarbonyl)-N-[3-[3-(2-chloro-6-methoxyphenyl)-5-isoxazolyl]phenyl]acetamide 867215-62-1P, 2,2-Dichloro-2-(methoxycarbonyl)-N-[3-[3-(2-cyclopropyl-6-trifluoromethylphenyl)-5-isoxazolyl]phenyl]acetamide 867215-63-2P, 2,2-Dichloro-2-(methoxycarbonyl)-N-[3-[3-(2-chloro-6-methoxyphenyl)-5-isoxazolyl]phenyl]acetamide **867215-64-3P**, 2,2-Dichloro-2-(methoxycarbonyl)-N-[3-[3-(4-chloro-2-dimethylaminopyridin-3-yl)-5-isoxazolyl]phenyl]acetamide 867215-65-4P, 2,2-Dichloro-2-(methoxycarbonyl)-N-[3-[3-(2-trifluoromethylphenyl)-5-isoxazolyl]phenyl]acetamide 867215-66-5P, 2,2-Dichloro-2-(methoxycarbonyl)-N-[3-[3-(2-fluoro-6-trifluoromethylphenyl)-5-isoxazolyl]phenyl]acetamide 867215-67-6P, 2,2-Dichloro-N-[3-[3-(2,6-dichlorophenyl)-5-isoxazolyl]phenyl]-N-[(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl]acetamide 867215-69-8P, 2,2-Dichloro-N-[3-[3-(2,6-

dichlorophenyl)isoxazol-5-yl]phenyl]-N-[(5-tert-butyl-2-oxo-1,3-dioxol-4-yl)methyl]acetamide 867215-71-2P, 2,2-Dichloro-N-[3-[3-(2-chloro-6-methoxyphenyl)-5-isoxazolyl]phenyl]-N-[(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl]acetamide 867215-72-3P, 2,2-Dichloro-N-[3-[3-(2,4-dichloropyridin-3-yl)-5-isoxazolyl]phenyl]-N-[(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl]acetamide 867215-73-4P, 2,2-Dichloro-N-[3-[3-(4-chloro-2-dimethylaminopyridin-3-yl)-5-isoxazolyl]phenyl]-N-[(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl]acetamide 867215-74-5P, 2,2-Dichloro-N-[3-[3-(2,6-dichlorophenyl)-5-isoxazolyl]phenyl]-N-[(5-isopropyl-2-oxo-1,3-dioxol-4-yl)methyl]acetamide 867215-75-6P, 2,2-Dichloro-N-[3-[3-(4-chloro-2-dimethylaminopyridin-3-yl)-5-isoxazolyl]phenyl]-N-[(5-isopropyl-2-oxo-1,3-dioxol-4-yl)methyl]acetamide 867215-76-7P, 2,2-Dichloro-N-[3-[3-(2-chloro-6-tert-butoxycarbonylphenyl)-5-isoxazolyl]phenyl]-N-[(5-isopropyl-2-oxo-1,3-dioxol-4-yl)methyl]acetamide 867215-77-8P, 2,2-Dichloro-N-[3-[3-(2-chloro-6-methoxyphenyl)-5-isoxazolyl]phenyl]-N-[(5-isopropyl-2-oxo-1,3-dioxol-4-yl)methyl]acetamide 867215-78-9P, 2,2-Dichloro-N-[3-[3-(2,6-dichlorophenyl)-5-isoxazolyl]phenyl]-N-[(5-propyl-2-oxo-1,3-dioxol-4-yl)methyl]acetamide 867215-79-0P, 2,2-Dichloro-N-[3-[3-(2,6-dichlorophenyl)-5-isoxazolyl]phenyl]-N-[(5-cyclohexyl-2-oxo-1,3-dioxol-4-yl)methyl]acetamide 867215-80-3P, 2,2-Dichloro-N-[3-[3-(2,6-dichlorophenyl)-5-isoxazolyl]phenyl]-N-[(5-ethyl-2-oxo-1,3-dioxol-4-yl)methyl]acetamide 867215-81-4P, 2,2-Dichloro-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridyl]-N-[(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl]acetamide 867215-82-5P, 2,2-Dichloro-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridyl]-N-[(5-isopropyl-2-oxo-1,3-dioxol-4-yl)methyl]acetamide 867215-84-7P, 2,2-Dichloro-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridyl]-N-[(5-pentyl-2-oxo-1,3-dioxol-4-yl)methyl]acetamide 867215-85-8P, 2,2-Dichloro-N-[3-[3-(2,6-dichlorophenyl)-5-isoxazolyl]phenyl]-N-[(5-ethoxycarbonyl-2-oxo-1,3-dioxol-4-yl)methyl]acetamide 867215-86-9P, 2,2-Dichloro-N-[3-[3-(2,6-dichlorophenyl)isoxazol-5-yl]phenyl]-N-[2-(phenylsulfonyl)ethyl]acetamide 867215-89-2P, 2,2-Dichloro-N-[2-[3-(2,6-dichlorophenyl)isoxazol-5-yl]pyridin-4-yl]-N-[3-oxo-3-(pyridin-3-yl)propyl]acetamide 867215-92-7P, 4-[3-[2,2-Dichloro-N-[2-[3-(2,6-dichlorophenyl)isoxazol-5-yl]pyridin-4-yl]acetamido]propanoyl]benzoic Acid 867215-96-1P, 2,2-Dichloro-N-[2-[3-(2,6-dichlorophenyl)isoxazol-5-yl]pyridin-4-yl]-N-[3-(morpholino)-3-oxopropyl]acetamide 867216-00-0P, Ethyl 2-[4-[3-[2,2-Dichloro-N-[3-[3-(2,6-dichlorophenyl)isoxazol-5-yl]phenyl]acetamido]propanoyl]phenyl]acetate 867216-01-1P, N-(4-Amino-3-oxo-5-phenylpentyl)-2,2-dichloro-N-[2-[3-(2,6-dichlorophenyl)isoxazol-5-yl]pyridin-4-yl]acetamide 867216-02-2P, 2,2-Dichloro-N-[2-[3-(2,6-dichlorophenyl)isoxazol-5-yl]pyridin-4-yl]-N-[3-oxo-3-(piperidin-4-yl)propyl]acetamide 867216-03-3P, 2,2-Dichloro-N-[2-[3-(2,6-dichlorophenyl)isoxazol-5-yl]pyridin-4-yl]-N-[3-oxo-3-(pyrrolidin-2-yl)propyl]acetamide 867216-04-4P, tert-Butyl 3-[3-[2,2-Dichloro-N-[2-[3-(2,6-dichlorophenyl)isoxazol-5-yl]pyridin-4-yl]acetamido]propanoyl]piperidine-1-carboxylate 867216-06-6P, 2,2-Dichloro-N-[2-[3-(2,6-dichlorophenyl)isoxazol-5-yl]pyridin-4-yl]-N-[3-oxo-3-(piperidin-3-yl)propyl]acetamide 867216-07-7P, tert-Butyl 4-[4-[3-[2,2-Dichloro-N-[2-[3-(2,6-dichlorophenyl)isoxazol-5-yl]pyridin-4-yl]acetamido]propanoyl]phenyl]piperazine-1-carboxylate 867216-08-8P, 4-[2-[2-Dichloro-N-[2-[3-(2,6-dichlorophenyl)isoxazol-5-yl]pyridin-4-yl]acetamido]methyl]-2,6-dimethylphenyl propylcarbamate 867216-11-3P, 2,2-Dichloro-N-[3-[3-(2,6-dichlorophenyl)isoxazol-5-yl]phenyl]-N'-methylmalonamide 867216-15-7P, 2,2-Dichloro-N-[3-[3-(2,6-dichlorophenyl)isoxazol-5-yl]phenyl]-N-[2-oxo-5-(pyrrolidin-2-yl)-1,3-dioxol-4-yl]methyl]acetamide 867216-16-8P, 2,2-Dichloro-N-[3-[3-(2,6-dichlorophenyl)isoxazol-5-yl]phenyl]-N-[2-oxo-5-(pyrrolidin-2-yl)-1,3-dioxol-4-yl]methyl]acetamide monotrifluoroacetate 867216-32-8P, 2,2-Dichloro-N-[2-[3-(2,6-dichlorophenyl)isoxazol-5-

yl]pyridin-4-yl]-N-[[2-(pyridin-2-yl)ethoxy]methyl]acetamide  
 867216-34-0P, 2,2-Dichloro-N-[3-[3-[2-chloro-6-(piperidin-4-  
 yloxy)phenyl]isoxazol-5-yl]phenyl]-N-[(5-isopropyl-2-oxo-1,3-dioxol-4-  
 yl)methyl]acetamide 867216-36-2P, 2,2-Dichloro-N-(3-ethynylphenyl)-N-[(5-  
 isopropyl-2-oxo-1,3-dioxol-4-yl)methyl]acetamide 867216-40-8P,  
 2,2-Dichloro-N-[2-[3-(2,6-Dichlorophenyl)isoxazol-5-yl]pyridin-4-yl]-N-[(1-  
 methyl-1H-imidazol-2-yl)methyl]acetamide 867216-42-0P,  
 [4-[3-[2,2-Dichloro-N-[2-[3-(2,6-dichlorophenyl)isoxazol-5-yl]pyridin-4-  
 yl]acetamido]propyl]benzyl]phosphonic Acid 867216-47-5P 867216-52-2P,  
 2,2-Dichloro-N-[3-[3-(2,6-dichlorophenyl)isoxazol-5-yl]phenyl]-N'-(3-  
 morpholinopropyl)malonamide 867216-53-3P, 2,2-Dichloro-N-[3-[3-(2,6-  
 dichlorophenyl)isoxazol-5-yl]phenyl]-N'-[(pyridin-2-yl)methyl]malonamide  
 867216-54-4P, 2,2-Dichloro-N-[3-[3-(2,6-dichlorophenyl)isoxazol-5-  
 yl]phenyl]-N'-(2-hydroxyethyl)malonamide 867216-55-5P, Propyl  
 [4-[2,2-Dichloro-N-[3-[3-(2,6-dichlorophenyl)isoxazol-5-  
 yl]phenyl]acetamido]methyl]phenyl]carbamate 867216-56-6P,  
 2,2-Dichloro-N-[3-[3-(2,6-dichlorophenyl)isoxazol-5-yl]phenyl]-N-[[2-oxo-5-  
 (piperidin-3-yl)-1,3-dioxol-4-yl]methyl]acetamide 867216-57-7P,  
 2,2-Dichloro-N-[3-[3-(2,6-dichlorophenyl)isoxazol-5-yl]phenyl]-N-[(5-  
 neopentyl-2-oxo-1,3-dioxol-4-yl)methyl]acetamide 867216-58-8P,  
 2,2-Dichloro-N-[(5-cyclobutyl-2-oxo-1,3-dioxol-4-yl)methyl]-N-[3-[3-(2,6-  
 dichlorophenyl)isoxazol-5-yl]phenyl]acetamide 867216-59-9P, Isopropyl  
 2,2-Dichloro-3-[[3-[3-(2-chloro-6-methoxyphenyl)isoxazol-5-  
 yl]phenyl]amino]-3-oxopropanoate 867216-60-2P, tert-Butyl  
 4-[[2,2-Dichloro-N-[2-[3-(2,6-dichlorophenyl)isoxazol-5-yl]pyridin-4-  
 yl]acetamido]methyl]benzoate 867216-61-3P, 2,2-Dichloro-N-[2-[3-  
 (2,6-dichlorophenyl)isoxazol-5-yl]pyridin-4-yl]-N-[4-(2-  
 morpholinoethoxy)benzyl]acetamide 867216-62-4P,  
 2,2-Dichloro-N-[2-[3-(2,6-dichlorophenyl)isoxazol-5-yl]pyridin-4-yl]-N-[4-  
 (4-ethylpiperazin-1-yl)benzyl]acetamide 867216-63-5P,  
 N-[(5-Benzyl-2-oxo-1,3-dioxol-4-yl)methyl]-2,2-dichloro-N-[3-[3-(2,6-  
 dichlorophenyl)isoxazol-5-yl]phenyl]acetamide 867216-64-6P,  
 2,2-Dichloro-N-[2-[3-(2,6-dichlorophenyl)isoxazol-5-yl]pyridin-4-yl]-N-(2-  
 morpholinoethyl)acetamide 867216-65-7P, 3-Chloro-2-[5-[3-[2,2-dichloro-N-  
 [(5-isopropyl-2-oxo-1,3-dioxol-4-yl)methyl]acetamido]phenyl]isoxazol-3-  
 yl]benzoic Acid 867216-66-8P, 2,2-Dichloro-N-[3-[3-[2-cyclopropyl-6-  
 (trifluoromethyl)phenyl]isoxazol-5-yl]phenyl]-N-[(5-isopropyl-2-oxo-1,3-  
 dioxol-4-yl)methyl]acetamide 867216-67-9P, 2,2-Dichloro-N-[(5-isopropyl-  
 2-oxo-1,3-dioxol-4-yl)methyl]-N-[3-[3-[2-methoxy-6-  
 (trifluoromethyl)phenyl]isoxazol-5-yl]phenyl]acetamide 867216-68-0P,  
 Methyl 3-Chloro-2-[5-[3-[2,2-dichloro-N-[(5-isopropyl-2-oxo-1,3-dioxol-4-  
 yl)methyl]acetamido]phenyl]isoxazol-3-yl]benzoate 867216-69-1P,  
 N-[3-[3-[2-(1-Acetylpiperidin-4-yloxy)-6-chlorophenyl]isoxazol-5-  
 yl]phenyl]-2,2-dichloro-N-[(5-isopropyl-2-oxo-1,3-dioxol-4-  
 yl)methyl]acetamide 867216-70-4P, 2,2-Dichloro-N-[2-[3-(2,6-  
 dichlorophenyl)isoxazol-5-yl]pyridin-4-yl]-N-[(5-neopentyl-2-oxo-1,3-  
 dioxol-4-yl)methyl]acetamide 867216-71-5P, 4-[3-[2,2-Dichloro-N-  
 [2-[3-(2,6-dichlorophenyl)isoxazol-5-yl]pyridin-4-  
 yl]acetamido]propyl]phenyl diethyl phosphate 867216-72-6P,  
 tert-Butyl 4-[4-[3-[2,2-Dichloro-N-[2-[3-(2,6-dichlorophenyl)isoxazol-5-  
 yl]pyridin-4-yl]acetamido]propyl]phenyl]piperazine-1-carboxylate  
 867216-73-7P, tert-Butyl 4-[3-[2,2-Dichloro-N-[2-[3-(2,6-  
 dichlorophenyl)isoxazol-5-yl]pyridin-4-yl]acetamido]propyl]benzoate  
 867216-74-8P, 2,2-Dichloro-N-[2-[3-(2,6-dichlorophenyl)isoxazol-5-  
 yl]pyridin-4-yl]-N-[3-[4-(piperazin-1-yl)phenyl]propyl]acetamide  
 867216-77-1P, 2,2-Dichloro-N-[3-[3-(2,6-dichlorophenyl)-5-  
 isoxazolyl]phenyl]-N-[2-(4-fluorobenzoyl)ethyl]Acetamide 867216-80-6P,  
 2,2-Dichloro-N-[3-[3-(2,6-dichlorophenyl)-5-isoxazolyl]phenyl]-N-[2-  
 (benzoyl)propyl]Acetamide 867216-82-8P 867216-83-9P,  
 2,2-Dichloro-N-[3-[3-(2,6-dichlorophenyl)-5-isoxazolyl]phenyl]-N-[2-

(benzoyl)ethyl]Acetamide 867216-84-0P, 2,2-Dichloro-N-[3-[3-(2,6-dichlorophenyl)-5-isoxazolyl]phenyl]-N-[2-(4-methoxybenzoyl)ethyl]Acetamide 867216-85-1P, 2,2-Dichloro-N-[3-[3-(2,6-dichlorophenyl)-5-isoxazolyl]phenyl]-N-[2-(4-chlorobenzoyl)ethyl]Acetamide 867216-86-2P, 2,2-Dichloro-N-[3-[3-(2,6-dichlorophenyl)-5-isoxazolyl]pyridin-4-yl]-N-[2-(4-fluorobenzoyl)ethyl]Acetamide 867216-87-3P, 2,2-Dichloro-N-[3-[3-[2-chloro-6-(N-acetyl-4-piperidinyloxy)phenyl]-5-isoxazolyl]phenyl]-N-[2-(4-fluorobenzoyl)ethyl]Acetamide 867216-88-4P, 2,2-Dichloro-N-[3-[3-(2-cyclopropyl-6-trifluoromethylphenyl)-5-isoxazolyl]phenyl]-N-[2-(4-fluorobenzoyl)ethyl]Acetamide 867216-89-5P, 2,2-Dichloro-N-[3-[3-(2-chloro-6-methoxyphenyl)-5-isoxazolyl]phenyl]-N-[2-(4-fluorobenzoyl)ethyl]Acetamide 867216-90-8P, 2,2-Dichloro-N-[3-[3-(2-chloro-6-tert-butoxycarbonylphenyl)-5-isoxazolyl]phenyl]-N-[2-(4-fluorobenzoyl)ethyl]Acetamide 867216-91-9P, 2,2-Dichloro-N-[3-[3-(2-chloro-6-hydroxycarbonylphenyl)-5-isoxazolyl]phenyl]-N-[2-(4-fluorobenzoyl)ethyl]Acetamide 867216-92-0P, 2,2-Dichloro-N-[3-[3-[2-chloro-6-(methoxycarbonyl)phenyl]-5-isoxazolyl]phenyl]-N-[2-(4-fluorobenzoyl)ethyl]Acetamide 867216-93-1P 867216-94-2P 867216-95-3P 867216-96-4P 867216-97-5P 867216-98-6P **867217-01-4P** **867217-04-7P** 867217-07-0P **867217-10-5P** 867217-13-8P **867217-15-0P** 867217-17-2P **867217-19-4P** 867217-21-8P **867217-23-0P** 867217-25-2P 867217-28-5P 867217-31-0P **867217-34-3P** 867217-39-8P 867217-40-1P **867217-41-2P** **867217-42-3P** **867217-43-4P** **867217-44-5P** 867217-45-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of substituted heterocyclic prodrugs for treating HCV infection)


IT **867215-83-6P**, 2,2-Dichloro-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridyl]-N-[(5-tert-butyl-2-oxo-1,3-dioxol-4-yl)methyl]acetamide

RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of substituted heterocyclic prodrugs for treating HCV infection)

RN 867215-83-6 CAPLUS

CN Acetamide, 2,2-dichloro-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]-N-[(5-(1,1-dimethylethyl)-2-oxo-1,3-dioxol-4-yl)methyl]- (9CI) (CA INDEX NAME)



IT **867215-95-0P**, tert-Butyl 4-[3-[2,2-Dichloro-N-[2-[3-(2,6-


dichlorophenyl)isoxazol-5-yl]pyridin-4-yl]acetamidolpropanoyl]benzoate  
**867216-46-4P**, Di-tert-butyl [[4-[3-[2,2-Dichloro-N-[2-[3-(2,6-dichlorophenyl)isoxazol-5-yl]pyridin-4-yl]acetamidolpropyl]phenyl]methyl]phosphonate

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(drug candidate; preparation of substituted heterocyclic prodrugs for treating HCV infection)


RN 867215-95-0 CAPLUS

CN Benzoic acid, 4-[3-[(dichloroacetyl)[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]amino]-1-oxopropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 867216-46-4 CAPLUS

CN Phosphonic acid, [[4-[3-[(dichloroacetyl)[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]amino]propyl]phenyl]methyl]-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



IT **667931-30-8P** **867215-60-9P**, 2,2-Dichloro-2-(tert-butoxycarbonyl)-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridyl]acetamide **867215-64-3P**, 2,2-Dichloro-2-(methoxycarbonyl)-N-[3-[3-(4-chloro-2-dimethylaminopyridin-3-yl)-5-isoxazolyl]phenyl]acetamide **867215-72-3P**, 2,2-Dichloro-N-[3-[3-(2,4-dichloropyridin-3-yl)-5-isoxazolyl]phenyl]-N-[(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl]acetamide **867215-73-4P**, 2,2-Dichloro-N-[3-[3-(4-chloro-2-dimethylaminopyridin-3-yl)-5-isoxazolyl]phenyl]-N-[(5-methyl-2-




oxo-1,3-dioxol-4-yl)methyl]acetamide **867215-75-6P**,  
2,2-Dichloro-N-[3-[3-(4-chloro-2-dimethylaminopyridin-3-yl)-5-isoxazolyl]phenyl]-N-[(5-isopropyl-2-oxo-1,3-dioxol-4-yl)methyl]acetamide **867215-81-4P**, 2,2-Dichloro-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridyl]-N-[(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl]acetamide **867215-82-5P**, 2,2-Dichloro-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridyl]-N-[(5-isopropyl-2-oxo-1,3-dioxol-4-yl)methyl]acetamide **867215-84-7P**, 2,2-Dichloro-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridyl]-N-[(5-pentyl-2-oxo-1,3-dioxol-4-yl)methyl]acetamide **867215-89-2P**, 2,2-Dichloro-N-[2-[3-(2,6-dichlorophenyl)isoxazol-5-yl]pyridin-4-yl]-N-[3-oxo-3-(pyridin-3-yl)propyl]acetamide **867215-92-7P**, 4-[3-[2,2-Dichloro-N-[2-[3-(2,6-dichlorophenyl)isoxazol-5-yl]pyridin-4-yl]acetamido]propanoyl]benzoic Acid **867215-96-1P**, 2,2-Dichloro-N-[2-[3-(2,6-dichlorophenyl)isoxazol-5-yl]pyridin-4-yl]-N-[3-(morpholino)-3-oxopropyl]acetamide **867216-01-1P**, N-(4-Amino-3-oxo-5-phenylpentyl)-2,2-dichloro-N-[2-[3-(2,6-dichlorophenyl)isoxazol-5-yl]pyridin-4-yl]acetamide **867216-02-2P**, 2,2-Dichloro-N-[2-[3-(2,6-dichlorophenyl)isoxazol-5-yl]pyridin-4-yl]-N-[3-oxo-3-(piperidin-4-yl)propyl]acetamide **867216-03-3P**, 2,2-Dichloro-N-[2-[3-(2,6-dichlorophenyl)isoxazol-5-yl]pyridin-4-yl]-N-[3-oxo-3-(pyrrolidin-2-yl)propyl]acetamide **867216-04-4P**, tert-Butyl 3-[3-[2,2-Dichloro-N-[2-[3-(2,6-dichlorophenyl)isoxazol-5-yl]pyridin-4-yl]acetamido]propanoyl]piperidine-1-carboxylate **867216-06-6P**, 2,2-Dichloro-N-[2-[3-(2,6-dichlorophenyl)isoxazol-5-yl]pyridin-4-yl]-N-[3-oxo-3-(piperidin-3-yl)propyl]acetamide **867216-07-7P**, tert-Butyl 4-[4-[3-[2,2-Dichloro-N-[2-[3-(2,6-dichlorophenyl)isoxazol-5-yl]pyridin-4-yl]acetamido]propanoyl]phenyl]piperazine-1-carboxylate **867216-08-8P**, 4-[[2,2-Dichloro-N-[2-[3-(2,6-dichlorophenyl)isoxazol-5-yl]pyridin-4-yl]acetamido]methyl]-2,6-dimethylphenyl propylcarbamate **867216-32-8P**, 2,2-Dichloro-N-[2-[3-(2,6-dichlorophenyl)isoxazol-5-yl]pyridin-4-yl]-N-[[2-(pyridin-2-yl)ethoxy]methyl]acetamide **867216-40-8P**, 2,2-Dichloro-N-[2-[3-(2,6-dichlorophenyl)isoxazol-5-yl]pyridin-4-yl]-N-[(1-methyl-1H-imidazol-2-yl)methyl]acetamide **867216-42-0P**, [4-[3-[2,2-Dichloro-N-[2-[3-(2,6-dichlorophenyl)isoxazol-5-yl]pyridin-4-yl]acetamido]propyl]benzyl]phosphonic Acid **867216-60-2P**, tert-Butyl 4-[[2,2-Dichloro-N-[2-[3-(2,6-dichlorophenyl)isoxazol-5-yl]pyridin-4-yl]acetamido]methyl]benzoate **867216-61-3P**, 2,2-Dichloro-N-[2-[3-(2,6-dichlorophenyl)isoxazol-5-yl]pyridin-4-yl]-N-[4-(2-morpholinoethoxy)benzyl]acetamide **867216-62-4P**, 2,2-Dichloro-N-[2-[3-(2,6-dichlorophenyl)isoxazol-5-yl]pyridin-4-yl]-N-[4-(4-ethylpiperazin-1-yl)benzyl]acetamide **867216-64-6P**, 2,2-Dichloro-N-[2-[3-(2,6-dichlorophenyl)isoxazol-5-yl]pyridin-4-yl]-N-(2-morpholinoethyl)acetamide **867216-70-4P**, 2,2-Dichloro-N-[2-[3-(2,6-dichlorophenyl)isoxazol-5-yl]pyridin-4-yl]-N-[(5-neopentyl-2-oxo-1,3-dioxol-4-yl)methyl]acetamide **867216-71-5P**, 4-[3-[2,2-Dichloro-N-[2-[3-(2,6-dichlorophenyl)isoxazol-5-yl]pyridin-4-yl]acetamido]propyl]phenyl diethyl phosphate **867216-72-6P**, tert-Butyl 4-[4-[3-[2,2-Dichloro-N-[2-[3-(2,6-dichlorophenyl)isoxazol-5-yl]pyridin-4-yl]acetamido]propyl]phenyl]piperazine-1-carboxylate **867216-73-7P**, tert-Butyl 4-[3-[2,2-Dichloro-N-[2-[3-(2,6-dichlorophenyl)isoxazol-5-yl]pyridin-4-yl]acetamido]propyl]benzoate **867216-74-8P**, 2,2-Dichloro-N-[2-[3-(2,6-dichlorophenyl)isoxazol-5-yl]pyridin-4-yl]-N-[3-[4-(piperazin-1-yl)phenyl]propyl]acetamide **867216-82-8P** **867217-01-4P** **867217-04-7P** **867217-10-5P** **867217-15-0P** **867217-19-4P** **867217-23-0P** **867217-34-3P** **867217-41-2P** **867217-42-3P** **867217-43-4P** **867217-44-5P**  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU

(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of substituted heterocyclic prodrugs for treating HCV infection)


RN 667931-30-8 CAPLUS

CN Acetamide, 2,2-dichloro-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]- (9CI) (CA INDEX NAME)




RN 867215-60-9 CAPLUS

CN Propanoic acid, 2,2-dichloro-3-[[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]amino]-3-oxo-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 867215-64-3 CAPLUS

CN Propanoic acid, 2,2-dichloro-3-[[3-[3-[4-chloro-2-(dimethylamino)-3-pyridinyl]-5-isoxazolyl]phenyl]amino]-3-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 867215-72-3 CAPLUS

CN Acetamide, 2,2-dichloro-N-[3-[3-(2,4-dichloro-3-pyridinyl)-5-isoxazolyl]phenyl]-N-[(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl]-(9CI) (CA INDEX NAME)



RN 867215-73-4 CAPLUS


CN Acetamide, 2,2-dichloro-N-[3-[3-[4-chloro-2-(dimethylamino)-3-pyridinyl]-5-isoxazolyl]phenyl]-N-[(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl]-(9CI) (CA INDEX NAME)



RN 867215-75-6 CAPLUS


CN Acetamide, 2,2-dichloro-N-[3-[3-[4-chloro-2-(dimethylamino)-3-pyridinyl]-5-isoxazolyl]phenyl]-N-[(5-(1-methylethyl)-2-oxo-1,3-dioxol-4-yl)methyl]-(9CI)

(9CI) (CA INDEX NAME)




RN 867215-81-4 CAPLUS

CN Acetamide, 2,2-dichloro-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]-N-[(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 867215-82-5 CAPLUS

CN Acetamide, 2,2-dichloro-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]-N-[[5-(1-methylethyl)-2-oxo-1,3-dioxol-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 867215-84-7 CAPLUS

CN Acetamide, 2,2-dichloro-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]-N-[(2-oxo-5-pentyl-1,3-dioxol-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 867215-89-2 CAPLUS

CN Acetamide, 2,2-dichloro-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]-N-[3-oxo-3-(3-pyridinyl)propyl]- (9CI) (CA INDEX NAME)




RN 867215-92-7 CAPLUS

CN Benzoic acid, 4-[3-[(dichloroacetyl)[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]amino]-1-oxopropyl]- (9CI) (CA INDEX NAME)




RN 867215-96-1 CAPLUS

CN Acetamide, 2,2-dichloro-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazoly]-4-pyridinyl]-N-[3-(4-morpholinyl)-3-oxopropyl]- (9CI) (CA INDEX NAME)




RN 867216-01-1 CAPLUS

CN Acetamide, N-(4-amino-3-oxo-5-phenylpentyl)-2,2-dichloro-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazoly]-4-pyridinyl]- (9CI) (CA INDEX NAME)




RN 867216-02-2 CAPLUS

CN Acetamide, 2,2-dichloro-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazoly]-4-pyridinyl]-N-[3-oxo-3-(4-piperidinyl)propyl]- (9CI) (CA INDEX NAME)




RN 867216-03-3 CAPLUS

CN Acetamide, 2,2-dichloro-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]-N-[3-oxo-3-(2-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)




RN 867216-04-4 CAPLUS

CN 1-Piperidinecarboxylic acid, 3-[3-[(dichloroacetyl)[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]amino]-1-oxopropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 867216-06-6 CAPLUS

CN Acetamide, 2,2-dichloro-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]-N-[3-oxo-3-(3-piperidinyl)propyl]- (9CI) (CA INDEX NAME)




RN 867216-07-7 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[4-[3-[(dichloroacetyl) 2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]amino]-1-oxopropyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 867216-08-8 CAPLUS


CN Carbamic acid, propyl-, 4-[[[(dichloroacetyl) 2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]amino]methyl]-2,6-dimethylphenyl ester (9CI) (CA INDEX NAME)



RN 867216-32-8 CAPLUS




CN Acetamide, 2,2-dichloro-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]-N-[[2-(2-pyridinyl)ethoxy]methyl]- (9CI) (CA INDEX NAME)




RN 867216-40-8 CAPLUS

CN Acetamide, 2,2-dichloro-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]-N-[(1-methyl-1H-imidazol-2-yl)methyl]- (9CI) (CA INDEX NAME)




RN 867216-42-0 CAPLUS

CN Phosphonic acid, [[4-[3-[(dichloroacetyl)[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]amino]propyl]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 867216-60-2 CAPLUS

CN Benzoic acid, 4-[[[(dichloroacetyl) [2-[3-(2,6-dichlorophenyl)-5-isoxazoly]]-4-pyridinyl]amino]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 867216-61-3 CAPLUS

CN Acetamide, 2,2-dichloro-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazoly]]-4-pyridinyl]-N-[[4-[2-(4-morpholinyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 867216-62-4 CAPLUS

CN Acetamide, 2,2-dichloro-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazoly]]-4-pyridinyl]-N-[[4-(4-ethyl-1-piperazinyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 867216-64-6 CAPLUS

CN Acetamide, 2,2-dichloro-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 867216-70-4 CAPLUS

CN Acetamide, 2,2-dichloro-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]-N-[5-(2,2-dimethylpropyl)-2-oxo-1,3-dioxol-4-yl]methyl]- (9CI) (CA INDEX NAME)




RN 867216-71-5 CAPLUS

CN Phosphoric acid, 4-[3-[(dichloroacetyl)[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]aminopropyl]phenyl diethyl ester (9CI) (CA INDEX NAME)




RN 867216-72-6 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[4-[3-[(dichloroacetyl) [2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]amino]propyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 867216-73-7 CAPLUS

CN Benzoic acid, 4-[3-[(dichloroacetyl) [2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]amino]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 867216-74-8 CAPLUS

CN Acetamide, 2,2-dichloro-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]-N-[3-[4-(1-piperazinyl)phenyl]propyl]- (9CI) (CA INDEX NAME)




RN 867216-82-8 CAPLUS

CN Acetamide, 2,2-dichloro-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]-N-[3-(4-fluorophenyl)-3-oxopropyl]- (9CI) (CA INDEX NAME)




RN 867217-01-4 CAPLUS

CN Acetamide, 2,2-dichloro-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]-N-[(4-fluorophenyl)methyl]- (9CI) (CA INDEX NAME)




RN 867217-04-7 CAPLUS

CN Acetamide, 2,2-dichloro-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]-N-[2-(4-fluorophenyl)ethyl]- (9CI) (CA INDEX NAME)




RN 867217-10-5 CAPLUS

CN Acetamide, N-[[4-(acetyloxy)-3,5-dimethylphenyl]methyl]-2,2-dichloro-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]- (9CI) (CA INDEX NAME)



RN 867217-15-0 CAPLUS


CN Glycine, N,N-dimethyl-, 4-[[[(dichloroacetyl) [2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]amino]methyl]-2,6-dimethylphenyl ester (9CI) (CA INDEX NAME)



RN 867217-19-4 CAPLUS


CN Glycine, N-[(1,1-dimethylethoxy)carbonyl]-N-methyl-, 4-

[[[(dichloroacetyl) [2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]amino]methyl]-2,6-dimethylphenyl ester (9CI) (CA INDEX NAME)




RN 867217-23-0 CAPLUS

CN Glycine, N-methyl-, 4-[[[(dichloroacetyl) [2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]amino]methyl]-2,6-dimethylphenyl ester (9CI) (CA INDEX NAME)




RN 867217-34-3 CAPLUS

CN Acetamide, 2,2-dichloro-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]-N-[3-(4-fluorophenyl)propyl]- (9CI) (CA INDEX NAME)




RN 867217-41-2 CAPLUS

CN Propanoic acid, 2,2-dichloro-3-[[3-[3-[2-chloro-4-(4-morpholinyl)-3-pyridinyl]-5-isoxazolyl]phenyl]amino]-3-oxo-, cyclohexyl ester (9CI) (CA INDEX NAME)



RN 867217-42-3 CAPLUS


CN Propanoic acid, 2,2-dichloro-3-[[3-[3-[2-chloro-4-(4-morpholinyl)-3-pyridinyl]-5-isoxazolyl]phenyl]amino]-3-oxo-, ethyl ester (9CI) (CA INDEX NAME)



RN 867217-43-4 CAPLUS


CN Propanoic acid, 2,2-dichloro-3-[[3-[3-[2-chloro-4-(4-morpholinyl)-3-pyridinyl]-5-isoxazolyl]phenyl]amino]-3-oxo-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)





RN 867217-44-5 CAPLUS

CN Propanoic acid, 2,2-dichloro-3-[[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]amino]-3-oxo-, cyclohexyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L50 ANSWER 5 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:979648 CAPLUS

DOCUMENT NUMBER: 143:266935

TITLE: Preparation of isoxazolylphenyl oxadiazole derivatives as inhibitors of hepatitis C virus replication

INVENTOR(S): Goff, Dane; Singh, Rajinder; Li, Hui

PATENT ASSIGNEE(S): Rigel Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 101 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005082898	A1	20050909	WO 2005-US5528	20050223
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,			

LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,  
 NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM,  
 SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW  
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,  
 AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,  
 EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,  
 RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,  
 MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:


US 2004-547009P

P 20040223


OTHER SOURCE(S):

MARPAT 143:266935

GI



I



II

AB Title compds. represented by the formula I [wherein ring B = (aromatic) heterocyclic ring; X, Y, Z = independently C, CH, (un)substituted N, S or N, provided X and Y are not both O; U, T = independently C, CH or N; R1-R6 = independently H, OH, SH, halo, etc.; n = 0-4; R7 is a leaving group; and pharmaceutically acceptable salts, hydrates, solvates, N-oxides, and prodrugs thereof] were prepared as inhibitors of hepatitis C virus (HCV) replication for the treatment of HCV infections. For example, II was given in a multi-step synthesis starting from 2,6-dichlorobenzaldoxime. I were tested for inhibition of HCV replication using a quant. Western blot anal.

IC ICM C07D413-10

ICS A61K031-4245; A61P031-00

CC 28-10 (Heterocyclic Compounds (More Than One Hetero Atom))

Section cross-reference(s): 1

REFERENCE COUNT:

7

THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS  
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L50 ANSWER 6 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN


ACCESSION NUMBER: 2004:996145 CAPLUS

DOCUMENT NUMBER: 141:424168


TITLE: Preparation of 1,3-diaryl-substituted five-membered  
 aromatic heterocycles and their di- and tetrahydro  
 derivatives as inhibitors of hepatitis C virus

replication for treatment of hepatitis C infection  
 INVENTOR(S) : Singh, Rajinder; Goff, Dane;  
 Partridge, John J.  
 PATENT ASSIGNEE(S) : Rigel Pharmaceuticals, Inc., USA  
 SOURCE: PCT Int. Appl., 210 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004099165	A2	20041118	WO 2004-US13452	20040430
WO 2004099165	A3	20051103		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 2004254227	A1	20041216	US 2004-836561	20040430
EP 1620412	A2	20060201	EP 2004-751046	20040430
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR			
PRIORITY APPLN. INFO.:			US 2003-467650P	P 20030502
			WO 2004-US13452	W 20040430
OTHER SOURCE(S) :	MARPAT 141:424168			
GI				



I



II

AB 1,3-Diaryl-substituted five-membered heterocycles I [B ring = aromatic, partially saturated, or fully saturated heterocycle; X, Y, Z = C, CH, N, NR, O, S;

U, T = C, CH, N; U, T are not both C, X and Y are not O; Z = CH when X = Y = N; R = H, (un)substituted alkyl, cycloalkyl, heterocycloalkyl, haloalkyl, alkoxy, alkylthio, monohalomethyl, dihalomethyl, trihalomethyl, etc.; R2, R3, R4, R5, R6, R8, R9, R10, R13 = H, HO, HS, NC, O2N, N3, halo, (un)substituted alkyl, cycloalkyl, cycloheteroalkyl, etc.; R11 = H, alkyl; R12 = monohalomethyl, dihalomethyl] such as II are prepared as replication inhibitors for the hepatitis C virus for treatment of hepatitis C infection. 2,6-Dichlorophenylacetylene and 3-nitro-N-hydroxybenzenecarboximidoyl chloride undergo thermal cycloaddn. to an isoxazole; reduction of the nitro group to an amine and acylation with dichloroacetyl chloride yields II. The title compds. inhibit hepatitis C replication (no data).

IC ICM C07D263-32

ICS C07D271-06; C07D275-02; C07D277-10; A61K031-00

CC 28-1 (Heterocyclic Compounds (More Than One Hetero Atom))  
Section cross-reference(s): 1

L50 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:996144 CAPLUS

DOCUMENT NUMBER: 141:410935

TITLE: Preparation of substituted diphenyl isoxazoles, pyrazoles and oxadiazoles for treating HCV infection

INVENTOR(S): Singh, Rajinder; Goff, Dane; Partridge, John

PATENT ASSIGNEE(S): Rigel Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 188 pp.


CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004099164	A1	20041118	WO 2004-US13492	20040503
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004266840	A1	20041230	US 2004-838133	20040503
PRIORITY APPLN. INFO.:			US 2003-467811P	P 20030502
OTHER SOURCE(S):		MARPAT 141:410935		

GI



I

AB The present invention relates to substituted di-Ph heterocycle compds. I [X, Y = N, O, provided that X and Y are not both O; Z = N, CH, provided that Z = CH when X and Y are both N; R2-R5, R8-R10, R13 = H, OH, SH, CN, etc.; R11 = H, alkyl; R12 = dihalomethyl; R6 = (un)substituted piperazino, piperidino, pyrrolidino, etc.] and pharmaceutical compns. thereof that inhibit replication of HCV virus. E.g., a 3-step synthesis of 2,2-dichloro-N-{3-[3-(2,6-dichlorophenyl)-5-isoxazolyl]phenyl}acetamide, starting from 2,6-dichlorobenzaldoxime, was given. Exemplary compds. I were tested in HCV replicon assay and/or in Western blot assay (biol. data given). The present invention also relates to the use of the compds. and/or compns. (such as liposome suspension) to inhibit HCV replication and/or proliferation and to treat or prevent HCV infections.

IC ICM C07D261-08

ICS C07D271-06; A61K031-42; A61K031-4245

CC 28-10 (Heterocyclic Compounds (More Than One Hetero Atom))

Section cross-reference(s): 1, 63


REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L50 ANSWER 8 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:376833 CAPLUS  
 DOCUMENT NUMBER: 138:368880  
 TITLE: Preparation of substituted diphenyl heterocycles for treating HCV infection  
 INVENTOR(S): Singh, Rajinder; Goff, Dane; Lu, Henry; Issankani, Sarkiz D.; Sun, Thomas  
 PATENT ASSIGNEE(S): Rigel Pharmaceuticals, Inc., USA  
 SOURCE: PCT Int. Appl., 103 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003040112	A1	20030515	WO 2002-US35131	20021101
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2465189	AA	20030515	CA 2002-2465189	20021101
US 2003165561	A1	20030904	US 2002-286017	20021101
US 6759538	B2	20040706		
BR 2002006266	A	20031230	BR 2002-6266	20021101
EP 1451162	A1	20040901	EP 2002-784378	20021101
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
JP 2005511604	T2	20050428	JP 2003-542158	20021101
NZ 532317	A	20051028	NZ 2002-532317	20021101
US 2004236112	A1	20041125	US 2004-873914	20040622
PRIORITY APPLN. INFO.:			US 2001-350107P	P 20011102
			US 2002-405472P	P 20020823
			US 2002-286017	A3 20021101
			WO 2002-US35131	W 20021101

OTHER SOURCE(S): MARPAT 138:368880  
 GI



AB The title compds. [I; X, Y = N, O, provided that X and Y are not both O; Z = N, CH, provided that Z = CH when X and Y are both N; R2-R6, R8-R10, R13 = H, OH, SH, etc.; R11 = alkyl; R12 = monohalomethyl, dihalomethyl] that inhibit replication of HCV virus, were prepared and formulated. Thus,

reacting 2,6-dichloro-N-hydroxybenzenecarboximidoyl chloride with 2,2-dichloro-N-(3-ethynylphenyl)acetamide (prepns. given) in the presence of Et<sub>3</sub>N in THF afforded I [X = N; Y = O; Z = CH; R<sub>2</sub> = Cl; R<sub>3</sub>-R<sub>5</sub> = H; R<sub>6</sub> = Cl; R<sub>8</sub>-R<sub>11</sub> = H; R<sub>12</sub> = CHCl<sub>2</sub>; R<sub>13</sub> = H] which was evaluated for in rats by both s.c. and i.v. administration, and doses as high as 30 mg/kg/day were well tolerated.

IC ICM C07D261-08

ICS A61K031-42

CC 28-6 (Heterocyclic Compounds (More Than One Hetero Atom))

Section cross-reference(s): 1, 63

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L50 ANSWER 9 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1997:218872 CAPLUS

DOCUMENT NUMBER: 126:293272

TITLE: Developing a general strategy for the solid supported synthesis of heterocycles: applications to the generation of molecular diversity and drug discovery

AUTHOR(S): Nuss, John M.; Desai, Manoj C.; Zuckermann, Ronald N.; Singh, Rajinder; Renhowe, Paul A.; Goff, Dane A.; Chinn, Jason P.; Wang, Liang; Dorr, Hilary; Brown, Edward G.; Subramanian, Sharadha

CORPORATE SOURCE: Chiron Corp., Emeryville, CA, 94608, USA

SOURCE: Pure and Applied Chemistry (1997), 69(3), 447-452

CODEN: PACHAS; ISSN: 0033-4545

PUBLISHER: Blackwell

DOCUMENT TYPE: Journal; General Review

LANGUAGE: English

AB The development of a general strategy for the generation of mol. diversity in the form of novel, non-amide based heterocyclic structures is described with 19 refs. The generation of diverse peptide and peptidomimetic libraries, the automation of these strategies and computational approaches to diversity generation are also discussed. The main focus of this lecture is the progression of these concepts into a strategy for small mol. library generation, and hence the generation of small mol. therapeutic leads.

CC 28-0 (Heterocyclic Compounds (More Than One Hetero Atom))

Section cross-reference(s): 34

REFERENCE COUNT: 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L50 ANSWER 10 OF 15 USPATFULL on STN

ACCESSION NUMBER: 2005:275188 USPATFULL

TITLE: Heterocyclic anti-viral compounds comprising metabolizable moieties and their uses

INVENTOR(S): Singh, Rajinder, Belmont, CA, UNITED STATES  
Goff, Dane, Redwood City, CA, UNITED STATES  
Kolluri, Rao S. S., Foster City, CA, UNITED STATES  
Darwish, Ihab S., San Mateo, CA, UNITED STATES  
Partridge, John J., Chapel Hill, NC, UNITED STATES

Cooper, Robin, St. George Island, FL, UNITED STATES

Lu, Henry H., Foster City, CA, UNITED STATES

Park, Gary, Moss Beach, CA, UNITED STATES

PATENT ASSIGNEE(S): Rigel Pharmaceuticals, Inc., South San Francisco, CA, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005239751	A1	20051027
APPLICATION INFO.:	US 2005-90823	A1	20050325 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2004-556625P	20040326 (60)
	US 2004-582903P	20040624 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	MCDONNELL BOEHNNEN HULBERT & BERGHOFF LLP, 300 S. WACKER DRIVE, 32ND FLOOR, CHICAGO, IL, 60606, US	
NUMBER OF CLAIMS:	54	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	24 Drawing Page(s)	
LINE COUNT:	4411	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


AB The present invention relates to substituted prodrug and compositions thereof useful for treating or preventing Hepatitis C virus (HCV) infections. In particular, the present invention relates to prodrugs of substituted diphenyl-, diheteroaryl- and mixed phenyl heteroaryl substituted five-membered heterocycle compounds, compositions comprising the compounds and the use of such compounds and compositions to inhibit HCV replication and/or proliferation as a therapeutic approach towards the treatment and/or prevention of HCV infections in humans and animals.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **867215-83-6P**, 2,2-Dichloro-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridyl]-N-[(5-tert-butyl-2-oxo-1,3-dioxol-4-yl)methyl]acetamide  
(drug candidate; preparation of substituted heterocyclic prodrugs for treating HCV infection)

RN 867215-83-6 USPATFULL

CN Acetamide, 2,2-dichloro-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]-N-[[5-(1,1-dimethylethyl)-2-oxo-1,3-dioxol-4-yl]methyl]-  
(9CI) (CA INDEX NAME)




IT **867215-95-0P**, tert-Butyl 4-[3-[2,2-Dichloro-N-[2-[3-(2,6-dichlorophenyl)isoxazol-5-yl]pyridin-4-yl]acetamido]propanoyl]benzoate  
**867216-46-4P**, Di-tert-butyl [[4-[3-[2,2-Dichloro-N-[2-[3-(2,6-dichlorophenyl)isoxazol-5-yl]pyridin-4-yl]acetamido]propyl]phenyl]methyl]phosphonate



(drug candidate; preparation of substituted heterocyclic prodrugs for treating HCV infection)


RN 867215-95-0 USPATFULL

CN Benzoic acid, 4-[3-[(dichloroacetyl)[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]amino]-1-oxopropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 867216-46-4 USPATFULL

CN Phosphonic acid, [[4-[3-[(dichloroacetyl)[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]amino]propyl]phenyl]methyl]-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)




IT 667931-30-8P 867215-60-9P, 2,2-Dichloro-2-(tert-butoxycarbonyl)-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridyl]acetamide 867215-64-3P, 2,2-Dichloro-2-(methoxycarbonyl)-N-[3-[3-(4-chloro-2-dimethylaminopyridin-3-yl)-5-isoxazolyl]phenyl]acetamide 867215-72-3P, 2,2-Dichloro-N-[3-[3-(2,4-dichloropyridin-3-yl)-5-isoxazolyl]phenyl]-N-[(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl]acetamide 867215-73-4P, 2,2-Dichloro-N-[3-[3-(4-chloro-2-dimethylaminopyridin-3-yl)-5-isoxazolyl]phenyl]-N-[(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl]acetamide 867215-75-6P, 2,2-Dichloro-N-[3-[3-(4-chloro-2-dimethylaminopyridin-3-yl)-5-isoxazolyl]phenyl]-N-[(5-isopropyl-2-oxo-1,3-dioxol-4-yl)methyl]acetamide 867215-81-4P, 2,2-Dichloro-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridyl]-N-[(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl]acetamide 867215-82-5P, 2,2-Dichloro-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridyl]-N-[(5-isopropyl-2-oxo-1,3-dioxol-

4-yl)methyl]acetamide **867215-84-7P**, 2,2-Dichloro-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridyl]-N-[(5-pentyl-2-oxo-1,3-dioxol-4-yl)methyl]acetamide **867215-89-2P**, 2,2-Dichloro-N-[2-[3-(2,6-dichlorophenyl)isoxazol-5-yl]pyridin-4-yl]-N-[3-oxo-3-(pyridin-3-yl)propyl]acetamide **867215-92-7P**, 4-[3-[2,2-Dichloro-N-[2-[3-(2,6-dichlorophenyl)isoxazol-5-yl]pyridin-4-yl]acetamido]propanoyl]benzoic Acid **867215-96-1P**, 2,2-Dichloro-N-[2-[3-(2,6-dichlorophenyl)isoxazol-5-yl]pyridin-4-yl]-N-[3-(morpholino)-3-oxopropyl]acetamide **867216-01-1P**, N-(4-Amino-3-oxo-5-phenylpentyl)-2,2-dichloro-N-[2-[3-(2,6-dichlorophenyl)isoxazol-5-yl]pyridin-4-yl]acetamide **867216-02-2P**, 2,2-Dichloro-N-[2-[3-(2,6-dichlorophenyl)isoxazol-5-yl]pyridin-4-yl]-N-[3-oxo-3-(piperidin-4-yl)propyl]acetamide **867216-03-3P**, 2,2-Dichloro-N-[2-[3-(2,6-dichlorophenyl)isoxazol-5-yl]pyridin-4-yl]-N-[3-oxo-3-(pyrrolidin-2-yl)propyl]acetamide **867216-04-4P**, tert-Butyl 3-[3-[2,2-Dichloro-N-[2-[3-(2,6-dichlorophenyl)isoxazol-5-yl]pyridin-4-yl]acetamido]propanoyl]piperidine-1-carboxylate **867216-06-6P**, 2,2-Dichloro-N-[2-[3-(2,6-dichlorophenyl)isoxazol-5-yl]pyridin-4-yl]-N-[3-oxo-3-(piperidin-3-yl)propyl]acetamide **867216-07-7P**, tert-Butyl 4-[4-[3-[2,2-Dichloro-N-[2-[3-(2,6-dichlorophenyl)isoxazol-5-yl]pyridin-4-yl]acetamido]propanoyl]phenyl]piperazine-1-carboxylate **867216-08-8P**, 4-[2,2-Dichloro-N-[2-[3-(2,6-dichlorophenyl)isoxazol-5-yl]pyridin-4-yl]acetamido]methyl]-2,6-dimethylphenyl propylcarbamate **867216-32-8P**, 2,2-Dichloro-N-[2-[3-(2,6-dichlorophenyl)isoxazol-5-yl]pyridin-4-yl]-N-[[2-(pyridin-2-yl)ethoxy]methyl]acetamide **867216-40-8P**, 2,2-Dichloro-N-[2-[3-(2,6-dichlorophenyl)isoxazol-5-yl]pyridin-4-yl]-N-[(1-methyl-1H-imidazol-2-yl)methyl]acetamide **867216-42-0P**, [4-[3-[2,2-Dichloro-N-[2-[3-(2,6-dichlorophenyl)isoxazol-5-yl]pyridin-4-yl]acetamido]propyl]benzyl]phosphonic Acid **867216-60-2P**, tert-Butyl 4-[2,2-Dichloro-N-[2-[3-(2,6-dichlorophenyl)isoxazol-5-yl]pyridin-4-yl]acetamido]methyl]benzoate **867216-61-3P**, 2,2-Dichloro-N-[2-[3-(2,6-dichlorophenyl)isoxazol-5-yl]pyridin-4-yl]-N-[4-(2-morpholinoethoxy)benzyl]acetamide **867216-62-4P**, 2,2-Dichloro-N-[2-[3-(2,6-dichlorophenyl)isoxazol-5-yl]pyridin-4-yl]-N-[4-(4-ethylpiperazin-1-yl)benzyl]acetamide **867216-64-6P**, 2,2-Dichloro-N-[2-[3-(2,6-dichlorophenyl)isoxazol-5-yl]pyridin-4-yl]-N-(2-morpholinoethyl)acetamide **867216-70-4P**, 2,2-Dichloro-N-[2-[3-(2,6-dichlorophenyl)isoxazol-5-yl]pyridin-4-yl]-N-[(5-neopentyl-2-oxo-1,3-dioxol-4-yl)methyl]acetamide **867216-71-5P**, 4-[3-[2,2-Dichloro-N-[2-[3-(2,6-dichlorophenyl)isoxazol-5-yl]pyridin-4-yl]acetamido]propyl]phenyl diethyl phosphate **867216-72-6P**, tert-Butyl 4-[4-[3-[2,2-Dichloro-N-[2-[3-(2,6-dichlorophenyl)isoxazol-5-yl]pyridin-4-yl]acetamido]propyl]phenyl]piperazine-1-carboxylate **867216-73-7P**, tert-Butyl 4-[3-[2,2-Dichloro-N-[2-[3-(2,6-dichlorophenyl)isoxazol-5-yl]pyridin-4-yl]acetamido]propyl]benzoate **867216-74-8P**, 2,2-Dichloro-N-[2-[3-(2,6-dichlorophenyl)isoxazol-5-yl]pyridin-4-yl]-N-[3-[4-(piperazin-1-yl)phenyl]propyl]acetamide **867216-82-8P** **867217-01-4P** **867217-04-7P** **867217-10-5P** **867217-15-0P** **867217-19-4P** **867217-23-0P** **867217-34-3P** **867217-41-2P** **867217-42-3P** **867217-43-4P** **867217-44-5P**

(drug candidate; preparation of substituted heterocyclic prodrugs for treating HCV infection)


RN 667931-30-8 USPTAFULL

CN Acetamide, 2,2-dichloro-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]- (9CI) (CA INDEX NAME)




RN 867215-60-9 USPATFULL

CN Propanoic acid, 2,2-dichloro-3-[[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]amino]-3-oxo-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 867215-64-3 USPATFULL

CN Propanoic acid, 2,2-dichloro-3-[[3-[3-[4-chloro-2-(dimethylamino)-3-pyridinyl]-5-isoxazolyl]phenyl]amino]-3-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 867215-72-3 USPATFULL

CN Acetamide, 2,2-dichloro-N-[3-[3-(2,4-dichloro-3-pyridinyl)-5-isoxazolyl]phenyl]-N-[(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 867215-73-4 USPATFULL

CN Acetamide, 2,2-dichloro-N-[3-[3-[4-chloro-2-(dimethylamino)-3-pyridinyl]-5-isoxazolyl]phenyl]-N-[(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl]- (9CI)  
(CA INDEX NAME)



RN 867215-75-6 USPATFULL


CN Acetamide, 2,2-dichloro-N-[3-[3-[4-chloro-2-(dimethylamino)-3-pyridinyl]-5-isoxazolyl]phenyl]-N-[(5-(1-methylethyl)-2-oxo-1,3-dioxol-4-yl)methyl]- (9CI)  
(CA INDEX NAME)



RN 867215-81-4 USPATFULL


CN Acetamide, 2,2-dichloro-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]-N-[(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl]- (9CI)  
(CA INDEX NAME)

NAME)




RN 867215-82-5 USPATFULL

CN Acetamide, 2,2-dichloro-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]-N-[[5-(1-methylethyl)-2-oxo-1,3-dioxol-4-yl]methyl]- (9CI)  
(CA INDEX NAME)




RN 867215-84-7 USPATFULL

CN Acetamide, 2,2-dichloro-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]-N-[[2-oxo-5-pentyl-1,3-dioxol-4-yl]methyl]- (9CI) (CA INDEX NAME)




RN 867215-89-2 USPTAFULL

CN Acetamide, 2,2-dichloro-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]-N-[3-oxo-3-(3-pyridinyl)propyl]- (9CI) (CA INDEX NAME)




RN 867215-92-7 USPTAFULL

CN Benzoic acid, 4-[3-[(dichloroacetyl)[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]amino]-1-oxopropyl]- (9CI) (CA INDEX NAME)




RN 867215-96-1 USPTAFULL

CN Acetamide, 2,2-dichloro-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]-N-[3-(4-morpholinyl)-3-oxopropyl]- (9CI) (CA INDEX NAME)




RN 867216-01-1 USPATFULL

CN Acetamide, N-(4-amino-3-oxo-5-phenylpentyl)-2,2-dichloro-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]- (9CI) (CA INDEX NAME)




RN 867216-02-2 USPATFULL

CN Acetamide, 2,2-dichloro-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]-N-[3-oxo-3-(4-piperidinyl)propyl]- (9CI) (CA INDEX NAME)




RN 867216-03-3 USPATFULL

CN Acetamide, 2,2-dichloro-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]-N-[3-oxo-3-(2-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)




RN 867216-04-4 USPTFULL

CN 1-Piperidinecarboxylic acid, 3-[3-[(dichloroacetyl) [2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]amino]-1-oxopropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 867216-06-6 USPTFULL


CN Acetamide, 2,2-dichloro-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]-N-[3-oxo-3-(3-piperidinyl)propyl]- (9CI) (CA INDEX NAME)



RN 867216-07-7 USPTFULL


CN 1-Piperazinecarboxylic acid, 4-[4-[3-[(dichloroacetyl) [2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]amino]-1-oxopropyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)






RN 867216-08-8 USPATFULL

CN Carbamic acid, propyl-, 4-[[[(dichloroacetyl) [2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]amino]methyl]-2,6-dimethylphenyl ester (9CI)  
(CA INDEX NAME)




RN 867216-32-8 USPATFULL

CN Acetamide, 2,2-dichloro-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]-N-[[2-(2-pyridinyl)ethoxy]methyl]- (9CI) (CA INDEX NAME)




RN 867216-40-8 USPATFULL

CN Acetamide, 2,2-dichloro-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]-N-[(1-methyl-1H-imidazol-2-yl)methyl]- (9CI) (CA INDEX NAME)




RN 867216-42-0 USPATFULL

CN Phosphonic acid, [[4-[3-[(dichloroacetyl) 2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]amino]propyl]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 867216-60-2 USPATFULL

CN Benzoic acid, 4-[[[(dichloroacetyl) 2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]amino]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 867216-61-3 USPATFULL

CN Acetamide, 2,2-dichloro-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]-N-[[4-[2-(4-morpholinyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 867216-62-4 USPATFULL

CN Acetamide, 2,2-dichloro-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]-N-[[4-(4-ethyl-1-piperazinyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 867216-64-6 USPATFULL

CN Acetamide, 2,2-dichloro-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 867216-70-4 USPATFULL

CN Acetamide, 2,2-dichloro-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]-N-[[5-(2,2-dimethylpropyl)-2-oxo-1,3-dioxol-4-yl]methyl]- (9CI) (CA INDEX NAME)




RN 867216-71-5 USPATFULL

CN Phosphoric acid, 4-[3-[(dichloroacetyl)[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]amino]propyl]phenyl diethyl ester (9CI) (CA INDEX NAME)




RN 867216-72-6 USPATFULL

CN 1-Piperazinecarboxylic acid, 4-[4-[3-[(dichloroacetyl)[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]amino]propyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 867216-73-7 USPATFULL

CN Benzoic acid, 4-[3-[(dichloroacetyl)[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]amino]propyl]-, 1,1-dimethylethyl ester (9CI)  
(CA INDEX NAME)


RN 867216-74-8 USPATFULL

CN Acetamide, 2,2-dichloro-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]-N-[3-[4-(1-piperazinyl)phenyl]propyl]- (9CI) (CA INDEX NAME)




RN 867216-82-8 USPATFULL

CN Acetamide, 2,2-dichloro-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]-N-[3-(4-fluorophenyl)-3-oxopropyl]- (9CI) (CA INDEX NAME)




RN 867217-01-4 USPATFULL

CN Acetamide, 2,2-dichloro-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]-N-[(4-fluorophenyl)methyl]- (9CI) (CA INDEX NAME)




RN 867217-04-7 USPATFULL

CN Acetamide, 2,2-dichloro-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]-N-[2-(4-fluorophenyl)ethyl]- (9CI) (CA INDEX NAME)




RN 867217-10-5 USPATFULL

CN Acetamide, N-[[4-(acetyloxy)-3,5-dimethylphenyl]methyl]-2,2-dichloro-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]- (9CI) (CA INDEX NAME)




RN 867217-15-0 USPATFULL

CN Glycine, N,N-dimethyl-, 4-[[[(dichloroacetyl) [2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]amino]methyl]-2,6-dimethylphenyl ester (9CI)  
(CA INDEX NAME)



RN 867217-19-4 USPATFULL


CN Glycine, N-[(1,1-dimethylethoxy)carbonyl]-N-methyl-, 4-[[[(dichloroacetyl) [2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]amino]methyl]-2,6-dimethylphenyl ester (9CI) (CA INDEX NAME)




RN 867217-23-0 USPATFULL

CCNC(=O)Oc1c(C)c(C)cc(CCN(Cc2ccc(NC(=O)CCl)c3ccccc3Cl)c2)c1

CN    Acetamide, 2,2-dichloro-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazoly]-4-pyridinyl]-N-[3-(4-fluorophenyl)propyl]- (9CI)    (CA INDEX NAME)




CN Propanoic acid, 2,2-dichloro-3-[[3-[3-[2-chloro-4-(4-morpholinyl)-3-pyridinyl]-5-isoxazolyl]phenyl]amino]-3-oxo-, cyclohexyl ester (9CI)  
(CA INDEX NAME)



Page 84




CN Propanoic acid, 2,2-dichloro-3-[[3-[3-[2-chloro-4-(4-morpholinyl)-3-pyridinyl]-5-isoxazolyl]phenyl]amino]-3-oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 867217-43-4 USPATFULL

CN Propanoic acid, 2,2-dichloro-3-[[3-[3-[2-chloro-4-(4-morpholinyl)-3-pyridinyl]-5-isoxazolyl]phenyl]amino]-3-oxo-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 867217-44-5 USPATFULL

CN Propanoic acid, 2,2-dichloro-3-[[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]amino]-3-oxo-, cyclohexyl ester (9CI) (CA INDEX NAME)



L50 ANSWER 11 OF 15 USPATFULL on STN

ACCESSION NUMBER: 2004:335746 USPATFULL

TITLE: Substituted diphenyl isoxazoles, pyrazoles and oxadiazoles useful for treating HCV infection

INVENTOR(S): Singh, Rajinder, Belmont, CA, UNITED STATES  
Goff, Dane, Redwood City, CA, UNITED STATES  
Partridge, John J., Chapel Hill, NC, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004266840	A1	20041230
APPLICATION INFO.:	US 2004-838133	A1	20040503 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-467811P	20030502 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Scott D. Rothenberger, Esq., DORSEY & WHITNEY LLP, Intellectual Property Department, 50 South Sixth Street, Suite 1500, Minneapolis, MN, 55402-1498	
NUMBER OF CLAIMS:	33	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	22 Drawing Page(s)	
LINE COUNT:	4515	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to substituted diphenyl heterocycle compounds and pharmaceutical compositions thereof that inhibit replication of HCV virus. The present invention also relates to the use of the compounds and/or compositions to inhibit HCV replication and/or proliferation and to treat or prevent HCV infections.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L50 ANSWER 12 OF 15 USPATFULL on STN

ACCESSION NUMBER: 2004:321572 USPATFULL

TITLE: Heterocyclic compounds and hydro isomers thereof

INVENTOR(S): Singh, Rajinder, Belmont, CA, UNITED STATES  
Goff, Dane, Redwood City, CA, UNITED STATES  
Partridge, John J., Chapel Hill, NC, UNITED STATES

NUMBER	KIND	DATE
-----	-----	-----

PATENT INFORMATION: US 2004254227 A1 20041216  
 APPLICATION INFO.: US 2004-836561 A1 20040430 (10)

	NUMBER	DATE
	-----	-----
PRIORITY INFORMATION:	US 2003-467650P	20030502 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Scott D. Rothenberger, Esq., DORSEY & WHITNEY LLP, Intellectual Property Department, 50 South Sixth Street, Suite 1500, Minneapolis, MN, 55402-1498	
NUMBER OF CLAIMS:	40	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	84 Drawing Page(s)	
LINE COUNT:	4269	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		
AB	The present invention relates to substituted diphenyl heterocycle compounds and pharmaceutical compositions thereof that inhibit replication of HCV virus. The present invention also relates to the use of the compounds and/or compositions to inhibit HCV replication and/or proliferation and to treat or prevent HCV infections.	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L50 ANSWER 13 OF 15 USPATFULL on STN

ACCESSION NUMBER: 2004:300242 USPATFULL  
 TITLE: Substituted diphenyl heterocycles useful for treating  
HCV infection  
 INVENTOR(S): Singh, Rajinder, Belmont, CA, UNITED STATES  
 Goff, Dane, Redwood, CA, UNITED STATES  
 Lu, Henry, Foster, CA, UNITED STATES  
 Issakani, Sarkiz D., San Jose, CA, UNITED STATES  
 Sun, Thomas, Fremont, CA, UNITED STATES

	NUMBER	KIND	DATE
	-----	-----	-----
PATENT INFORMATION:	US 2004236112	A1	20041125
APPLICATION INFO.:	US 2004-873914	A1	20040622 (10)
RELATED APPLN. INFO.:	Division of Ser. No. US 2002-286017, filed on 1 Nov 2002, GRANTED, Pat. No. US 6759538		

	NUMBER	DATE
	-----	-----
PRIORITY INFORMATION:	US 2001-350107P	20011102 (60)
	US 2002-405472P	20020823 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Scott D. Rothenberger, Esq., DORSEY & WHITNEY LLP, Intellectual Property Department, 50 South Sixth Street, Suite 1500, Minneapolis, MN, 55402-1498	
NUMBER OF CLAIMS:	18	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	16 Drawing Page(s)	
LINE COUNT:	2838	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		
AB	The present invention relates to substituted diphenyl heterocycle compounds and pharmaceutical compositions thereof that inhibit replication of HCV virus. The present invention also relates to the use of the compounds and/or compositions to inhibit HCV replication and/or proliferation and to treat or prevent HCV infections.	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L50 ANSWER 14 OF 15 USPATFULL on STN

ACCESSION NUMBER: 2004:166007 USPATFULL

TITLE: Pyridyl substituted heterocycles useful for treating or preventing HCV infection

INVENTOR(S): Singh, Rajinder, Belmont, CA, UNITED STATES  
Goff, Dane, Redwood City, CA, UNITED STATES  
Partridge, John, Chapel Hill, NC, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004127497	A1	20040701
APPLICATION INFO.:	US 2003-646348	A1	20030822 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-405467P	20020823 (60)
	US 2002-417837P	20021011 (60)
	US 2003-471373P	20030515 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: Scott D. Rothenberger, DORSEY & WHITNEY LLP,  
Intellectual Property Department, 50 South Sixth  
Street, Suite 1500, Minneapolis, MN, 55402-1498

NUMBER OF CLAIMS: 58

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 84 Drawing Page(s)

LINE COUNT: 2422

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to pyridyl substituted heterocycles and hydro isomers thereof and pharmaceutical compositions thereof that inhibit replication and/or proliferation of HCV virus. The present invention also relates to the use of the pyridyl heterocycles and hydro isomers thereof and/or pharmaceutical compositions comprising the compounds to treat or prevent HCV infections.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 667931-22-8P 667931-24-0P 667931-28-4P  
667931-30-8P 667931-32-0P 667931-34-2P  
667931-36-4P 667931-38-6P 667931-40-0P  
667931-42-2P 667931-44-4P 667931-46-6P  
667931-48-8P 667931-50-2P 667931-52-4P  
667931-60-4P 667931-62-6P 667931-64-8P  
667931-68-2P 667931-80-8P

(drug candidate; prepare and cytotoxicity of pyridylisoxazoles for treatment of hepatitis C virus infections)


RN 667931-22-8 USPATFULL

CN Acetamide, 2,2-dichloro-N-[2-[3-(2-chloro-6-fluorophenyl)-5-isoxazolyl]-4-pyridinyl]- (9CI) (CA INDEX NAME)




RN 667931-24-0 USPATFULL

CN Acetamide, 2,2-dichloro-N-[2-[3-[2-fluoro-6-(trifluoromethyl)phenyl]-5-isoxazolyl]-4-pyridinyl]- (9CI) (CA INDEX NAME)




RN 667931-28-4 USPATFULL

CN Acetamide, 2,2-dichloro-N-[5-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 667931-30-8 USPATFULL

CN Acetamide, 2,2-dichloro-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]- (9CI) (CA INDEX NAME)




RN 667931-32-0 USPATFULL

CN Acetamide, 2,2-dichloro-N-[3-[3-(3,5-dichloro-4-pyridinyl)-5-isoxazolyl]phenyl]- (9CI) (CA INDEX NAME)




RN 667931-34-2 USPATFULL

CN Acetamide, 2,2-dichloro-N-[5-[3-(2-chloro-6-fluorophenyl)-5-isoxazolyl]-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 667931-36-4 USPATFULL

CN Acetamide, 2,2-dichloro-N-[5-[3-(2-fluoro-6-methoxyphenyl)-5-isoxazolyl]-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 667931-38-6 USPATFULL

CN Acetamide, 2,2-dichloro-N-[2-[3-(2,6-dimethylphenyl)-5-isoxazolyl]-4-pyridinyl]- (9CI) (CA INDEX NAME)




RN 667931-40-0 USPATFULL

CN Acetamide, 2,2-dichloro-N-[5-[3-(2,6-dimethylphenyl)-5-isoxazolyl]-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 667931-42-2 USPATFULL

CN Acetamide, 2,2-dichloro-N-[5-[3-(2,6-difluorophenyl)-5-isoxazolyl]-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 667931-44-4 USPATFULL

CN Acetamide, 2,2-dichloro-N-[5-[3-(2,3-dichlorophenyl)-5-isoxazolyl]-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 667931-46-6 USPATFULL


CN Acetamide, 2,2-dichloro-N-[2-[3-[2-(4-morpholinyl)-6-(trifluoromethyl)phenyl]-5-isoxazolyl]-4-pyridinyl]- (9CI) (CA INDEX NAME)



RN 667931-48-8 USPATFULL


CN Acetamide, 2,2-dichloro-N-[3-[3-(3-methyl-2-pyridinyl)-5-isoxazolyl]phenyl]- (9CI) (CA INDEX NAME)






RN 667931-50-2 USPATFULL

CN Acetamide, 2,2-dichloro-N-[6-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 667931-52-4 USPATFULL

CN Acetamide, 2,2-dichloro-N-[5-[3-[2-fluoro-6-(trifluoromethyl)phenyl]-5-isoxazolyl]-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 667931-60-4 USPATFULL

CN Acetamide, 2,2-dichloro-N-[2-[3-[2-fluoro-6-(4-morpholinylsulfonyl)phenyl]-5-isoxazolyl]-4-pyridinyl]- (9CI) (CA INDEX NAME)




RN 667931-62-6 USPATFULL

CN Acetamide, 2,2-dichloro-N-[2-[3-[2-methoxy-6-(trifluoromethyl)phenyl]-5-isoxazolyl]-4-pyridinyl]- (9CI) (CA INDEX NAME)




RN 667931-64-8 USPATFULL

CN Acetamide, 2,2-dichloro-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 667931-68-2 USPATFULL

CN Acetamide, 2,2-dichloro-N-[5-[3-[2-methoxy-6-(trifluoromethyl)phenyl]-5-isoxazolyl]-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 667931-80-8 USPATFULL

CN Acetamide, 2,2-dichloro-N-[5-[3-[2-chloro-6-[4-(2-pyridinyl)-1-piperazinyl]phenyl]-5-isoxazolyl]-3-pyridinyl]- (9CI) (CA INDEX NAME)




IT 667931-26-2P 667931-56-8P 667931-58-0P  
 667931-66-0P 667931-70-6P 667931-72-8P  
 667931-74-0P 667931-78-4P 667931-82-0P  
 667931-84-2P 667931-87-5P 667931-89-7P  
 667931-91-1P 667931-92-2P 667931-94-4P  
 667931-96-6P 667931-98-8P 667932-00-5P  
 667932-02-7P 667932-04-9P 667932-06-1P  
 667932-08-3P 667932-10-7P 667932-12-9P  
 667932-14-1P 667932-16-3P

(drug candidate; prepare and cytotoxicity of pyridylisoxazoles for treatment of hepatitis C virus infections)


RN 667931-26-2 USPATFULL

CN Acetamide, 2,2-dichloro-N-[2-[3-(2-fluoro-6-methoxyphenyl)-5-isoxazolyl]-4-pyridinyl]- (9CI) (CA INDEX NAME)




RN 667931-56-8 USPATFULL

CN Acetamide, 2,2-dichloro-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-1-oxido-4-pyridinyl]- (9CI) (CA INDEX NAME)




RN 667931-58-0 USPATFULL

CN 3-Pyridinecarboxylic acid, 2-[5-[3-[(dichloroacetyl)amino]phenyl]-3-isoxazolyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 667931-66-0 USPATFULL

CN Acetamide, 2,2-dichloro-N-[2-[3-[2-chloro-6-[4-(2-pyridinyl)-1-piperazinyl]phenyl]-5-isoxazolyl]-4-pyridinyl]- (9CI) (CA INDEX NAME)




RN 667931-70-6 USPATFULL

CN Acetamide, 2,2-dichloro-N-[5-[3-[2-[4-(2-pyridinyl)-1-piperazinyl]-6-(trifluoromethyl)phenyl]-5-isoxazolyl]-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 667931-72-8 USPATFULL

CN Acetamide, N-[5-[3-[2-(4-acetyl-1-piperazinyl)-6-chlorophenyl]-5-isoxazolyl]-3-pyridinyl]-2,2-dichloro- (9CI) (CA INDEX NAME)




RN 667931-74-0 USPATFULL

CN Acetamide, 2,2-dichloro-N-[5-[3-[2-chloro-6-(4-ethyl-1-piperazinyl)phenyl]-5-isoxazolyl]-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 667931-78-4 USPATFULL

CN Acetamide, 2,2-dichloro-N-[5-[3-[2-(trifluoromethyl)phenyl]-5-isoxazolyl]-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 667931-82-0 USPATFULL

CN 1-Piperazinecarboxylic acid, 4-[3-chloro-2-[5-[5-[(dichloroacetyl)amino]-3-pyridinyl]-3-isoxazolyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 667931-84-2 USPATFULL

CN Acetamide, 2,2-dichloro-N-[5-[3-[2-chloro-6-(1-piperazinyl)phenyl]-5-isoxazolyl]-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 667931-87-5 USPATFULL

CN Acetamide, 2,2-dichloro-N-[5-[3-[2-chloro-6-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]phenyl]-5-isoxazolyl]-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 667931-89-7 USPATFULL

CN Acetamide, 2,2-dichloro-N-[5-[3-(2-chloro-6-hydroxyphenyl)-5-isoxazolyl]-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 667931-91-1 USPATFULL


CN Carbamic acid, ethyl-, 3-chloro-2-[5-[5-[(dichloroacetyl)amino]-3-pyridinyl]-3-isoxazolyl]phenyl ester (9CI) (CA INDEX NAME)



RN 667931-92-2 USPATFULL




CN 1-Piperazinecarboxamide, 4-[3-chloro-2-[5-[5-[(dichloroacetyl)amino]-3-pyridinyl]-3-isoxazolyl]phenyl]-N-ethyl- (9CI) (CA INDEX NAME)




RN 667931-94-4 USPATFULL

CN Acetamide, 2,2-dichloro-N-[2-[3-[2-chloro-6-[[1,1-dimethylethyl)dimethylsilyl]oxy]phenyl]-5-isoxazolyl]-4-pyridinyl]- (9CI) (CA INDEX NAME)




RN 667931-96-6 USPATFULL

CN Carbamic acid, propyl-, 3-chloro-2-[5-[4-[(dichloroacetyl)amino]-2-pyridinyl]-3-isoxazolyl]phenyl ester (9CI) (CA INDEX NAME)




RN 667931-98-8 USPATFULL

CN Acetamide, 2,2-dichloro-N-[2-[3-[2-chloro-6-(methoxymethoxy)phenyl]-5-isoxazolyl]-4-pyridinyl]- (9CI) (CA INDEX NAME)




RN 667932-00-5 USPATFULL

CN Acetamide, 2,2-dichloro-N-[2-[3-(2-chloro-6-hydroxyphenyl)-5-isoxazolyl]-4-pyridinyl]- (9CI) (CA INDEX NAME)




RN 667932-02-7 USPATFULL

CN Acetamide, 2,2-dichloro-N-[3-[3-[4-chloro-2-(dimethylamino)-3-pyridinyl]-5-isoxazolyl]phenyl]- (9CI) (CA INDEX NAME)




RN 667932-04-9 USPATFULL

CN Acetamide, 2,2-dichloro-N-[3-[3-(2,4-dichloro-3-pyridinyl)-5-isoxazolyl]phenyl]- (9CI) (CA INDEX NAME)




RN 667932-06-1 USPATFULL

CN Acetamide, 2,2-dichloro-N-[3-[3-(2-chloro-4-(4-morpholinyl)-3-pyridinyl)-5-isoxazolyl]phenyl]- (9CI) (CA INDEX NAME)




RN 667932-08-3 USPATFULL

CN Acetamide, N-[3-[3-(6-bromo-2-pyridinyl)-5-isoxazolyl]phenyl]-2,2-dichloro- (9CI) (CA INDEX NAME)



RN 667932-10-7 USPATFULL

CN Acetamide, 2,2-dichloro-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 667932-12-9 USPATFULL

CN Acetamide, 2,2-dichloro-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]-, mono(4-methylbenzenesulfonate) (9CI) (CA INDEX NAME)

CM 1

CRN 667931-30-8

CMF C16 H9 Cl4 N3 O2




RN 667932-16-3 USPATFULL

CN Acetamide, 2,2-dichloro-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]-, mononitrate (9CI) (CA INDEX NAME)

CM 1

CRN 667931-30-8


CMF C16 H9 Cl4 N3 O2



CM 2

CRN 7697-37-2

CMF H N O3



L50 ANSWER 15 OF 15 USPATFULL on STN

ACCESSION NUMBER: 2003:237404 USPATFULL

TITLE: Substituted diphenyl heterocycles useful for treating HCV infection

INVENTOR(S): Singh, Rajinder, Belmont, CA, UNITED STATES


Goff, Dane, Redwood, CA, UNITED STATES

Lu, Henry, Foster City, CA, UNITED STATES

Issakani, Sarkiz D., San Jose, CA, UNITED STATES


Sun, Thomas, Fremont, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003165561	A1	20030904
	US 6759538	B2	20040706
APPLICATION INFO.:	US 2002-286017	A1	20021101 (10)



CM 2

CRN 104-15-4  
CMF C7 H8 O3 S




RN 667932-14-1 USPATFULL

CN Ethanesulfonic acid, compd. with 2,2-dichloro-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]acetamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 667931-30-8  
CMF C16 H9 Cl4 N3 O2



CM 2

CRN 594-45-6  
CMF C2 H6 O3 S

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-350107P	20011102 (60)
	US 2002-405472P	20020823 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	DORSEY & WHITNEY LLP, INTELLECTUAL PROPERTY DEPARTMENT, 4 EMBARCADERO CENTER, SUITE 3400, SAN FRANCISCO, CA, 94111	
NUMBER OF CLAIMS:	37	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	16 Drawing Page(s)	
LINE COUNT:	2867	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		
AB	The present invention relates to substituted diphenyl heterocycle compounds and pharmaceutical compositions thereof that inhibit replication of HCV virus. The present invention also relates to the use of the compounds and/or compositions to inhibit HCV replication and/or proliferation and to treat or prevent HCV infections.	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

STRUCTURE

Davis 10/646348

02/17/2006

=> □

SEARCH

=> file registry

FILE 'REGISTRY' ENTERED AT 11:38:43 ON 17 FEB 2006  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 15 FEB 2006 HIGHEST RN 874326-73-5  
DICTIONARY FILE UPDATES: 15 FEB 2006 HIGHEST RN 874326-73-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

\*\*\*\*\*  
\*  
\* The CA roles and document type information have been removed from \*  
\* the IDE default display format and the ED field has been added, \*  
\* effective March 20, 2005. A new display format, IDERL, is now \*  
\* available and contains the CA role and document type information. \*  
\*  
\*\*\*\*\*

Structure search iteration limits have been increased. See HELP SLIMITS  
for details.

REGISTRY includes numerically searchable data for experimental and  
predicted properties as well as tags indicating availability of  
experimental property data in the original document. For information  
on property searching in REGISTRY, refer to:




<http://www.cas.org/ONLINE/UG/regprops.html>

=> d stat que L19



L1 STR






C 77 N 78






Page 1-A





Page 1-B




Page 2-A



Page 2-B



Page 3-A



Page 3-B

VAR G1=5/11/17/23

VAR G2=77/78

VAR G3=33/39/45/51/61

NODE ATTRIBUTES:

NSPEC	IS R	AT	1
NSPEC	IS R	AT	2
NSPEC	IS R	AT	3
NSPEC	IS R	AT	4
NSPEC	IS R	AT	5
NSPEC	IS R	AT	6
NSPEC	IS R	AT	7
NSPEC	IS R	AT	8
NSPEC	IS R	AT	9
NSPEC	IS R	AT	10
NSPEC	IS R	AT	11
NSPEC	IS R	AT	12
NSPEC	IS R	AT	13
NSPEC	IS R	AT	14
NSPEC	IS R	AT	15
NSPEC	IS R	AT	16
NSPEC	IS R	AT	17
NSPEC	IS R	AT	18
NSPEC	IS R	AT	19
NSPEC	IS R	AT	20
NSPEC	IS R	AT	21
NSPEC	IS R	AT	22
NSPEC	IS R	AT	23
NSPEC	IS R	AT	24
NSPEC	IS C	AT	25
NSPEC	IS R	AT	26
NSPEC	IS R	AT	27
NSPEC	IS R	AT	28
NSPEC	IS R	AT	29
NSPEC	IS R	AT	30
NSPEC	IS R	AT	31
NSPEC	IS R	AT	32
NSPEC	IS R	AT	33
NSPEC	IS R	AT	34

NSPEC	IS	R	AT	35
NSPEC	IS	R	AT	36
NSPEC	IS	R	AT	37
NSPEC	IS	R	AT	38
NSPEC	IS	R	AT	39
NSPEC	IS	R	AT	40
NSPEC	IS	R	AT	41
NSPEC	IS	R	AT	42
NSPEC	IS	R	AT	43
NSPEC	IS	R	AT	44
NSPEC	IS	R	AT	45
NSPEC	IS	R	AT	46
NSPEC	IS	R	AT	47
NSPEC	IS	R	AT	48
NSPEC	IS	R	AT	49
NSPEC	IS	R	AT	50
NSPEC	IS	R	AT	51
NSPEC	IS	R	AT	52
NSPEC	IS	R	AT	53
NSPEC	IS	R	AT	54
NSPEC	IS	C	AT	55
NSPEC	IS	C	AT	56
NSPEC	IS	C	AT	57
NSPEC	IS	C	AT	58
NSPEC	IS	R	AT	59
NSPEC	IS	R	AT	60
NSPEC	IS	R	AT	61
NSPEC	IS	R	AT	62
NSPEC	IS	R	AT	63
NSPEC	IS	R	AT	64
NSPEC	IS	C	AT	65
NSPEC	IS	C	AT	66
NSPEC	IS	C	AT	67
NSPEC	IS	C	AT	68
NSPEC	IS	C	AT	69
NSPEC	IS	C	AT	70
NSPEC	IS	C	AT	71
NSPEC	IS	C	AT	72
NSPEC	IS	C	AT	73
NSPEC	IS	C	AT	74
NSPEC	IS	C	AT	75
NSPEC	IS	C	AT	76
CONNECT	IS	E3	RC	AT 66
CONNECT	IS	E3	RC	AT 67
CONNECT	IS	E3	RC	AT 68
CONNECT	IS	E3	RC	AT 69
CONNECT	IS	E3	RC	AT 70
CONNECT	IS	E1	RC	AT 71
CONNECT	IS	E1	RC	AT 72
CONNECT	IS	E1	RC	AT 73
CONNECT	IS	E1	RC	AT 74
CONNECT	IS	E1	RC	AT 75
DEFAULT	MLEVEL	IS	ATOM	
MLEVEL	IS	CLASS	AT	55 56 57 58 65 66 67 68 69 70 71 72 73 74 75
DEFAULT	ECLEVEL	IS	LIMITED	



GRAPH ATTRIBUTES:  
RING(S) ARE ISOLATED OR EMBEDDED  
NUMBER OF NODES IS 78

```


L2  ( 4356201)SEA FILE=REGISTRY ABB=ON  PLU=ON  NC5/ESS
L3      281 SEA FILE=REGISTRY SUB=L2  SSS FUL L1
L10      STR

```


C 107N 108






Page 113




Page 2-A



Page 2-B



Page 3-A



Page 3-B

VAR G1=5/11/17/23

VAR G2=107/108

VAR G3=32/38/44/50/60

VAR G4=27/78/90

NODE ATTRIBUTES:

NSPEC	IS	R	AT	1
NSPEC	IS	R	AT	2
NSPEC	IS	R	AT	3
NSPEC	IS	R	AT	4
NSPEC	IS	R	AT	5
NSPEC	IS	R	AT	6
NSPEC	IS	R	AT	7
NSPEC	IS	R	AT	8
NSPEC	IS	R	AT	9
NSPEC	IS	R	AT	10
NSPEC	IS	R	AT	11
NSPEC	IS	R	AT	12
NSPEC	IS	R	AT	13
NSPEC	IS	R	AT	14
NSPEC	IS	R	AT	15
NSPEC	IS	R	AT	16
NSPEC	IS	R	AT	17
NSPEC	IS	R	AT	18
NSPEC	IS	R	AT	19
NSPEC	IS	R	AT	20
NSPEC	IS	R	AT	21
NSPEC	IS	R	AT	22
NSPEC	IS	R	AT	23
NSPEC	IS	R	AT	24
NSPEC	IS	R	AT	25
NSPEC	IS	R	AT	26
NSPEC	IS	R	AT	27
NSPEC	IS	R	AT	28
NSPEC	IS	R	AT	29
NSPEC	IS	R	AT	30

NSPEC	IS R	AT	31
NSPEC	IS R	AT	32
NSPEC	IS R	AT	33
NSPEC	IS R	AT	34
NSPEC	IS R	AT	35
NSPEC	IS R	AT	36
NSPEC	IS R	AT	37
NSPEC	IS R	AT	38
NSPEC	IS R	AT	39
NSPEC	IS R	AT	40
NSPEC	IS R	AT	41
NSPEC	IS R	AT	42
NSPEC	IS R	AT	43
NSPEC	IS R	AT	44
NSPEC	IS R	AT	45
NSPEC	IS R	AT	46
NSPEC	IS R	AT	47
NSPEC	IS R	AT	48
NSPEC	IS R	AT	49
NSPEC	IS R	AT	50
NSPEC	IS R	AT	51
NSPEC	IS R	AT	52
NSPEC	IS R	AT	53
NSPEC	IS C	AT	54
NSPEC	IS C	AT	55
NSPEC	IS C	AT	56
NSPEC	IS C	AT	57
NSPEC	IS R	AT	58
NSPEC	IS R	AT	59
NSPEC	IS R	AT	60
NSPEC	IS R	AT	61
NSPEC	IS R	AT	62
NSPEC	IS R	AT	63
NSPEC	IS C	AT	64
NSPEC	IS C	AT	65
NSPEC	IS C	AT	66
NSPEC	IS C	AT	67
NSPEC	IS C	AT	68
NSPEC	IS C	AT	69
NSPEC	IS C	AT	70
NSPEC	IS C	AT	71
NSPEC	IS C	AT	72
NSPEC	IS C	AT	73
NSPEC	IS C	AT	74
NSPEC	IS C	AT	75
NSPEC	IS R	AT	76
NSPEC	IS R	AT	77
NSPEC	IS R	AT	78
NSPEC	IS R	AT	79
NSPEC	IS R	AT	80
NSPEC	IS R	AT	81
NSPEC	IS R	AT	82
NSPEC	IS R	AT	83
NSPEC	IS R	AT	84
NSPEC	IS R	AT	85
NSPEC	IS C	AT	86
NSPEC	IS C	AT	87
NSPEC	IS R	AT	88
NSPEC	IS R	AT	89
NSPEC	IS R	AT	90



```

NSPEC   IS R      AT  91
NSPEC   IS R      AT  92
NSPEC   IS R      AT  93
NSPEC   IS R      AT  94
NSPEC   IS R      AT  95
NSPEC   IS R      AT  96
NSPEC   IS R      AT  97
NSPEC   IS R      AT  98
NSPEC   IS R      AT  99
NSPEC   IS R      AT 100
NSPEC   IS R      AT 101
NSPEC   IS R      AT 102
NSPEC   IS R      AT 103
NSPEC   IS R      AT 104
NSPEC   IS R      AT 105
NSPEC   IS C      AT 106
CONNECT IS E3    RC AT  65
CONNECT IS E3    RC AT  66
CONNECT IS E3    RC AT  67
CONNECT IS E3    RC AT  68
CONNECT IS E3    RC AT  69
CONNECT IS E1    RC AT  70
CONNECT IS E1    RC AT  71
CONNECT IS E1    RC AT  72
CONNECT IS E1    RC AT  73
CONNECT IS E1    RC AT  74
CONNECT IS E2    RC AT 100
CONNECT IS E2    RC AT 102
DEFAULT MLEVEL IS ATOM
MLEVEL   IS CLASS AT  54 55 56 57 64 65 66 67 68 69 70 71 72 73 74
DEFAULT ECLEVEL IS LIMITED

```

## GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED  
NUMBER OF NODES IS 108

## STEREO ATTRIBUTES: NONE

```

L12      180 SEA FILE=REGISTRY SUB=L3 SSS FUL L10
L13      1 SEA FILE=REGISTRY ABB=ON PLU=ON "CARBAMIC ACID, (3-(5-(3,4-BI
        S(PHENYLMETHOXY) PHENYL) -1-(2-PYRIDINYL) -1H-PYRAZOL-3-YL) PHENYL)
        -, PHENYLMETHYL ESTER"/CN
L14      1 SEA FILE=REGISTRY ABB=ON PLU=ON "BENZAMIDE, N-(4-(2-(2-CHLORO
        PHENYL) -4-(3-METHYLPHENYL) -5-THIAZOLYL) -2-PYRIDINYL) -"/CN
L15      1 SEA FILE=REGISTRY ABB=ON PLU=ON "BENZENEACETAMIDE, N-(4-(2-(2
        -CHLOROPHENYL) -4-(3-METHYLPHENYL) -5-THIAZOLYL) -2-PYRIDINYL) -"/C
        N
L16      1 SEA FILE=REGISTRY ABB=ON PLU=ON "BENZENEPROPANAMIDE,
        N-(4-(2-(2-CHLOROPHENYL) -4-(3-METHYLPHENYL) -5-THIAZOLYL) -2-PYRI
        DINYL) -"/CN
L17      4 SEA FILE=REGISTRY ABB=ON PLU=ON (L13 OR L14 OR L15 OR L16)
L18      101 SEA FILE=REGISTRY ABB=ON PLU=ON L3 NOT L12
L19      105 SEA FILE=REGISTRY ABB=ON PLU=ON L18 OR L17

```

=> d L21

L21      ANALYZE L19 1- LC :      4 TERMS

TERM #    # OCC   # DOC   % DOC LC

-----

```

1      104      104  99.05 CA
2      104      104  99.05 CAPLUS
3      102      102  97.14 USPATFULI
4       49       49  46.67 TOXCENTER
*****  END OF L21***

```

=> file caplus

FILE 'CAPLUS' ENTERED AT 11:38:46 ON 17 FEB 2006  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 17 Feb 2006 VOL 144 ISS 9  
 FILE LAST UPDATED: 16 Feb 2006 (20060216/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>  
 'OBI' IS DEFAULT SEARCH FIELD FOR 'CAPLUS' FILE

=> d que nos L20

```

L1          STR
L2 ( 4356201)SEA FILE=REGISTRY ABB=ON PLU=ON NC5/ESS
L3          281 SEA FILE=REGISTRY SUB=L2 SSS FUL L1
L10         STR
L12         180 SEA FILE=REGISTRY SUB=L3 SSS FUL L10
L13         1 SEA FILE=REGISTRY ABB=ON PLU=ON "CARBAMIC ACID, (3-(5-(3,4-BI
          S (PHENYLMETHOXY) PHENYL) -1-(2-PYRIDINYL) -1H-PYRAZOL-3-YL) PHENYL)
          -, PHENYLMETHYL ESTER"/CN
L14         1 SEA FILE=REGISTRY ABB=ON PLU=ON "BENZAMIDE, N-(4-(2-(2-CHLORO
          PHENYL) -4-(3-METHYLPHENYL) -5-THIAZOLYL) -2-PYRIDINYL) -"/CN
L15         1 SEA FILE=REGISTRY ABB=ON PLU=ON "BENZENEACETAMIDE, N-(4-(2-(2
          -CHLOROPHENYL) -4-(3-METHYLPHENYL) -5-THIAZOLYL) -2-PYRIDINYL) -"/C
          N
L16         1 SEA FILE=REGISTRY ABB=ON PLU=ON "BENZENEPROPANAMIDE,
          N-(4-(2-(2-CHLOROPHENYL) -4-(3-METHYLPHENYL) -5-THIAZOLYL) -2-PYRI
          DINYL) -"/CN
L17         4 SEA FILE=REGISTRY ABB=ON PLU=ON (L13 OR L14 OR L15 OR L16)
L18         101 SEA FILE=REGISTRY ABB=ON PLU=ON L3 NOT L12
L19         105 SEA FILE=REGISTRY ABB=ON PLU=ON L18 OR L17
L20         14 SEA FILE=CAPLUS ABB=ON PLU=ON L19

```

=> s L20 not L47

~~L51~~ ~~12 L20 NOT L47~~ →

*printed with author search*

=> file uspatfull

FILE 'USPATFULL' ENTERED AT 11:38:48 ON 17 FEB 2006  
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 16 Feb 2006 (20060216/PD)  
FILE LAST UPDATED: 16 Feb 2006 (20060216/ED)  
HIGHEST GRANTED PATENT NUMBER: US7000250  
HIGHEST APPLICATION PUBLICATION NUMBER: US2006037120  
CA INDEXING IS CURRENT THROUGH 14 Feb 2006 (20060214/UPCA)  
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 16 Feb 2006 (20060216/PD)  
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Dec 2005  
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Dec 2005

=> d que nos L22

L1 STR  
L2 ( 4356201) SEA FILE=REGISTRY ABB=ON PLU=ON NC5/ESS  
L3 281 SEA FILE=REGISTRY SUB=L2 SSS FUL L1  
L10 STR  
L12 180 SEA FILE=REGISTRY SUB=L3 SSS FUL L10  
L13 1 SEA FILE=REGISTRY ABB=ON PLU=ON "CARBAMIC ACID, (3-(5-(3,4-BI  
S(PHENYLMETHOXY) PHENYL) -1-(2-PYRIDINYL) -1H-PYRAZOL-3-YL) PHENYL)  
-, PHENYLMETHYL ESTER"/CN  
L14 1 SEA FILE=REGISTRY ABB=ON PLU=ON "BENZAMIDE, N-(4-(2-(2-CHLORO  
PHENYL) -4-(3-METHYLPHENYL) -5-THIAZOLYL) -2-PYRIDINYL) -"/CN  
L15 1 SEA FILE=REGISTRY ABB=ON PLU=ON "BENZENEACETAMIDE, N-(4-(2-(2  
-CHLOROPHENYL) -4-(3-METHYLPHENYL) -5-THIAZOLYL) -2-PYRIDINYL) -"/C  
N  
L16 1 SEA FILE=REGISTRY ABB=ON PLU=ON "BENZENEPROPANAMIDE,  
N-(4-(2-(2-CHLOROPHENYL) -4-(3-METHYLPHENYL) -5-THIAZOLYL) -2-PYRI  
DINYL) -"/CN  
L17 4 SEA FILE=REGISTRY ABB=ON PLU=ON (L13 OR L14 OR L15 OR L16)  
L18 101 SEA FILE=REGISTRY ABB=ON PLU=ON L3 NOT L12  
L19 105 SEA FILE=REGISTRY ABB=ON PLU=ON L18 OR L17  
L22 13 SEA FILE=USPATFULL ABB=ON PLU=ON L19

=> s L22 not L48

~~L52~~ ~~11 L22 NOT L48~~ →

*printed with author search*

=> file toxcenter

FILE 'TOXCENTER' ENTERED AT 11:38:50 ON 17 FEB 2006  
COPYRIGHT (C) 2006 ACS

FILE COVERS 1907 TO 14 Feb 2006 (20060214/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TOXCENTER has been enhanced with new files segments and search fields.  
See HELP CONTENT for more information.

TOXCENTER thesauri in the /CN, /CT, and /MN fields incorporate the MeSH 2006 vocabulary.

See <http://www.nlm.nih.gov/mesh/>

[http://www.nlm.nih.gov/pubs/techbull/nd05/nd05\\_med\\_data\\_changes.html](http://www.nlm.nih.gov/pubs/techbull/nd05/nd05_med_data_changes.html)

[http://www.nlm.nih.gov/pubs/techbull/nd05/nd05\\_2006\\_MeSH.html](http://www.nlm.nih.gov/pubs/techbull/nd05/nd05_2006_MeSH.html)

for a description of changes.

=> d que nos L23

```

L1          STR
L2 ( 4356201)SEA FILE=REGISTRY ABB=ON  PLU=ON  NC5/ESS
L3          281 SEA FILE=REGISTRY SUB=L2 SSS FUL L1
L10         STR
L12         180 SEA FILE=REGISTRY SUB=L3 SSS FUL L10
L13         1 SEA FILE=REGISTRY ABB=ON  PLU=ON  "CARBAMIC ACID, (3-(5-(3,4-BI
S (PHENYLMETHOXY) PHENYL) -1-(2-PYRIDINYL) -1H-PYRAZOL-3-YL) PHENYL)
-, PHENYLMETHYL ESTER"/CN
L14         1 SEA FILE=REGISTRY ABB=ON  PLU=ON  "BENZAMIDE, N-(4-(2-(2-CHLORO
PHENYL) -4-(3-METHYLPHENYL) -5-THIAZOLYL) -2-PYRIDINYL) -"/CN
L15         1 SEA FILE=REGISTRY ABB=ON  PLU=ON  "BENZENEACETAMIDE, N-(4-(2-(2
-CHLOROPHENYL) -4-(3-METHYLPHENYL) -5-THIAZOLYL) -2-PYRIDINYL) -"/C
N
L16         1 SEA FILE=REGISTRY ABB=ON  PLU=ON  "BENZENEPROPANAMIDE,
N-(4-(2-(2-CHLOROPHENYL) -4-(3-METHYLPHENYL) -5-THIAZOLYL) -2-PYRI
DINYL) -"/CN
L17         4 SEA FILE=REGISTRY ABB=ON  PLU=ON  (L13 OR L14 OR L15 OR L16)
L18         101 SEA FILE=REGISTRY ABB=ON  PLU=ON  L3 NOT L12
L19         105 SEA FILE=REGISTRY ABB=ON  PLU=ON  L18 OR L17
L23         4 SEA FILE=TOXCENTER ABB=ON  PLU=ON  L19

```

=> s L23 not L49

L53 3 L23 NOT L49

*printed with  
author search*

=> => dup rem L51 L52 L53

FILE 'CAPLUS' ENTERED AT 11:39:50 ON 17 FEB 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 11:39:50 ON 17 FEB 2006

CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'TOXCENTER' ENTERED AT 11:39:50 ON 17 FEB 2006

COPYRIGHT (C) 2006 ACS

PROCESSING COMPLETED FOR L51

PROCESSING COMPLETED FOR L52

PROCESSING COMPLETED FOR L53

L54 23 DUP REM ~~L51 L52 L53~~ (3 DUPLICATES REMOVED)

ANSWERS '1-12' FROM ~~FILE CAPLUS~~

ANSWERS '13-23' FROM ~~FILE USPATFULL~~

=> d ibib abs hitind hitstr L54 1-12; d ibib abs hitstr L54 13-23

L54 ANSWER 1 OF 23 CAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 1

ACCESSION NUMBER: 2005:612074 CAPLUS

DOCUMENT NUMBER: 143:109761

TITLE: Compositions and methods for treating hepatitis C

virus (HCV) infection with haloalkylamide antiviral agents and for protecting the antiviral agent from hydrolases

INVENTOR(S): Holsztynska, Elzbieta J.; Lo, Ray; Sun, Thomas W.; Wang, Steven X.

PATENT ASSIGNEE(S): Rigel Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 98 pp.  
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005063225	A1	20050714	WO 2004-US42717	20041218
WO 2005063225	C1	20050825		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW


RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2005249805 A1 20051110 US 2004-17531 20041218

PRIORITY APPLN. INFO.: US 2003-531543P P 20031219

OTHER SOURCE(S): MARPAT 143:109761

GI



AB Provided are compns. and methods for protecting a compound comprising a haloalkylamide moiety from metabolic transformation by hydrolases. In one aspect, the disclosure is directed to increasing the bioavailability and tissue delivery of a anti-HCV compound comprising a haloalkylamide moiety by protecting the compound from inactivation by carboxylesterases. Specific approaches for limiting metabolic transformation include use of carboxylesterase inhibitors to inhibit metabolism of the compound, or use of orally administered compns. designed to deliver the compound to the small intestine or large intestine. Further provided are methods of treating or preventing HCV infection in a subject. Sodium fluoride and bis(p-nitrophenyl)phosphate gave complete inhibition of I degradation by human liver microsomes.

IC ICM A61K031-16

CC 1-5 (Pharmacology)

IT 286841-27-8 667931-30-8

RL: BSU (Biological study, unclassified); PAC (Pharmacological activity);

PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study);  
USES (Uses)

(as antiviral agent; treatment of hepatitis C virus infection with  
antiviral haloalkylamide agents and inhibitors for protecting the  
antiviral agent from inactivation by hydrolases)


IT 667931-30-8

RL: BSU (Biological study, unclassified); PAC (Pharmacological activity);  
PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study);  
USES (Uses)

(as antiviral agent; treatment of hepatitis C virus infection with  
antiviral haloalkylamide agents and inhibitors for protecting the  
antiviral agent from inactivation by hydrolases)

RN 667931-30-8 CAPLUS

CN Acetamide, 2,2-dichloro-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L54 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 2

ACCESSION NUMBER: 2005:14218 CAPLUS

DOCUMENT NUMBER: 142:109454

TITLE: Methods of identifying hepatitis C virus gene NS5B  
polymerase inhibitors and their uses

INVENTOR(S): Lu, Henry

PATENT ASSIGNEE(S): Rigel Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 96 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005000308	A2	20050106	WO 2004-US15665	20040517
WO 2005000308	A3	20050324		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,

EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,  
 SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,  
 SN, TD, TG

US 2005009877 A1 20050113 US 2004-847822 20040517  
 PRIORITY APPLN. INFO.: US 2003-471444P P 20030515  
 OTHER SOURCE(S): MARPAT 142:109454  
 GI



I

AB The present invention relates to a variety of screening methods, utilizing both biochem. and cellular assays as well as in silico assays, for use in the discovery of agents active in the treating or preventing Hepatitis C virus (HCV) infections. The invention further relates to methods of inhibiting an HCV NS5B polymerase and to the treatment and/or prevention of HCV infections with compds. having specified binding properties. The compds. bind to a region identified as the Rigel pocket, which is defined by the amino acid residues at positions 142, 148, 213, 316, 444, 445, 447, 451, 452, and 465 of NS5B. Four claimed structures are representative of these pocket-binding inhibitors (I; A ring = (substituted)Ph or pyridyl; five-membered B ring is saturated, unsatd., or aromatic; X, Y, Z = NH, N, O, S, except that X and Y are not simultaneously O; the C ring = Ph, pyridyl, R11 = H, alkyl; R12 = ClCH<sub>2</sub>, Cl<sub>2</sub>CH). One of these structures is 2,2-dichloro-N-[2-[3-[2-(4-morpholinyl)-6-(trifluoromethyl)phenyl]-5-isoxazolyl]-4-pyridinyl]acetamide (I; A ring = trifluoromethyl and morpholino-substituted Ph; B ring = isoxazole; C ring = pyridine; R11 = H; R12 = Cl<sub>2</sub>CH). The examples describe a replicon assay that was used to identify compds. A-C and counterscreens to identify resistant replicons and to investigate a mechanism of action for the compds.

IC ICM A61K031-443

ICS A61K031-4439; A61P031-12

CC 7-3 (Enzymes)

Section cross-reference(s): 1, 3, 10, 28

IT 286841-27-8 667931-24-0 667931-30-8

667931-46-6

RL: PEP (Physical, engineering or chemical process); PYP (Physical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)

(methods of identifying hepatitis C virus gene NS5B polymerase inhibitors and their uses)


IT 667931-24-0 667931-30-8 667931-46-6

RL: PEP (Physical, engineering or chemical process); PYP (Physical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)

(methods of identifying hepatitis C virus gene NS5B polymerase inhibitors and their uses)


RN 667931-24-0 CAPLUS

CN Acetamide, 2,2-dichloro-N-[2-[3-[2-fluoro-6-(trifluoromethyl)phenyl]-5-isoxazolyl]-4-pyridinyl]- (9CI) (CA INDEX NAME)




RN 667931-30-8 CAPLUS

CN Acetamide, 2,2-dichloro-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]- (9CI) (CA INDEX NAME)



RN 667931-46-6 CAPLUS

CN Acetamide, 2,2-dichloro-N-[2-[3-[2-(4-morpholinyl)-6-(trifluoromethyl)phenyl]-5-isoxazolyl]-4-pyridinyl]- (9CI) (CA INDEX NAME)





L54 ANSWER 3 OF 23 CAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 3  
 ACCESSION NUMBER: 2002:504649 CAPLUS  
 DOCUMENT NUMBER: 137:83638  
 TITLE: Concomitant drugs of p38MAP kinase inhibitors and/or  
 TNF- $\alpha$  production inhibitors with other specified  
 agents  
 INVENTOR(S): Ohkawa, Shigenori; Naruo, Kenichi; Miwatashi, Seiji  
 PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan  
 SOURCE: PCT Int. Appl., 278 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002051442	A1	20020704	WO 2001-JP11353	20011225
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2436739	AA	20020704	CA 2001-2436739	20011225
JP 2002302458	A2	20021018	JP 2001-392778	20011225
EP 1354603	A1	20031022	EP 2001-271876	20011225
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
US 2004097555	A1	20040520	US 2003-451839	20030625
PRIORITY APPLN. INFO.:			JP 2000-396220	A 20001226
			JP 2001-27572	A 20010202
			WO 2001-JP11353	W 20011225

OTHER SOURCE(S): MARPAT 137:83638

AB Drugs comprising a combination of one or more p38MAP kinase inhibitors and/or TNF- $\alpha$  production inhibitors with one or more agents selected from the group consisting of: (1) nonsteroidal anti-inflammatory agents; (2) disease-modification antirheumatics; (3) anti-cytokine drugs; (4) immunomodulators; (5) steroidal drugs; and (6) c-JUN N-terminal kinase inhibitors. These concomitant drugs are useful as preventives and remedies for diseases such as rheumatism and arthritis and other diseases. For example, tablets containing [4-(3,5-dimethylphenyl)-5-(2-phenylmethoxy-4-pyridyl)-1,3-thiazol-2-yl]amine 50 mg/tablet are administered with tablets containing rofecoxib 5 mg/tablet.

IC ICM A61K045-06  
 ICS A61K031-4439; A61K031-4545; A61K031-497; A61K031-506; A61K031-5377; A61P001-04; A61P001-16; A61P003-10; A61P007-06; A61P009-02; A61P009-04; A61P009-10; A61P011-00; A61P011-06; A61P013-12; A61P017-04; A61P017-06; A61P019-02; A61P019-10

CC 63-6 (Pharmaceuticals)

Section cross-reference(s): 1

IT 224039-49-0P	224039-51-4P	224039-54-7P	224039-55-8P	224039-56-9P
224039-57-0P	224039-58-1P	224039-59-2P	224039-60-5P	224039-61-6P
224039-63-8P	224039-64-9P	224039-65-0P	224039-66-1P	224039-67-2P
224039-68-3P	224039-70-7P	224039-72-9P	224039-73-0P	224039-74-1P
224039-76-3P	224039-77-4P	224039-78-5P	224039-79-6P	224039-81-0P

224039-82-1P	224039-83-2P	224039-85-4P	224039-86-5P	224039-87-6P
224039-88-7P	224039-90-1P	224039-91-2P	224039-92-3P	224039-93-4P
224039-95-6P	224039-96-7P	224039-97-8P	224039-99-0P	224040-00-0P
224040-01-1P	224040-02-2P	224040-03-3P	224040-04-4P	224040-06-6P
224040-07-7P	224040-08-8P	224040-10-2P	224040-11-3P	224040-12-4P
224040-13-5P	224040-14-6P	224040-16-8P	224040-17-9P	224040-18-0P
224040-19-1P	224040-21-5P	224040-22-6P	224040-23-7P	224040-24-8P
224040-26-0P	224040-27-1P	224040-28-2P	224040-30-6P	224040-31-7P
224040-33-9P	224040-34-0P	224040-36-2P	224040-37-3P	224040-38-4P
224040-40-8P	224040-41-9P	224040-42-0P	224040-43-1P	224040-44-2P
224040-45-3P	224040-46-4P	224040-47-5P	224040-57-7P	252198-63-3P
252198-66-6P	252198-74-6P	252198-75-7P	252198-97-3P	284486-00-6P
303162-67-6P	303162-68-7P	303162-69-8P	303162-70-1P	303162-71-2P
303162-72-3P	303162-73-4P	303162-74-5P	303162-75-6P	303162-76-7P
<b>303162-77-8P</b>	303162-78-9P	303162-79-0P	303162-80-3P	
303162-81-4P	303162-82-5P	303162-84-7P	303162-85-8P	303162-86-9P
303162-87-0P	303162-88-1P	303162-89-2P	303162-90-5P	
<b>303162-91-6P</b>	<b>303162-92-7P</b>	303162-93-8P	303162-94-9P	
303162-95-0P	303162-96-1P	303162-97-2P	303162-98-3P	303162-99-4P
303163-00-0P	303163-01-1P	303163-02-2P	303163-03-3P	303163-04-4P
303163-05-5P	303163-06-6P	303163-07-7P	303163-08-8P	303163-09-9P
303163-10-2P	303163-11-3P	303163-12-4P	303163-13-5P	303163-14-6P
303163-15-7P	303163-16-8P	303163-17-9P	303163-18-0P	303163-19-1P
303163-20-4P	303163-21-5P	303163-22-6P	303163-23-7P	303163-24-8P
303163-25-9P	303163-26-0P	303163-27-1P	303163-28-2P	303163-29-3P
303163-30-6P	303163-31-7P	303163-32-8P	303163-33-9P	303163-34-0P
303163-35-1P	303163-36-2P	303163-37-3P	303163-38-4P	303163-39-5P
303163-40-8P	303163-41-9P	303163-42-0P	303163-43-1P	303163-44-2P
303787-77-1P	303787-98-6P	325767-68-8P	325767-69-9P	325767-71-3P
325767-72-4P	325767-73-5P	325767-74-6P	325767-75-7P	325767-76-8P
325767-77-9P	325767-79-1P	325767-80-4P	325767-81-5P	325767-82-6P
325767-83-7P	325767-84-8P	325767-85-9P	325767-86-0P	325767-87-1P
325767-88-2P	325767-89-3P	325767-90-6P	325767-91-7P	325767-92-8P
325767-93-9P	325767-94-0P	325767-95-1P	325767-96-2P	325767-97-3P
325767-99-5P	325768-00-1P	325768-02-3P	325768-03-4P	325768-04-5P
325768-05-6P	325768-06-7P	325768-07-8P	325768-08-9P	325768-09-0P
325768-10-3P	325768-11-4P	325768-12-5P	325768-13-6P	325768-14-7P
325768-15-8P	325768-16-9P	325768-17-0P	325768-18-1P	325768-19-2P
325768-20-5P	325768-21-6P	325768-22-7P	325768-23-8P	325768-24-9P
325768-25-0P	325768-27-2P	325768-28-3P	325768-29-4P	325768-30-7P
325768-31-8P	325768-32-9P	325768-33-0P	325768-34-1P	325768-35-2P
325768-36-3P	325768-37-4P	325768-38-5P	325768-40-9P	325768-41-0P
325768-42-1P	325768-43-2P	325768-44-3P		

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(combination drugs containing p38MAP kinase inhibitors and/or TNF- $\alpha$  production inhibitors with other specified agents)


IT **303162-77-8P 303162-91-6P 303162-92-7P**

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(combination drugs containing p38MAP kinase inhibitors and/or TNF- $\alpha$  production inhibitors with other specified agents)


RN 303162-77-8 CAPLUS

CN Benzeneacetamide, N-[4-[2-(2-chlorophenyl)-4-(3-methylphenyl)-5-thiazolyl]-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 303162-91-6 CAPLUS

CN Benzanide, N-[4-[2-(2-chlorophenyl)-4-(3-methylphenyl)-5-thiazolyl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 303162-92-7 CAPLUS

CN Benzenepropanamide, N-[4-[2-(2-chlorophenyl)-4-(3-methylphenyl)-5-thiazolyl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 58 THERE ARE 58 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L54 ANSWER 4 OF 23 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2006:54669 CAPLUS

DOCUMENT NUMBER: 144:135282

TITLE: A manufacturing method for solid dispersions of p38  
MAP kinase inhibitors

INVENTOR(S): Omachi, Yoshihiro; Kurasawa, Takashi

PATENT ASSIGNEE(S): Takeda Pharmaceutical Company Limited, Japan

SOURCE: PCT Int. Appl., 98 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006006691	A2	20060119	WO 2005-JP13099	20050708
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRIORITY APPLN. INFO.: JP 2004-203799 A 20040709

AB The present invention provides a solid dispersion containing (i) a drug, (ii) polymeric carrier(s), (iii) plasticizer(s), and (iv) drug release-controlling component(s). According to the present invention, the solubility of poorly soluble or insol. drugs, such as p38 MAP kinase inhibitors,

can be improved and a drug release-controlling function can be provided simultaneously in a single manufacturing process, and a solid dispersion having a uniform composition and permitting sustained release of drugs can be provided. Thus, N-[4-[2-ethyl-4-(3-methylphenyl)-1,3-thiazol-5-yl]-2-pyridyl]benzamide 4 g was mixed with hydroxypropyl Me cellulose phthalate (HP-55) 6 g, hydroxypropyl Me cellulose (TC-5) 3 g, and polyethylene oxide 7 g, and the mixture was extruded at a barrel temperature of 90° and a screw rotation speed of 80 rpm to give an extruded product of a solid dispersion. The extruded product obtained was cut into a length of about 10 mm to give a pellet sample. The oral absorption of pellet solid dispersion obtained and the comparative film-coated tablet was evaluated in dogs. The solid dispersion showed an AUC that was not much different from that of the comparative film-coated tablet, but a Cmax decreased to about 40%, and a Tmax was prolonged to about 5 h and an MRT to about 3 h, thus exhibiting clear sustained drug release.

IC ICM A61K009-16

ICS A61K031-4439

CC 63-6 (Pharmaceuticals)

Section cross-reference(s): 1

IT	303162-57-4	303162-58-5	303162-59-6	303162-60-9	303162-61-0
	303162-62-1	303162-67-6	303162-68-7	303162-69-8	303162-70-1
	303162-71-2	303162-72-3	303162-73-4	303162-74-5	303162-75-6
	303162-76-7	<b>303162-77-8</b>	303162-78-9	303162-79-0	
	303162-80-3	303162-81-4	303162-82-5	303162-85-8	303162-86-9
	303162-87-0	303162-88-1	303162-89-2	303162-90-5	<b>303162-91-6</b>
	<b>303162-92-7</b>	303162-93-8	303162-94-9	303162-95-0	
	303162-96-1	303162-97-2	303162-98-3	303162-99-4	303163-00-0
	303163-01-1	303163-02-2	303163-03-3	303163-04-4	303163-05-5
	303163-06-6	303163-07-7	303163-08-8	303163-09-9	303163-10-2
	303163-11-3	303163-12-4	303163-13-5	303163-14-6	303163-15-7
	303163-16-8	303163-17-9	303163-18-0	303163-19-1	303163-20-4
	303163-21-5	303163-22-6	303163-23-7	303163-24-8	303163-25-9

303163-26-0 303163-28-2 303163-29-3 303163-30-6 303163-31-7  
 303163-32-8 303163-33-9 303163-34-0 303163-35-1 303163-36-2  
 303163-37-3 303163-38-4 303163-39-5 303163-40-8 303163-41-9  
 303163-42-0 303163-43-1 303163-44-2 365430-63-3 365430-65-5

RL: PKT (Pharmacokinetics); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(solid dispersions for sustained release of p38 MAP kinase inhibitors)


IT 303162-77-8 303162-91-6 303162-92-7

RL: PKT (Pharmacokinetics); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(solid dispersions for sustained release of p38 MAP kinase inhibitors)


RN 303162-77-8 CAPLUS

CN Benzeneacetamide, N-[4-[2-(2-chlorophenyl)-4-(3-methylphenyl)-5-thiazolyl]-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 303162-91-6 CAPLUS

CN Benzanide, N-[4-[2-(2-chlorophenyl)-4-(3-methylphenyl)-5-thiazolyl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 303162-92-7 CAPLUS

CN Benzenepropanamide, N-[4-[2-(2-chlorophenyl)-4-(3-methylphenyl)-5-thiazolyl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



L54 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:471983 CAPLUS

DOCUMENT NUMBER: 143:13356

TITLE: Synergistically effective combinations of dihaloacetamide compounds and interferon or ribavirin against HCV infections

INVENTOR(S): Lu, Henry

PATENT ASSIGNEE(S): Rigel Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 32 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005049065	A2	20050602	WO 2004-US39011	20041119
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2005129659	A1	20050616	US 2004-993212	20041119
PRIORITY APPLN. INFO.:			US 2003-523405P	P 20031119
OTHER SOURCE(S): MARPAT 143:13356				

AB The present invention relates to anti-HCV dihaloacetamide compds. in synergistic combination with an interferon and/or ribavirin and pharmaceutical compns. thereof for inhibition of the replication of HCV virus. The present invention also relates to the use of the compns. to inhibit HCV replication and/or proliferation and to treat or prevent HCV infections.

IC ICM A61K038-00

CC 63-6 (Pharmaceuticals)

Section cross-reference(s): 15

IT 286841-27-8 667931-30-8

RL: PAC (Pharmacological activity); PEP (Physical, engineering or chemical process); PYP (Physical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)

(synergistically effective combinations of dihaloacetamide compds. and interferon or ribavirin against HCV infections)


IT 667931-30-8

RL: PAC (Pharmacological activity); PEP (Physical, engineering or chemical process); PYP (Physical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)

(synergistically effective combinations of dihaloacetamide compds. and interferon or ribavirin against HCV infections)

RN 667931-30-8 CAPLUS

CN Acetamide, 2,2-dichloro-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazoly]-4-pyridinyl]- (9CI) (CA INDEX NAME)



L54 ANSWER 6 OF 23 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:1124567 CAPLUS

DOCUMENT NUMBER: 142:74572

TITLE: Preparation of heterocyclic compounds for treating hepatitis C virus

INVENTOR(S): Vourloumis, Dionisios; Takahashi, Masayuki; Winters, Geoff; Zhou, Jinglan; Duchene, Russell

PATENT ASSIGNEE(S): Anadys Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 416 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English



FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004110351	A2	20041223	WO 2004-US15249	20040514
WO 2004110351	A3	20050428		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 2005075375	A1	20050407	US 2004-845587	20040514
PRIORITY APPLN. INFO.:			US 2003-470200P	P 20030514

OTHER SOURCE(S) :  
GI

MARPAT 142:74572



AB The title compds. I [X, Y, Z = C, N; W = N, O, S; R1, R3-R5 = H, halo, NO2, etc.; R2 = H, alkyl], useful for treating Hepatitis C virus, were prepared E.g., a multi-step synthesis of II, starting from 2'-hydroxy-5'-methoxyacetophenone, was given. The compds. I were tested for inhibition of HCV replication in in vitro assays (the results of EC50 assay are given for 640 compds. I). The pharmaceutical composition comprising the compound I is disclosed.

IC ICM A61K

CC 28-10 (Heterocyclic Compounds (More Than One Hetero Atom))  
Section cross-reference(s): 1, 63

IT 814256-93-4P 814257-49-3P 814258-88-3P 814258-89-4P 814258-90-7P  
814258-95-2P 814258-96-3P 814259-02-4P 814259-03-5P 814259-04-6P  
814259-05-7P **814259-16-0P** 814259-17-1P 814259-20-6P  
814259-26-2P 814259-28-4P 814262-17-4P 814262-19-6P 814263-49-5P  
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(preparation of disubstituted pyrazoles, oxadiazoles and triazoles for treating hepatitis C virus)

IT 814258-70-3P 814258-71-4P 814258-72-5P 814258-73-6P 814258-74-7P  
814258-75-8P 814258-76-9P 814258-77-0P 814258-78-1P 814258-79-2P  
814258-80-5P 814258-81-6P 814258-82-7P 814258-83-8P 814258-84-9P  
814258-85-0P 814258-86-1P 814258-87-2P 814258-91-8P 814258-92-9P  
814258-93-0P 814258-94-1P 814258-97-4P 814258-98-5P 814258-99-6P  
814259-00-2P 814259-01-3P 814259-06-8P 814259-07-9P 814259-08-0P  
814259-09-1P 814259-10-4P 814259-11-5P 814259-12-6P 814259-13-7P  
814259-14-8P 814259-15-9P 814259-18-2P 814259-19-3P 814259-21-7P  
814259-22-8P 814259-23-9P 814259-24-0P **814259-25-1P**  
814259-29-5P 814259-30-8P 814259-31-9P 814259-32-0P 814259-33-1P  
814259-34-2P 814259-35-3P 814259-36-4P 814259-37-5P 814259-38-6P  
814259-39-7P 814259-40-0P **814259-41-1P** 814259-42-2P  
814259-43-3P 814259-44-4P 814259-45-5P 814259-46-6P 814259-47-7P  
814259-48-8P **814259-49-9P** 814259-50-2P 814259-51-3P  
814259-52-4P 814259-53-5P 814259-54-6P 814259-55-7P 814259-56-8P  
814259-57-9P 814259-58-0P 814259-59-1P 814259-60-4P 814259-61-5P  
814259-62-6P 814259-63-7P 814259-64-8P 814259-65-9P 814259-66-0P  
814259-67-1P 814259-68-2P 814259-69-3P 814259-70-6P 814259-71-7P  
814259-72-8P 814259-73-9P 814259-74-0P 814259-75-1P 814259-76-2P  
814259-77-3P 814259-78-4P 814259-79-5P 814259-80-8P 814259-81-9P  
814259-82-0P 814259-83-1P 814259-84-2P 814259-85-3P 814259-86-4P



814259-87-5P	814259-88-6P	814259-89-7P	814259-90-0P	814259-91-1P
814259-92-2P	814259-93-3P	814259-94-4P	814259-95-5P	814259-96-6P
814259-97-7P	814259-98-8P	814259-99-9P	814260-00-9P	814260-01-0P
814260-02-1P	814260-03-2P	814260-04-3P	814260-05-4P	814260-06-5P
814260-07-6P	814260-08-7P	814260-09-8P	814260-10-1P	814260-11-2P
814260-12-3P	814260-13-4P	814260-14-5P	814260-15-6P	814260-16-7P
814260-17-8P	814260-18-9P	814260-19-0P	814260-20-3P	814260-21-4P
814260-22-5P	814260-23-6P	814260-24-7P	814260-25-8P	814260-26-9P
814260-27-0P	814260-28-1P	814260-29-2P	814260-30-5P	814260-31-6P
814260-32-7P	814260-33-8P	814260-34-9P	814260-35-0P	814260-36-1P
814260-37-2P	814260-38-3P	814260-39-4P	814260-40-7P	814260-41-8P
814260-42-9P	814260-43-0P	814260-44-1P	814260-45-2P	814260-46-3P
814260-47-4P	814260-48-5P	814260-49-6P	814260-50-9P	814260-51-0P
814260-52-1P	814260-53-2P	814260-54-3P	814260-55-4P	814260-56-5P
814260-57-6P	814260-58-7P	814260-59-8P	814260-60-1P	814260-61-2P
814260-62-3P	814260-63-4P	814260-64-5P	814260-65-6P	814260-66-7P
814260-67-8P	814260-68-9P	814260-69-0P	814260-70-3P	814260-71-4P
814260-72-5P	814260-73-6P	814260-74-7P	814260-75-8P	814260-76-9P
814260-77-0P	814260-78-1P	814260-79-2P	814260-80-5P	814260-81-6P
814260-82-7P	814260-83-8P	814260-84-9P	814260-85-0P	814260-86-1P
814260-87-2P	814260-88-3P	814260-89-4P	814260-90-7P	814260-91-8P
814260-92-9P	814260-93-0P	814260-94-1P	814260-95-2P	814260-96-3P
814260-97-4P	814260-98-5P	814260-99-6P	814261-00-2P	814261-01-3P
814261-02-4P	814261-03-5P	814261-04-6P	814261-05-7P	814261-06-8P
814261-07-9P	814261-08-0P	814261-09-1P	814261-10-4P	814261-11-5P
814261-12-6P	814261-13-7P	814261-14-8P	814261-15-9P	814261-16-0P
814261-17-1P	814261-18-2P			

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of disubstituted pyrazoles, oxadiazoles and triazoles for treating hepatitis C virus)


IT 814259-16-0P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of disubstituted pyrazoles, oxadiazoles and triazoles for treating hepatitis C virus)

RN 814259-16-0 CAPLUS

CN Carbamic acid, [4-hydroxy-3-[3-(3-methyl-2-pyridinyl)-1,2,4-oxadiazol-5-yl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



IT 814259-25-1P 814259-41-1P 814259-49-9P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of disubstituted pyrazoles, oxadiazoles and triazoles for

treating hepatitis C virus)


RN 814259-25-1 CAPLUS

CN Acetamide, N-[4-hydroxy-3-[3-(3-methyl-2-pyridinyl)-1,2,4-oxadiazol-5-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 814259-41-1 CAPLUS

CN Benzamide, N-[4-hydroxy-3-[3-(3-methyl-2-pyridinyl)-1,2,4-oxadiazol-5-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 814259-49-9 CAPLUS

CN Carbamic acid, [2-hydroxy-3-[3-(3-methyl-2-pyridinyl)-1,2,4-oxadiazol-5-yl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



L54 ANSWER 7 OF 23 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:333699 CAPLUS

DOCUMENT NUMBER: 140:357334

TITLE: Preparation of pyrazole derivatives as antifungal agents

INVENTOR(S): Konno, Fujiko; Nakazawa, Kyoko; Hirota, Hiroyuki; Ishida, Kazuya; Kaneko, Yasushi; Okouchi, Hisako

PATENT ASSIGNEE(S): SSP Co., Ltd., Japan

SOURCE: PCT Int. Appl., 102 pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

## PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004033432	A1	20040422	WO 2003-JP12856	20031008
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.:			JP 2002-296127	A 20021009
OTHER SOURCE(S):			MARPAT 140:357334	
GI				



AB The title compds. I [R1 = alkyl, etc.; R3 = H, alkyl, etc.; R2 = H, halo, etc.; R4, R5 = H, acyl, etc.; or OR4 and OR5 together form alkylenedioxy; and X represents a methine group or a nitrogen atom] are prepared Compds. of this invention in vitro showed MIC values of 0.5 µg/mL to 4 µg/mL against *Candida albicans* ATCC 90028, vs. MIC of 0.25 µg/mL shown by fluconazole. Two compds. of this invention showed MIC value of 1 µg/mL against *Aspergillus fumigatus* IFM 41935, vs. MIC of > 64 µg/mL shown by fluconazole.

IC ICM C07D231-12

ICS C07D401-04; C07D401-14; C07D409-14; C07D417-04; C07D403-04;  
 A61K031-415; A61K031-428; A61K031-4439; A61K031-444; A61K031-454;  
 A61K031-496; A61K031-506; A61K031-5377; A61K031-4545; A61P031-10

CC 28-8 (Heterocyclic Compounds (More Than One Hetero Atom))

Section cross-reference(s): 1, 10

IT 60-34-4 94-02-0, Ethyl 3-oxo-3-phenylpropanoate 98-80-6, Phenylboronic acid 98-86-2, Acetophenone, reactions 100-63-0 108-24-7, Acetic anhydride 110-91-8, Morpholine, reactions 302-01-2, Hydrazine, reactions 616-45-5, 2-Pyrrolidinone 630-08-0, Carbon monoxide, reactions 1073-70-7 1120-90-7, 3-Iodopyridine 2458-26-6, 3-Phenylpyrazole 2859-78-1, 4-Bromo-1,2-dimethoxybenzene 3054-95-3, 3,3-Diethoxypropene 3453-00-7, Diethyl 2-oxo-2-phenylethylphosphonate 4487-59-6, 2-Bromo-5-nitropyridine 4930-98-7, 2-Hydrazinopyridine 5447-02-9, 3,4-Bis(benzyloxy)benzaldehyde 7681-82-5, Sodium iodide, reactions 25620-54-6, Bromochloroethane 58045-88-8 62885-51-2 112334-44-8 133115-72-7 204847-72-3 681234-50-4 681234-55-9 681234-59-3 681234-61-7 681234-63-9 681234-67-3 681234-69-5 681234-75-3


RL: RCT (Reactant); RACT (Reactant or reagent)  
 (preparation of pyrazole derivs. as antifungal agents)

IT 681234-75-3

RL: RCT (Reactant); RACT (Reactant or reagent)  
(preparation of pyrazole derivs. as antifungal agents)

RN 681234-75-3 CAPLUS

CN Carbamic acid, [3-[5-[3,4-bis(phenylmethoxy)phenyl]-1-(2-pyridinyl)-1H-pyrazol-3-yl]phenyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L54 ANSWER 8 OF 23 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:287841 CAPLUS

DOCUMENT NUMBER: 140:321349

TITLE: Preparation of pyrazole derivatives as p38 MAP kinase inhibitors and cytokine production inhibitors

INVENTOR(S): Hagihara, Masahiko; Shibakawa, Nobuhiko; Nishihara, Masamichi; Shirai, Toshiyuki; Shimizu, Motohisa; Hasegawa, Tohru; Tokunaga, Yasunori; Suzuki, Naoto; Wada, Yukinori

PATENT ASSIGNEE(S): Ube Industries, Ltd., Japan

SOURCE: PCT Int. Appl., 276 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent



LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004029043	A1	20040408	WO 2003-JP12254	20030925
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2500225	AA	20040408	CA 2003-2500225	20030925
EP 1553096	A1	20050713	EP 2003-798497	20030925

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK  
 PRIORITY APPLN. INFO.: JP 2002-279385 A 20020925  
 WO 2003-JP12254 W 20030925  
 OTHER SOURCE(S): MARPAT 140:321349  
 GI



AB The title compds. I [R1 is optionally substituted phenyl; R2 is H, halogeno, alkyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, or substituted amino; Q is CH or N; R3 is H, alkyl, or amino; and R4 is a group represented by the general formula Q1, etc.; R7 is H or alkyl; R8 is H, alkyl, or substituted amino; R9 is H or alkyl] are prepared Compds. of this invention in vitro showed IC50 values of 0.2 nM to 8.8 nM against p38 MAP kinase. Formulations are given.

IC ICM C07D401-14  
 ICS C07D403-14; C07D487-04; A61K031-501; A61K031-5025; A61K031-506;  
 A61P001-04; A61P003-10; A61P009-10; A61P017-06; A61P019-02;  
 A61P019-10; A61P025-00; A61P029-00; A61P037-08; A61P043-00


CC 28-8 (Heterocyclic Compounds (More Than One Hetero Atom))  
 Section cross-reference(s): 1, 63

IT 148671-39-0P, 3-Dimethylamino-1-(4-fluorophenyl)-2-(pyridin-4-yl)-2-propen-1-one 216504-75-5P 216505-71-4P 216506-58-0P 216506-68-2P  
 677319-68-5P 677319-70-9P 677319-72-1P 677319-74-3P 677319-76-5P  
 677319-78-7P 677319-81-2P 677319-84-5P 677319-86-7P 677319-88-9P  
 677319-90-3P 677319-92-5P 677319-94-7P 677319-97-0P 677319-99-2P  
 677320-01-3P 677320-03-5P 677320-05-7P 677320-07-9P 677320-09-1P  
 677320-11-5P 677320-13-7P 677320-15-9P 677320-17-1P 677320-19-3P  
 677320-21-7P 677320-23-9P 677320-25-1P 677320-27-3P 677320-29-5P  
 677320-31-9P 677320-33-1P 677320-35-3P 677320-37-5P 677320-39-7P  
 677320-41-1P 677320-43-3P 677320-45-5P 677320-47-7P  
 677320-49-9P 677320-51-3P 677320-53-5P 677320-55-7P 677320-57-9P  
 677320-59-1P 677320-61-5P 677320-63-7P 677320-66-0P 677320-68-2P  
 677320-70-6P 677320-72-8P 677320-74-0P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation of pyrazole derivs. as p38 MAP kinase inhibitors and cytokine production inhibitors)

IT 677320-43-3P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation of pyrazole derivs. as p38 MAP kinase inhibitors and cytokine production inhibitors)

RN 677320-43-3 CAPLUS

CN Carbamic acid, [4-[1-(6-chloro-4-methyl-3-pyridinyl)-3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 59 THERE ARE 59 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L54 ANSWER 9 OF 23 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:282532 CAPLUS

DOCUMENT NUMBER: 138:287681

TITLE: Preparation of heteroaryl substituted tetrazole modulators of metabotropic glutamate receptor-5

INVENTOR(S): Cosford, Nicholas D.; Roppe, Jeffrey; Chen, Chixu; Smith, Nicholas; Reger, Thomas

PATENT ASSIGNEE(S): Merck & Co., Inc., USA

SOURCE: PCT Int. Appl., 119 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 5


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003029210	A2	20030410	WO 2002-US31294	20021001
WO 2003029210	A3	20031120		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2462289	AA	20030410	CA 2002-2462289	20021001
EP 1434773	A2	20040707	EP 2002-776076	20021001
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK			
JP 2005508344	T2	20050331	JP 2003-532460	20021001
WO 2004030637	A2	20040415	WO 2003-US9717	20030331
WO 2004030637	A3	20040923		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,  
 KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,  
 FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,  
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2004186295 A1 20040923 US 2004-491613 20040402  
 PRIORITY APPLN. INFO.: US 2001-327132P P 20011004  
 WO 2002-US31294 W 20021001  
 WO 2002-US40147 A 20021213  
 WO 2002-US41720 A 20021213  
 WO 2002-US40237 A 20021216  
 WO 2002-US40486 A 20021217

OTHER SOURCE(S): MARPAT 138:287681  
 GI



AB Title compds. I [X, Y = (un)substituted (hetero)aryl; A, B = alkyl, alkyl-SO-alkyl, alkyl-SO<sub>2</sub>-alkyl, etc.] are prepared. For instance, 2-formylpyridine is condensed with toluenesulfonyl hydrazide to form the hydrazone. 3-Chloroaniline is converted to the diazonium salt and reacted with the hydrazone to form 2-[2-(3-chlorophenyl)-2H-tetrazol-5-yl]pyridine (II) as a pale orange solid. Compds. of the invention have IC<sub>50</sub> < 10μM for mGluR5 in the calcium flux assay. I are mGluR5 modulators useful in the treatment of psychiatric and mood disorders such as, schizophrenia, anxiety, depression, and panic, as well as in the treatment of pain and other diseases.

IC ICM C07D

CC 28-10 (Heterocyclic Compounds (More Than One Hetero Atom))

Section cross-reference(s): 1

IT 507268-12-4P, 2-[2-(3-Chlorophenyl)-2H-tetrazol-5-yl]pyridine  
 507268-13-5P, 3-(5-Pyridin-2-yl-2H-tetrazol-2-yl)benzonitrile  
 507268-14-6P, 2-(2-Pyridin-3-yl-2H-tetrazol-5-yl)pyridine 507268-15-7P,  
 2-(3-Chlorophenyl)-5-(2-methyl-1,3-thiazol-4-yl)-2H-tetrazole  
 507268-16-8P, 3-[5-(2-Methylthiazol-4-yl)-2H-tetrazol-2-yl]benzonitrile  
 507268-17-9P, 2-[5-(3-Bromophenyl)-2H-tetrazol-2-yl]pyridine  
 507268-18-0P, 2-[5-(3-Chlorophenyl)-2H-tetrazol-2-yl]pyridine  
 507268-19-1P, 3-(2-Pyridin-2-yl-2H-tetrazol-5-yl)benzonitrile  
 507268-20-4P, 2-[2-(3,5-Difluorophenyl)-2H-tetrazol-5-yl]pyridine  
 507268-21-5P, 2-[2-(3-Methoxyphenyl)-2H-tetrazol-5-yl]pyridine  
 507268-22-6P, 2-[2-(3-Trifluoromethylphenyl)-2H-tetrazol-5-yl]pyridine  
 507268-23-7P, 2-[2-(3-Iodophenyl)-2H-tetrazol-5-yl]pyridine  
 507268-24-8P, 2-[2-(3-Bromophenyl)-2H-tetrazol-5-yl]pyridine  
 507268-25-9P, 2-[2-(3-Methylmercaptophenyl)-2H-tetrazol-5-yl]pyridine  
 507268-26-0P, 2-[2-(4-Fluorophenyl)-2H-tetrazol-5-yl]pyridine  
 507268-27-1P, 2-[2-(3-Fluorophenyl)-2H-tetrazol-5-yl]pyridine  
 507268-28-2P, 2-[2-(2-Methoxyphenyl)-2H-tetrazol-5-yl]pyridine  
 507268-29-3P, 2-[2-(3-Ethylphenyl)-2H-tetrazol-5-yl]pyridine  
 507268-30-6P, 2-[2-(3-Methylphenyl)-2H-tetrazol-5-yl]pyridine  
 507268-31-7P, 2-[2-(2-Chloro-3-pyridyl)-2H-tetrazol-5-yl]pyridine  
 507268-32-8P, 2-[2-(3,5-Dichlorophenyl)-2H-tetrazol-5-yl]pyridine  
 507268-33-9P, 2-[2-(2-Chlorophenyl)-2H-tetrazol-5-yl]pyridine  
 507268-34-0P, 2-[2-(4-Methoxyphenyl)-2H-tetrazol-5-yl]pyridine

507268-35-1P, 2-[2-(4-Pyridyl)-2H-tetrazol-5-yl]pyridine 507268-36-2P,  
2-[2-(3,5-Dimethylphenyl)-2H-tetrazol-5-yl]pyridine 507268-37-3P,  
3-[5-(6-Methylpyridin-2-yl)-2H-tetrazol-2-yl]benzonitrile 507268-38-4P,  
3-[5-(4-Methylpyridin-2-yl)-2H-tetrazol-2-yl]benzonitrile 507268-39-5P,  
2-[2-(3-Isopropylphenyl)-2H-tetrazol-5-yl]pyridine 507268-40-8P,  
2-[2-[3-(Trifluoromethoxy)phenyl]-2H-tetrazol-5-yl]pyridine  
507268-41-9P, 2-[2-(3-Ethoxyphenyl)-2H-tetrazol-5-yl]pyridine  
507268-42-0P, 2-[2-[3-Methoxy-5-(trifluoromethyl)phenyl]-2H-tetrazol-5-  
yl]pyridine 507268-43-1P, 3-[5-(1,3-Thiazol-2-yl)-2H-tetrazol-2-  
yl]benzonitrile 507268-44-2P, 3-[5-(5-Methylpyridin-2-yl)-2H-tetrazol-2-  
yl]benzonitrile 507268-45-3P, 3-[5-(3-Methylpyridin-2-yl)-2H-tetrazol-2-  
yl]benzonitrile 507268-46-4P, 3-[5-(1-Methyl-1H-imidazol-2-yl)-2H-  
tetrazol-2-yl]benzonitrile 507268-47-5P, 2-[2-(3,4-Dimethylphenyl)-2H-  
tetrazol-5-yl]pyridine 507268-48-6P, 2-[2-(3,4,5-Trichlorophenyl)-2H-  
tetrazol-5-yl]pyridine 507268-49-7P, 3-[5-(1,3-Thiazol-4-yl)-2H-tetrazol-  
2-yl]benzonitrile 507268-50-0P, 2-[2-(2,5-Dichlorophenyl)-2H-tetrazol-5-  
yl]pyridine 507268-51-1P, 2-[2-(3,4-Difluorophenyl)-2H-tetrazol-5-  
yl]pyridine 507268-52-2P, 2-[2-(3-Chloro-4-methylphenyl)-2H-tetrazol-5-  
yl]pyridine 507268-53-3P, 2-[2-(2,3-Dichlorophenyl)-2H-tetrazol-5-  
yl]pyridine 507268-54-4P, 2-[2-[3-Methyl-5-(trifluoromethyl)phenyl]-2H-  
tetrazol-5-yl]pyridine 507268-55-5P, 2-[2-(3-Bromo-4-methylphenyl)-2H-  
tetrazol-5-yl]pyridine 507268-56-6P, 2-[2-(3-Chloro-4-iodophenyl)-2H-  
tetrazol-5-yl]pyridine 507268-58-8P, 2-[2-[3-Fluoro-5-  
(trifluoromethyl)phenyl]-2H-tetrazol-5-yl]pyridine 507268-59-9P,  
3-(5-Pyrazin-2-yl-2H-tetrazol-2-yl)benzonitrile 507268-60-2P,  
2-[2-(2,3-Dihydro-1H-inden-5-yl)-2H-tetrazol-5-yl]pyridine 507268-61-3P,  
2-[2-(1,3-Dihydro-2-benzofuran-5-yl)-2H-tetrazol-5-yl]pyridine  
507268-62-4P, 2-[2-(4-Methoxy-2-naphthyl)-2H-tetrazol-5-yl]pyridine  
507268-63-5P, 2-[2-(1-Naphthyl)-2H-tetrazol-5-yl]pyridine 507268-64-6P,  
2-[2-(3,5-Dimethoxyphenyl)-2H-tetrazol-5-yl]pyridine 507268-66-8P,  
2-[2-(4-Phenoxyphenyl)-2H-tetrazol-5-yl]pyridine 507268-67-9P,  
3-[5-(3-Fluoropyridin-2-yl)-2H-tetrazol-2-yl]benzonitrile 507268-68-0P,  
3-(5-(Isoxazol-3-yl)-2H-tetrazol-2-yl)benzonitrile 507268-69-1P,  
3-[5-(1-Methyl-1H-pyrazol-3-yl)-2H-tetrazol-2-yl]benzonitrile  
507268-70-4P, 3-(5-(Oxazol-4-yl)-2H-tetrazol-2-yl)benzonitrile  
507268-71-5P 507268-72-6P, 3-[5-(1H-Imidazol-2-yl)-2H-tetrazol-2-  
yl]benzonitrile 507268-73-7P, 3-[5-(5-Hydroxypyridin-2-yl)-2H-tetrazol-2-  
yl]benzonitrile 507268-74-8P, 3-[5-(5-Bromopyridin-2-yl)-2H-tetrazol-2-  
yl]-5-fluorobenzonitrile 507268-75-9P, 3-Fluoro-5-[5-(3-fluoropyridin-2-  
yl)-2H-tetrazol-2-yl]benzonitrile 507268-76-0P, 3-Fluoro-5-[5-(oxazol-2-  
yl)-2H-tetrazol-2-yl]benzonitrile 507268-77-1P, 3-[3-Fluoro-5-[5-(1H-  
imidazol-2-yl)-2H-tetrazol-2-yl]phenoxy]pyridine 507268-78-2P,  
3-Fluoro-5-[5-(4-methyl-1H-imidazol-2-yl)-2H-tetrazol-2-yl]benzonitrile  
507268-79-3P, 3-[3-Fluoro-5-[5-(1H-[1,2,3]triazol-4-yl)-2H-tetrazol-2-  
yl]phenoxy]pyridine 507268-80-6P, 2-[2-[3-Fluoro-5-(pyridin-3-  
yloxy)phenyl]-2H-tetrazol-5-yl]pyrimidine 507268-81-7P,  
3-[3-Fluoro-5-[5-(1H-pyrazol-3-yl)-2H-tetrazol-2-yl]phenoxy]pyridine  
507268-82-8P, 3-[3-Fluoro-5-[5-(1-methyl-1H-pyrazol-3-yl)-2H-tetrazol-2-  
yl]phenoxy]pyridine 507268-83-9P, 3-Fluoro-5-[5-(1-methyl-1H-pyrazol-3-  
yl)-2H-tetrazol-2-yl]benzonitrile 507268-84-0P, N-[4-(5-Pyridin-2-yl-2H-  
tetrazol-2-yl)phenyl]pyridin-3-amine 507268-85-1P, 2-[2-[4-(Pyridin-3-  
ylmethyl)phenyl]-2H-tetrazol-5-yl]pyridine 507268-86-2P,  
N-[3-(5-Pyridin-2-yl-2H-tetrazol-2-yl)phenyl]pyridin-3-amine  
507268-87-3P, N-[3-(5-Pyridin-2-yl-2H-tetrazol-2-yl)phenyl]pyridin-2-amine  
507268-88-4P, 2-[2-[3-(Pyridin-2-yloxy)phenyl]-2H-tetrazol-5-yl]pyridine  
507268-89-5P, 2-[2-(3-Ethynylphenyl)-2H-tetrazol-5-yl]pyridine  
507268-90-8P, 2-[2-[4-(Pyridin-3-yloxy)phenyl]-2H-tetrazol-5-yl]pyridine  
507268-91-9P, 2-[2-[3-(Pyridin-3-yloxy)phenyl]-2H-tetrazol-5-yl]pyridine  
507268-92-0P, 2-[2-(3-Nitrophenyl)-2H-tetrazol-5-yl]pyridine  
507268-93-1P, 2-Methyl-3-[3-(5-pyridin-2-yl-2H-tetrazol-2-



yl)phenoxy]pyridine 507268-94-2P, 2-Methyl-N-[3-(5-pyridin-2-yl-2H-tetrazol-2-yl)phenyl]pyridin-3-amine 507268-95-3P, N-Methyl-N-[3-(5-pyridin-2-yl-2H-tetrazol-2-yl)phenyl]pyridin-3-amine 507268-96-4P, N-[3-Fluoro-5-(5-pyridin-2-yl-2H-tetrazol-2-yl)phenyl]-N-methylpyridin-3-amine 507268-97-5P, 2-[2-[3-Fluoro-5-(pyridin-3-yloxy)phenyl]-2H-tetrazol-5-yl]pyridine 507268-98-6P, N-[3-Fluoro-5-(5-pyridin-2-yl-2H-tetrazol-2-yl)phenyl]pyridin-3-amine 507268-99-7P, N-[3-[5-(5-Bromopyridin-2-yl)-2H-tetrazol-2-yl]-5-fluorophenyl]pyridin-3-amine 507269-00-3P, 2-[2-[3-Fluoro-5-(pyridin-3-ylmethyl)phenyl]-2H-tetrazol-5-yl]pyridine 507269-01-4P, 5-[3-Fluoro-5-(5-pyridin-2-yl-2H-tetrazol-2-yl)benzyl]-2-methylpyridine 507269-02-5P, 3-[3-Fluoro-5-[5-(1,3-thiazol-2-yl)-2H-tetrazol-2-yl]phenoxy]pyridine 507269-03-6P, 2-[2-[3-Fluoro-5-(pyridin-3-ylthio)phenyl]-2H-tetrazol-5-yl]pyridine 507269-04-7P, 2-[2-[3-Fluoro-5-[(pyridin-3-yloxy)methyl]phenyl]-2H-tetrazol-5-yl]pyridine 507269-05-8P, 3-Fluoro-2-[2-[3-fluoro-5-(pyridin-3-yloxy)phenyl]-2H-tetrazol-5-yl]pyridine 507269-06-9P, 2-[2-[3-Fluoro-5-(pyridin-3-yloxy)phenyl]-2H-tetrazol-5-yl]-6-methylpyridine 507269-07-0P 507269-08-1P, 3-Bromo-5-(5-pyridin-2-yl-2H-tetrazol-2-yl)pyridine 507269-09-2P, 2-[2-[4-(Allyloxy)-3-methoxyphenyl]-2H-tetrazol-5-yl]pyridine 507269-10-5P, 2-Methoxy-4-(5-pyridin-2-yl-2H-tetrazol-2-yl)phenol 507269-11-6P 507269-12-7P, 2-[2-(4-Bromo-3-methoxyphenyl)-2H-tetrazol-5-yl]pyridine 507269-13-8P, 2-[2-[3-Methoxy-4-(pyridin-2-yloxy)phenyl]-2H-tetrazol-5-yl]pyridine 507269-14-9P, 5-(5-Pyridin-2-yl-2H-tetrazol-2-yl)nicotinonitrile 507269-15-0P, [3-(5-Pyridin-2-yl-2H-tetrazol-2-yl)phenoxy]acetoneitrile 507269-16-1P, N-Pyridin-3-yl-5-(5-pyridin-2-yl-2H-tetrazol-2-yl)pyridin-3-amine 507269-17-2P, 3-(Pyridin-3-yloxy)-5-(5-pyridin-2-yl-2H-tetrazol-2-yl)pyridine 507269-18-3P, 3-Bromo-5-[5-(1H-imidazol-2-yl)-2H-tetrazol-2-yl]pyridine 507269-19-4P, 2-(Pyridin-3-yloxy)-5-(5-pyridin-2-yl-2H-tetrazol-2-yl)pyridine 507269-20-7P, 2-[(5-Chloropyridin-3-yl)oxy]-5-(5-pyridin-2-yl-2H-tetrazol-2-yl)pyridine 507269-21-8P, 2-Methyl-5-[[5-(5-pyridin-2-yl-2H-tetrazol-2-yl)pyridin-2-yl]oxy]pyridine 507269-22-9P, 2-Methyl-3-[[5-(5-pyridin-2-yl-2H-tetrazol-2-yl)pyridin-2-yl]oxy]pyridine 507269-23-0P, 2-[(4-Methylpyridin-3-yl)oxy]-5-(5-pyridin-2-yl-2H-tetrazol-2-yl)pyridine 507269-24-1P, 2-(Pyridin-4-yloxy)-5-(5-pyridin-2-yl-2H-tetrazol-2-yl)pyridine 507269-25-2P, 2-Bromo-5-(5-pyridin-2-yl-2H-tetrazol-2-yl)benzonitrile 507269-26-3P, 3-(5-Pyridin-2-yl-2H-tetrazol-2-yl)aniline 507269-27-4P, 3-Fluoro-5-(5-pyridin-2-yl-2H-tetrazol-2-yl)benzonitrile 507269-28-5P, 2-[2-[3-Bromo-5-(trifluoromethyl)phenyl]-2H-tetrazol-5-yl]pyridine 507269-29-6P, 3-(5-(Pyridin-2-yl)-2H-tetrazol-2-yl)-5-(trifluoromethyl)benzonitrile 507269-30-9P, 3-Nitro-5-(5-pyridin-2-yl-2H-tetrazol-2-yl)benzonitrile 507269-31-0P, 3-Amino-5-(5-pyridin-2-yl-2H-tetrazol-2-yl)benzonitrile 507269-32-1P, 3-Chloro-5-(5-pyridin-2-yl-2H-tetrazol-2-yl)benzonitrile 507269-33-2P 507269-34-3P 507269-35-4P, 2-[5-[3-Chloro-5-(pyridin-3-yloxy)phenyl]-2H-tetrazol-2-yl]pyridine 507269-36-5P, 2-[5-(3-Bromo-5-chlorophenyl)-2H-tetrazol-2-yl]pyridine 507269-37-6P, 3-Chloro-5-(2-pyridin-2-yl-2H-tetrazol-5-yl)benzonitrile 507269-38-7P, 3-Methyl-5-(2-pyridin-2-yl-2H-tetrazol-5-yl)benzonitrile 507269-39-8P, [3-(5-Pyridin-2-yl-2H-tetrazol-2-yl)phenyl]methanol 507269-40-1P, [3-(5-Pyridin-2-yl-2H-tetrazol-2-yl)phenyl]acetoneitrile 507269-41-2P, N-Methyl-3-(5-pyridin-2-yl-2H-tetrazol-2-yl)aniline 507269-42-3P, 2-[2-[3-(1H-Imidazol-1-ylmethyl)phenyl]-2H-tetrazol-5-yl]pyridine 507269-43-4P, 2-Methoxy-N-[3-(5-pyridin-2-yl-2H-tetrazol-2-yl)phenyl]aniline 507269-44-5P, 2-[2-(3-Fluoro-5-iodophenyl)-2H-tetrazol-5-yl]pyridine 507269-45-6P, 3-Fluoro-5-[5-(1H-imidazol-2-yl)-2H-tetrazol-2-yl]benzonitrile 507269-47-8P, 3-[5-(4,5-Dibromo-1H-imidazol-2-yl)-2H-tetrazol-2-yl]-5-fluorobenzonitrile 507269-49-0P, 2-[2-[3-Fluoro-5-(pyridin-3-ylmethoxy)phenyl]-2H-tetrazol-5-yl]pyridine 507269-50-3P, 2-[[3-Fluoro-5-(5-pyridin-2-yl-2H-tetrazol-2-yl)phenoxy]methyl]benzonitril

e 507269-51-4P, N-[3-Fluoro-5-[5-(1H-imidazol-2-yl)-2H-tetrazol-2-yl]phenyl]-N-methylpyridin-3-amine 507269-52-5P, 3-Chloro-5-[5-(1H-imidazol-2-yl)-2H-tetrazol-2-yl]benzonitrile 507269-53-6P, 3-[3-Fluoro-5-[5-(1-methyl-1H-imidazol-2-yl)-2H-tetrazol-2-yl]phenoxy]pyridine 507269-54-7P, 4-Chloro-2-(5-pyridin-2-yl-2H-tetrazol-2-yl)benzonitrile 507269-55-8P, 2-[2-(2,4-Dichlorophenyl)-2H-tetrazol-5-yl]pyridine 507269-56-9P, 2-[2-(5-Chloro-2-methoxyphenyl)-2H-tetrazol-5-yl]pyridine 507269-57-0P, 3-[5-(2-Methyl-2H-pyrazol-3-yl)-2H-tetrazol-2-yl]benzonitrile 507269-58-1P, 3-[5-(1H-Imidazol-4-yl)-2H-tetrazol-2-yl]benzonitrile 507269-59-2P, 3-[5-(5-Methoxypyridin-2-yl)-2H-tetrazol-2-yl]benzonitrile 507269-60-5P, 3-[5-(1H-Benzimidazol-2-yl)-2H-tetrazol-2-yl]benzonitrile 507269-61-6P, 4-Bromo-3-fluoro-5-[5-(3-fluoropyridin-2-yl)-2H-tetrazol-2-yl]benzonitrile 507269-62-7P, 3-[3-[5-(4,5-Dibromo-1H-imidazol-2-yl)-2H-tetrazol-2-yl]-5-fluorophenoxy]pyridine 507269-63-8P, 7-[2-[3-Fluoro-5-(pyridin-3-yloxy)phenyl]-2H-tetrazol-5-yl]pyrazolo[1,5-a]pyridine 507269-64-9P, 2-[2-(5-Methylisoxazol-3-yl)-2H-tetrazol-5-yl]pyridine 507269-65-0P, N-Phenyl-N-[4-(5-pyridin-2-yl-2H-tetrazol-2-yl)phenyl]amine 507269-66-1P, N-[4-(5-Pyridin-2-yl-2H-tetrazol-2-yl)phenyl]pyridin-2-amine 507269-67-2P, N-Phenyl-N-[3-(5-pyridin-2-yl-2H-tetrazol-2-yl)phenyl]amine 507269-68-3P, 2-[2-[4-(Pyridin-2-yloxy)phenyl]-2H-tetrazol-5-yl]pyridine 507269-69-4P, 2-[2-[3-(3-Methoxyphenoxy)phenyl]-2H-tetrazol-5-yl]pyridine 507269-70-7P, 2-Bromo-6-[2-[3-fluoro-5-(pyridin-3-yloxy)phenyl]-2H-tetrazol-5-yl]pyridine 507269-71-8P, 2-[2-[3-Fluoro-5-(pyridin-3-yloxy)phenyl]-2H-tetrazol-5-yl]-6-methoxypyridine 507269-72-9P 507269-73-0P, 2-Chloro-5-(5-pyridin-2-yl-2H-tetrazol-2-yl)pyridine 507269-74-1P, 3-[5-(1H-Imidazol-2-yl)-2H-tetrazol-2-yl]pyridine 507269-75-2P, 2-(2-Pyridin-2-yl-2H-tetrazol-5-yl)pyridine 507269-76-3P, N,N-Dimethyl-5-(5-pyridin-2-yl-2H-tetrazol-2-yl)pyridin-2-amine 507269-77-4P, N-Pyridin-2-yl-5-(5-pyridin-2-yl-2H-tetrazol-2-yl)pyridin-2-amine 507269-78-5P, N-Pyridin-3-yl-5-(5-pyridin-2-yl-2H-tetrazol-2-yl)pyridin-2-amine 507269-79-6P, 3-Chloro-N-[5-(5-(pyridin-2-yl)-2H-tetrazol-2-yl)pyridin-2-yl]-5-(trifluoromethyl)pyridin-2-amine 507269-80-9P, 3-(5-Quinolin-2-yl-2H-tetrazol-2-yl)benzonitrile 507269-81-0P, 3-(5-Isoquinolin-3-yl-2H-tetrazol-2-yl)benzonitrile 507269-82-1P, 2-[2-(4-Bromo-3-fluorophenyl)-2H-tetrazol-5-yl]pyridine 507269-83-2P, 2-[2-[3,5-Bis(trifluoromethyl)phenyl]-2H-tetrazol-5-yl]pyridine 507269-84-3P, 2-[2-[4-Bromo-3-(trifluoromethyl)phenyl]-2H-tetrazol-5-yl]pyridine 507269-85-4P 507269-86-5P, 2-[3-(5-Pyridin-2-yl-2H-tetrazol-2-yl)phenoxy]ethylamine 507269-87-6P, 2-[2-[3-Fluoro-5-(pyridin-2-ylmethoxy)phenyl]-2H-tetrazol-5-yl]pyridine 507269-88-7P, 2-[2-(2,6-Dichlorophenyl)-2H-tetrazol-5-yl]pyridine 507269-89-8P, [3-(5-Pyridin-2-yl-2H-tetrazol-2-yl)phenyl]acetic acid 507269-90-1P, 2-[2-(3-Iodo-4-methylphenyl)-2H-tetrazol-5-yl]pyridine 507269-91-2P, 2-[2-(4-Chloro-3-methylphenyl)-2H-tetrazol-5-yl]pyridine 507269-92-3P, 2-[2-(1,3-Benzodioxol-5-yl)-2H-tetrazol-5-yl]pyridine 507269-93-4P, 2-[2-[2-Chloro-5-(trifluoromethyl)phenyl]-2H-tetrazol-5-yl]pyridine 507269-94-5P, 2-Chloro-4-(5-pyridin-2-yl-2H-tetrazol-2-yl)benzonitrile 507269-95-6P, 2-[2-(4-Bromo-3-methylphenyl)-2H-tetrazol-5-yl]pyridine 507269-96-7P, 2-[2-(3,4-Dichlorophenyl)-2H-tetrazol-5-yl]pyridine 507269-97-8P, 2-[2-(3-Chloro-4-fluorophenyl)-2H-tetrazol-5-yl]pyridine 507269-98-9P, 2-[2-(3-Fluoro-4-methylphenyl)-2H-tetrazol-5-yl]pyridine 507269-99-0P, 1-[3-(5-Pyridin-2-yl-2H-tetrazol-2-yl)phenyl]ethanol 507270-00-0P, 1-[3-(5-Pyridin-2-yl-2H-tetrazol-2-yl)phenyl]ethanone 507270-01-1P, 2-[2-(3-Phenoxyphenyl)-2H-tetrazol-5-yl]pyridine 507270-02-2P, 2-[2-[3-(Benzyloxy)phenyl]-2H-tetrazol-5-yl]pyridine 507270-03-3P, 2-[2-[3-(Methylsulfonyl)phenyl]-2H-tetrazol-5-yl]pyridine 507270-04-4P, N-[3-(5-Pyridin-2-yl-2H-tetrazol-2-yl)phenyl]acetamide 507270-05-5P, 2-(5-Pyridin-2-yl-2H-tetrazol-2-yl)benzonitrile 507270-06-6P, 2-(2-Phenyl-2H-tetrazol-5-yl)pyridine

507270-07-7P, [2-Methoxy-4-(5-pyridin-2-yl-2H-tetrazol-2-yl)phenyl]acetonitrile 507270-08-8P, 2-[2-(3-Methoxy-4-methylphenyl)-2H-tetrazol-5-yl]pyridine 507270-09-9P, 2-[2-Methoxy-4-(5-(pyridin-2-yl)-2H-tetrazol-2-yl)phenyl]-2-methylpropanenitrile 507270-10-2P, 2-[Cyano[2-methoxy-4-(5-pyridin-2-yl-2H-tetrazol-2-yl)phenyl]methyl]nicotinonitrile 507270-11-3P, 2-[2-Methoxy-4-(5-pyridin-2-yl-2H-tetrazol-2-yl)phenyl]succinonitrile 507270-12-4P, 2-[2-Methoxy-4-(5-pyridin-2-yl-2H-tetrazol-2-yl)phenyl]propane-1,2,3-tricarbonitrile 507270-13-5P, 2-[2-Methoxy-4-(5-pyridin-2-yl-2H-tetrazol-2-yl)phenyl]propanenitrile 507270-14-6P 507270-15-7P, (6-Fluoropyridin-2-yl)[2-methoxy-4-(5-pyridin-2-yl-2H-tetrazol-2-yl)phenyl]acetonitrile 507270-16-8P, [2-Methoxy-4-(5-pyridin-2-yl-2H-tetrazol-2-yl)phenyl](pyridin-2-yl)acetonitrile 507270-17-9P, 2-[2-[4-(Methylthio)phenyl]-2H-tetrazol-5-yl]pyridine 507270-18-0P, 2-[4-(Trifluoromethoxy)phenyl]-2H-tetrazol-5-yl]pyridine 507270-19-1P, 4-[5-Pyridin-2-yl-2H-tetrazol-2-yl]benzonitrile 507270-20-4P, 2-[2-(4-Chlorophenyl)-2H-tetrazol-5-yl]pyridine 507270-21-5P, 2-[2-(2-Naphthyl)-2H-tetrazol-5-yl]pyridine 507270-22-6P, 2-[2-(3,5-Di-(tert-butyl)phenyl)-2H-tetrazol-5-yl]pyridine 507270-23-7P, 2-Fluoro-5-(5-pyridin-2-yl-2H-tetrazol-2-yl)benzonitrile 507270-24-8P, 2-[2-[4-(Bromomethyl)-3-methoxyphenyl]-2H-tetrazol-5-yl]pyridine 507270-25-9P, 2-Methoxy-4-(5-pyridin-2-yl-2H-tetrazol-2-yl)benzoic acid 507270-26-0P, 2-[2-Methoxy-4-(5-pyridin-2-yl-2H-tetrazol-2-yl)phenyl]ethanamine 507270-27-1P 507270-28-2P, 2-[2-Methoxy-4-(5-pyridin-2-yl-2H-tetrazol-2-yl)phenyl]propan-2-ol 507270-29-3P, 2-Methoxy-4-(5-pyridin-2-yl-2H-tetrazol-2-yl)benzamide 507270-30-6P, 2-Methoxy-4-(5-pyridin-2-yl-2H-tetrazol-2-yl)benzonitrile 507270-31-7P, 3-Bromo-6-(5-pyridin-2-yl-2H-tetrazol-2-yl)-1H-indole 507270-32-8P, 6-(5-Pyridin-2-yl-2H-tetrazol-2-yl)-1H-indole 507270-33-9P, 6-(5-Pyridin-2-yl-2H-tetrazol-2-yl)-1H-indole-1-carbonitrile 507270-34-0P, 6-(5-Pyridin-2-yl-2H-tetrazol-2-yl)-1H-indole-3-carbonitrile 507270-35-1P, 3-Methoxy-5-(5-pyridin-2-yl-2H-tetrazol-2-yl)benzonitrile 507270-36-2P, 3-[5-(1H-Imidazol-2-yl)-2H-tetrazol-2-yl]-5-methylbenzonitrile 507270-37-3P, 3-[3-Fluoro-5-[5-(4-methyl-1H-imidazol-2-yl)-2H-tetrazol-2-yl]phenoxy]pyridine 507270-38-4P, 3-Methyl-5-[5-(5-methyl-1H-imidazol-2-yl)-2H-tetrazol-2-yl]benzonitrile 507270-39-5P, 3-Chloro-5-[5-(5-methyl-1H-imidazol-2-yl)-2H-tetrazol-2-yl]benzonitrile 507270-40-8P, 3-Fluoro-5-[5-(1,3-thiazol-2-yl)-2H-tetrazol-2-yl]benzonitrile 507270-41-9P, 3-Fluoro-5-[5-(1,3-thiazol-4-yl)-2H-tetrazol-2-yl]benzonitrile 507270-42-0P, 3-[3-Fluoro-5-[5-(1,3-thiazol-4-yl)-2H-tetrazol-2-yl]phenoxy]pyridine 507270-43-1P, 3-Fluoro-5-[5-[4-(trifluoromethyl)-1H-imidazol-2-yl]-2H-tetrazol-2-yl]benzonitrile 507270-44-2P, 3-[5-(4-Methyl-1H-imidazol-2-yl)-2H-tetrazol-2-yl]-5-(pyridin-3-yloxy)benzonitrile 507270-45-3P, 3-Methoxy-5-[5-(4-methyl-1H-imidazol-2-yl)-2H-tetrazol-2-yl]benzonitrile

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of diaryl substituted tetrazole modulators of metabotropic glutamate receptor-5)


IT 507270-04-4P, N-[3-(5-Pyridin-2-yl-2H-tetrazol-2-yl)phenyl]acetamide

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of diaryl substituted tetrazole modulators of metabotropic glutamate receptor-5)

RN 507270-04-4 CAPLUS

CN Acetamide, N-[3-[5-(2-pyridinyl)-2H-tetrazol-2-yl]phenyl]- (9CI) (CA INDEX NAME)



L54 ANSWER 10 OF 23 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2002:964216 CAPLUS

DOCUMENT NUMBER: 138:33356

TITLE: Medicinal compositions as p38MAP kinase and/or TNF- $\alpha$  production inhibitor for pain

INVENTOR(S): Ohkawa, Shigenori; Naruo, Kenichi; Morimoto, Shigeru; Nagase, Yoshinori; Miwatashi, Seiji

PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan

SOURCE: PCT Int. Appl., 563 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002100433	A1	20021219	WO 2002-JP5726	20020610
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2450400	AA	20021219	CA 2002-2450400	20020610
JP 2003063993	A2	20030305	JP 2002-168226	20020610
EP 1402900	A1	20040331	EP 2002-733431	20020610
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 2005080113	A1	20050414	US 2003-480551	20020610
PRIORITY APPLN. INFO.:			JP 2001-175224	A 20010611
			JP 2001-175273	A 20010611
			WO 2002-JP5726	W 20020610

OTHER SOURCE(S): MARPAT 138:33356

AB Prevention/treatment for pain and/or suppression of the activation and/or inhibition of the formation of osteoclasts by using a p38MAP kinase inhibitor and/or a TNF- $\alpha$  production inhibitor. A method of HDL1 relieving a P 450-inhibitory effect of a compound having a pyridyl group or its salt characterized by introducing a substituent into the  $\alpha$ -position of the nitrogen atom in the pyridyl group of the above compound or its salt, or for relieving a P 450-inhibitory effect of a compound having a pyridyl group and an aromatic hydrocarbyl group or its salt characterized by introducing a polar group into the aromatic hydrocarbyl group of the above compound or its salt.

IC ICM A61K045-00

ICS A61K045-06; A61K031-4439; A61K031-444; A61K031-4545; A61K031-496; A61K031-5377; A61P029-00; A61P043-00; C07D417-04; C07D417-14

CC 1-11 (Pharmacology)  
Section cross-reference(s): 28, 63  
IT 224041-28-5, 2-Bromo-1-(3,5-dimethylphenyl)-2-(4-pyridyl)ethanone  
hydrobromide 224041-29-6, 2-Bromo-1-(3,4-methylenedioxyphenyl)-2-(4-  
pyridyl)ethanone hydrobromide 224041-30-9, 2-Bromo-1-(2-naphthyl)-2-(4-  
pyridyl)ethanone hydrobromide 242801-86-1, 4-Phenyl-1-  
piperazinecarbothioamide 252198-66-6 252198-74-6 252198-75-7  
252198-96-2, 1-(4-Cyclohexylphenyl)-2-(4-pyridyl)ethanone 252198-97-3  
284486-00-6 303162-27-8 303162-28-9, 2-Bromo-1-(3,5-dimethylphenyl)-2-  
(2-phenylmethoxy-4-pyridyl)ethanone hydrobromide 303162-30-3,  
2-(2-tert-Butoxycarbonylamino-4-pyridyl)-1-(4-methoxyphenyl)ethanone  
303162-31-4, [5-(2-Amino-4-pyridyl)-4-(4-methoxyphenyl)-1,3-thiazol-2-  
yl]amine 303162-34-7, 2-(2-tert-Butoxycarbonylamino-4-pyridyl)-1-(3,5-  
dimethylphenyl)ethanone 303162-37-0, 2-(2-tert-Butoxycarbonylamino-4-  
pyridyl)-1-(3-methylphenyl)ethanone 303162-38-1, 4-[2-Methyl-4-(3-  
methylphenyl)-1,3-thiazol-5-yl]-2-pyridylamine 303162-39-2,  
4-[2-Ethyl-4-(3-methylphenyl)-1,3-thiazol-5-yl]-2-pyridylamine  
303162-40-5 303162-41-6, 4-[4-(4-Methoxyphenyl)-2-methyl-1,3-thiazol-5-  
yl]-2-pyridylamine 303162-43-8, 2-(2-Amino-4-pyridyl)-2-bromo-1-(3-  
methylphenyl)ethanone hydrobromide 303162-45-0,  
4-[2-(4-Fluorophenyl)-4-(3-methylphenyl)-1,3-thiazol-5-yl]-2-pyridylamine  
303162-46-1, 4-[2-(2-Chlorophenyl)-4-(3-methylphenyl)-1,3-thiazol-5-yl]-2-  
pyridylamine 303162-47-2 303162-48-3, 4-[2-Butyl-4-(3-methylphenyl)-  
1,3-thiazol-5-yl]-2-pyridylamine 303162-49-4, 2-(2-Fluoro-4-pyridyl)-1-(3-  
methoxyphenyl)ethanone 303162-50-7, 2-(2-Fluoro-4-pyridyl)-1-(3-  
methoxyphenyl)ethanone 303162-52-9, [5-(2-Fluoro-4-pyridyl)-4-(3-  
methylphenyl)-1,3-thiazol-2-yl]amine 303162-54-1, [5-(2-Fluoro-4-  
pyridyl)-4-(3-methoxyphenyl)-1,3-thiazol-2-yl]amine 303162-55-2,  
5-(2-Fluoro-4-pyridyl)-4-(3-methylphenyl)-2-[4-(methylthio)phenyl]-1,3-  
thiazole 303162-57-4, [4-(3,5-Dimethylphenyl)-5-(2-phenylmethoxy-4-  
pyridyl)-1,3-thiazol-2-yl]amine 303162-58-5, N-[4-[2-Benzoylamino-4-(4-  
methoxyphenyl)-1,3-thiazol-5-yl]-2-pyridyl]benzamide 303162-59-6,  
N-[4-(4-Methoxyphenyl)-5-[2-[(3-pyridinecarboxylamino)]-4-pyridyl]-1,3-  
thiazol-2-yl]nicotinamide 303162-60-9, N-[4-[2-Amino-4-(4-methoxyphenyl)-  
1,3-thiazol-5-yl]-2-pyridyl]benzamide 303162-61-0, N-[4-[2-Amino-4-(3,5-  
dimethylphenyl)-1,3-thiazol-5-yl]-2-pyridyl]benzamide 303162-62-1,  
N-[4-[2-Amino-4-(3,5-dimethylphenyl)-1,3-thiazol-5-yl]-2-  
pyridyl]benzylamine 303162-64-3, N-[4-[2-Amino-4-(3,5-dimethylphenyl)-  
1,3-thiazol-5-yl]-2-pyridyl]benzamide hydrochloride 303162-66-5,  
N-[4-[2-Amino-4-(3,5-dimethylphenyl)-1,3-thiazol-5-yl]-2-  
pyridyl]benzylamine dihydrochloride 303162-67-6, N-[5-(2-Benzoylamino-4-  
pyridyl)-4-(3,5-dimethylphenyl)-1,3-thiazol-2-yl]acetamide 303162-68-7  
303162-69-8, N-[4-[4-(4-Methoxyphenyl)-2-methylamino-1,3-thiazol-5-yl]-2-  
pyridyl]benzamide 303162-70-1, N-[4-[2-Amino-4-(3-methylphenyl)-1,3-  
thiazol-5-yl]-2-pyridyl]benzamide 303162-71-2, N-[4-[4-(4-Methoxyphenyl)-  
2-methyl-1,3-thiazol-5-yl]-2-pyridyl]benzamide 303162-72-3,  
N-[4-[2-(4-Fluorophenyl)-4-(3-methylphenyl)-1,3-thiazol-5-yl]-2-  
pyridyl]phenylacetamide 303162-73-4, N-[4-[4-(4-Methoxyphenyl)-2-methyl-  
1,3-thiazol-5-yl]-2-pyridyl]phenylacetamide 303162-74-5,  
N-[4-[2-Ethyl-4-(3-methylphenyl)-1,3-thiazol-5-yl]-2-  
pyridyl]phenylacetamide 303162-75-6, N-[4-[4-(3-Methylphenyl)-2-propyl-  
1,3-thiazol-5-yl]-2-pyridyl]phenylacetamide 303162-76-7,  
N-[4-[2-Butyl-4-(3-methylphenyl)-1,3-thiazol-5-yl]-2-  
pyridyl]phenylacetamide 303162-77-8, N-[4-[2-(2-Chlorophenyl)-4-  
(3-methylphenyl)-1,3-thiazol-5-yl]-2-pyridyl]phenylacetamide  
303162-78-9, N-[4-[4-(3-Methylphenyl)-2-(4-methylthiophenyl)-1,3-thiazol-5-  
yl]-2-pyridyl]phenylacetamide 303162-79-0 303162-80-3,  
N-[4-[2-Ethyl-4-(3-methylphenyl)-1,3-thiazol-5-yl]-2-pyridyl]-3-  
phenylpropionamide 303162-81-4, N-[4-[2-Ethyl-4-(3-methylphenyl)-1,3-  
thiazol-5-yl]-2-pyridyl]-3-(4-methoxyphenyl)propionamide 303162-82-5,

N-[4-[2-Ethyl-4-(3-methylphenyl)-1,3-thiazol-5-yl]-2-pyridyl]-3-(4-fluorophenyl)propionamide 303162-85-8, N-[4-[4-(3-Methylphenyl)-2-propyl-1,3-thiazol-5-yl]-2-pyridyl]benzamide 303162-86-9, N-[4-[4-(3-Methylphenyl)-2-propyl-1,3-thiazol-5-yl]-2-pyridyl]-3-phenylpropionamide 303162-87-0, N-[4-[2-Butyl-4-(3-methylphenyl)-1,3-thiazol-5-yl]-2-pyridyl]benzamide 303162-88-1, N-[4-[2-Butyl-4-(3-methylphenyl)-1,3-thiazol-5-yl]-2-pyridyl]-3-phenylpropanamide 303162-89-2 303162-90-5, N-[4-[2-(4-Fluorophenyl)-4-(3-methylphenyl)-1,3-thiazol-5-yl]-2-pyridyl]-3-phenylpropanamide 303162-91-6, N-[4-[2-(2-Chlorophenyl)-4-(3-methylphenyl)-1,3-thiazol-5-yl]-2-pyridyl]benzamide 303162-92-7, N-[4-[2-(2-Chlorophenyl)-4-(3-methylphenyl)-1,3-thiazol-5-yl]-2-pyridyl]-3-phenylpropionamide 303162-93-8, N-[4-[4-(3-Methylphenyl)-2-(4-methylthiophenyl)-1,3-thiazol-5-yl]-2-pyridyl]benzamide 303162-94-9, N-[4-[4-(3-Methylphenyl)-2-(4-methylthiophenyl)-1,3-thiazol-5-yl]-2-pyridyl]-3-phenylpropionamide 303162-95-0, N-[4-[4-(3-Methylphenyl)-2-(4-methylthiophenyl)-1,3-thiazol-5-yl]-2-pyridyl]-2-thiophencarboxamide 303162-96-1 303162-97-2, N-[4-[2-Ethyl-4-(3-Methylphenyl)-1,3-thiazol-5-yl]-2-pyridyl]-N-methylphenylacetamide 303162-98-3 303162-99-4, N-Benzyl-N-[4-[4-(4-Methoxyphenyl)-2-methyl-1,3-thiazol-5-yl]-2-pyridyl]amine 303163-00-0 303163-01-1, N-[4-[2-Ethyl-4-(3-Methylphenyl)-1,3-thiazol-5-yl]-2-pyridyl]-N-(2-phenylethyl)amine 303163-02-2, N-[4-[2-Ethyl-4-(3-Methylphenyl)-1,3-thiazol-5-yl]-2-pyridyl]-N-(3-phenylpropyl)amine 303163-03-3, N-Benzyl-N-[4-[4-(3-Methylphenyl)-2-propyl-1,3-thiazol-5-yl]-2-pyridyl]amine 303163-04-4, N-[4-[4-(3-Methylphenyl)-2-propyl-1,3-thiazol-5-yl]-2-pyridyl]-N-(2-phenylethyl)amine 303163-05-5, N-[4-[4-(3-Methylphenyl)-2-propyl-1,3-thiazol-5-yl]-2-pyridyl]-N-(3-phenylpropyl)amine 303163-06-6, N-Benzyl-N-[4-[2-butyl-4-(3-Methylphenyl)-1,3-thiazol-5-yl]-2-pyridyl]amine 303163-07-7, N-[4-[2-Butyl-4-(3-Methylphenyl)-1,3-thiazol-5-yl]-2-pyridyl]-N-(2-phenylethyl)amine 303163-08-8, N-[4-[2-Butyl-4-(3-Methylphenyl)-1,3-thiazol-5-yl]-2-pyridyl]-N-(3-phenylpropyl)amine 303163-09-9, N-Benzyl-N-[4-[2-(4-fluorophenyl)-4-(3-Methylphenyl)-1,3-thiazol-5-yl]-2-pyridyl]amine 303163-10-2, N-[4-[2-(4-Fluorophenyl)-4-(3-Methylphenyl)-1,3-thiazol-5-yl]-2-pyridyl]-N-(2-phenylethyl)amine 303163-11-3, N-[4-[2-(4-Fluorophenyl)-4-(3-Methylphenyl)-1,3-thiazol-5-yl]-2-pyridyl]-N-(3-phenylpropyl)amine 303163-12-4, N-Benzyl-N-[4-[2-(2-chlorophenyl)-4-(3-Methylphenyl)-1,3-thiazol-5-yl]-2-pyridyl]amine 303163-13-5, N-[4-[2-(2-Chlorophenyl)-4-(3-Methylphenyl)-1,3-thiazol-5-yl]-2-pyridyl]-N-(2-phenylethyl)amine 303163-14-6, N-[4-[2-(2-Chlorophenyl)-4-(3-Methylphenyl)-1,3-thiazol-5-yl]-2-pyridyl]-N-(3-phenylpropyl)amine 303163-15-7 303163-16-8, N-[4-[4-(3-Methylphenyl)-2-(4-methylthiophenyl)-1,3-thiazol-5-yl]-2-pyridyl]-N-(2-phenylethyl)amine 303163-17-9, N-[4-[4-(3-Methylphenyl)-2-(4-methylthiophenyl)-1,3-thiazol-5-yl]-2-pyridyl]-N-(3-phenylpropyl)amine 303163-18-0, N-[4-[4-(3-Methylphenyl)-2-(4-methylthiophenyl)-1,3-thiazol-5-yl]-2-pyridyl]-N-(2-naphthylmethyl)amine 303163-19-1, N-[4-[4-(3-Methylphenyl)-2-(4-methylsulfonylphenyl)-1,3-thiazol-5-yl]-2-pyridyl]benzamide 303163-20-4, N-[4-[4-(3-Methylphenyl)-2-(4-methylsulfonylphenyl)-1,3-thiazol-5-yl]-2-pyridyl]phenylacetamide 303163-21-5 303163-22-6, N-[4-[4-(3-Methylphenyl)-2-(4-methylsulfonylphenyl)-1,3-thiazol-5-yl]-2-pyridyl]-2-thiophenecarboxamide 303163-23-7 303163-24-8, N-Benzyl-N-[4-[4-(3-Methylphenyl)-2-(4-methylsulfonylphenyl)-1,3-thiazol-5-yl]-2-pyridyl]amine 303163-25-9, N-[4-[4-(3-Methylphenyl)-2-(4-methylsulfonylphenyl)-1,3-thiazol-5-yl]-2-pyridyl]-N-(3-phenylpropyl)amine 303163-26-0, N-[4-[4-(3-Methylphenyl)-2-(4-methylsulfonylphenyl)-1,3-thiazol-5-yl]-2-pyridyl]-N-(2-naphthylmethyl)amine 303163-27-1 303163-28-2, N-[4-[2-Amino-4-(3-Methylphenyl)-1,3-thiazol-5-yl]-2-pyridyl]-N-(4-methoxybenzyl)amine 303163-29-3, N-[4-[2-Amino-4-(3-Methylphenyl)-1,3-thiazol-5-yl]-2-pyridyl]-N-(3-methoxybenzyl)amine 303163-30-6, N-[4-[2-Amino-4-(3-Methylphenyl)-

1,3-thiazol-5-yl]-2-pyridyl]-N-(2-methoxybenzyl)amine 303163-31-7,  
 N-[4-[2-Amino-4-(3-Methylphenyl)-1,3-thiazol-5-yl]-2-pyridyl]-N-(4-chlorobenzyl)amine 303163-32-8, N-[4-[2-Amino-4-(3-Methylphenyl)-1,3-thiazol-5-yl]-2-pyridyl]-N-(3-chlorobenzyl)amine 303163-33-9  
 303163-34-0, (S) N-[4-[2-Amino-4-(3-Methylphenyl)-1,3-thiazol-5-yl]-2-pyridyl]-N-(1-phenylethyl)amine 303163-35-1, N-[4-[2-Amino-4-(3-Methylphenyl)-1,3-thiazol-5-yl]-2-pyridyl]-N-benzyl-N-methylamine 303163-36-2, N-[4-[2-Amino-4-(3-Methoxyphenyl)-1,3-thiazol-5-yl]-2-pyridyl]-N-benzylamine 303163-37-3, N-[4-[4-(3-Methylphenyl)-2-(4-methylsulfonylphenyl)-1,3-thiazol-5-yl]-2-pyridyl]-N-(2-phenylethyl)amine 303163-38-4, N-(4-Fluorobenzyl)-N-[4-[4-(3-Methylphenyl)-2-(4-methylsulfonylphenyl)-1,3-thiazol-5-yl]-2-pyridyl]amine 303163-39-5, N-Benzyl-N-methyl-N-[4-[4-(3-Methylphenyl)-2-(4-methylsulfonylphenyl)-1,3-thiazol-5-yl]-2-pyridyl]amine 303163-40-8, N-Methyl-N-[4-[4-(3-Methylphenyl)-2-(4-methylsulfonylphenyl)-1,3-thiazol-5-yl]-2-pyridyl]-N-(2-phenylethyl)amine 303163-41-9, N-[4-[4-(3-Methylphenyl)-2-(4-methylsulfonylphenyl)-1,3-thiazol-5-yl]-2-pyridyl]-N-(2-thienylmethyl)amine 303163-42-0, 4-(3-Methylphenyl)-2-(4-methylsulfonylphenyl)-5-(2-phenylthio-4-pyridyl)-1,3-thiazole 303163-43-1, 5-(2-Benzylthio-4-pyridyl)-4-(3-Methylphenyl)-2-(4-methylsulfonylphenyl)-1,3-thiazole 303163-44-2 303787-77-1  
 303787-79-3, 2-Bromo-1-(4-chlorophenyl)-2-(3-pyridyl)ethanone hydrobromide 303787-81-7 303787-83-9, 2-Bromo-1-(3-methylphenyl)-2-(3-pyridyl)ethanone hydrobromide 303787-85-1, 2-Bromo-1-(3-methoxyphenyl)-2-(3-pyridyl)ethanone hydrobromide 303787-87-3 303787-89-5, 2-Bromo-1-(3-methoxyphenyl)-2-(4-pyridyl)ethanone hydrobromide 303787-91-9, 2-Bromo-2-(4-pyridyl)-1-(4-trifluoromethoxyphenyl)ethanone hydrobromide 303787-98-6 325707-98-0 325767-68-8 325767-69-9  
 325767-71-3 325767-72-4 325767-73-5 325767-74-6 325767-75-7  
 325767-77-9 325767-79-1 325767-80-4 325767-81-5 325767-82-6  
 325767-83-7 325767-84-8 325767-85-9 325767-86-0 325767-87-1  
 325767-88-2 325767-89-3 325767-90-6 325767-91-7 325767-92-8  
 325767-93-9 325767-94-0 325767-95-1 325767-96-2 325767-97-3  
 325767-98-4 325767-99-5 325768-00-1 325768-02-3 325768-03-4  
 325768-04-5 325768-05-6 325768-06-7 325768-07-8 325768-08-9  
 325768-09-0 325768-10-3 325768-11-4 325768-12-5 325768-13-6  
 325768-14-7 325768-15-8 325768-16-9 325768-17-0 325768-18-1  
 325768-19-2 325768-20-5 325768-21-6 325768-22-7 325768-23-8  
 325768-24-9 325768-25-0 325768-27-2 325768-28-3 325768-29-4  
 325768-30-7 325768-31-8 325768-32-9 325768-33-0 325768-34-1  
 325768-35-2 325768-36-3 325768-37-4 325768-38-5 325768-39-6  
 325768-40-9 325768-41-0 325768-42-1 325768-43-2 325768-44-3  
 325768-45-4 325768-46-5 325768-47-6 325768-48-7 325768-49-8  
 325768-50-1 325768-51-2 325768-52-3 325768-53-4 325768-54-5  
 325768-55-6 325768-56-7 325768-57-8 325768-58-9 325768-59-0  
 325768-60-3 325768-61-4 325768-62-5 325768-63-6 325768-64-7  
 325768-65-8 325768-66-9 325768-67-0 325768-68-1 325768-69-2  
 325768-70-5 325768-71-6 325768-72-7 325768-73-8 325768-75-0  
 325768-76-1 325768-77-2 325768-78-3 325768-79-4 325768-80-7  
 325768-81-8 325768-82-9 325768-83-0 325768-84-1

RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)


(medicinal compns. as p38MAP kinase and/or TNF- $\alpha$  production inhibitor for pain)

IT 303162-77-8, N-[4-[2-(2-Chlorophenyl)-4-(3-methylphenyl)-1,3-thiazol-5-yl]-2-pyridyl]phenylacetamide 303162-91-6, N-[4-[2-(2-Chlorophenyl)-4-(3-methylphenyl)-1,3-thiazol-5-yl]-2-pyridyl]benzamide 303162-92-7, N-[4-[2-(2-Chlorophenyl)-4-(3-methylphenyl)-1,3-thiazol-5-yl]-2-pyridyl]-3-phenylpropionamide  
 RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic

use); BIOL (Biological study); USES (Uses)  
 (medicinal compns. as p38MAP kinase and/or TNF- $\alpha$  production inhibitor  
 for pain)


RN 303162-77-8 CAPLUS

CN Benzeneacetamide, N-[4-[2-(2-chlorophenyl)-4-(3-methylphenyl)-5-thiazolyl]-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 303162-91-6 CAPLUS

CN Benamide, N-[4-[2-(2-chlorophenyl)-4-(3-methylphenyl)-5-thiazolyl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 303162-92-7 CAPLUS

CN Benzenepropanamide, N-[4-[2-(2-chlorophenyl)-4-(3-methylphenyl)-5-thiazolyl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT:

20

THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS  
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT



L54 ANSWER 11 OF 23 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2002:449677 CAPLUS

DOCUMENT NUMBER: 137:33288

TITLE: Preparation of substituted thiazole derivatives bearing 3-pyridyl groups as steroid C17,20 lyase inhibitors, process for preparing the same and use thereof

INVENTOR(S): Kusaka, Masami; Kuroda, Noritaka; Nara, Yoshi; Hashiguchi, Shohei; Tasaka, Akihiro; Yamaoka, Masuo; Kaku, Tomohiro

PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan

SOURCE: PCT Int. Appl., 190 pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002046186	A1	20020613	WO 2001-JP10723	20011207
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ; LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2431171	AA	20020613	CA 2001-2431171	20011207
AU 2002021080	A5	20020618	AU 2002-21080	20011207
JP 2002234843	A2	20020823	JP 2001-375062	20011207
EP 1348706	A1	20031001	EP 2001-999258	20011207
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 2004072876	A1	20040415	US 2003-433910	20030604
PRIORITY APPLN. INFO.:			JP 2000-373868	A 20001208
			WO 2001-JP10723	W 20011207
OTHER SOURCE(S):			MARPAT 137:33288	
GI				



AB Disclosed are pharmaceutical compns., more particularly, steroid C17,20 lyase inhibitors characterized by containing a compound of the general formula (I) or a salt or prodrug thereof (wherein A1 is an optionally substituted aromatic hydrocarbon group or an optionally substituted heterocyclic group; and one of A2 or A3 is hydrogen, halogeno, an optionally substituted C1-4 aliphatic hydrocarbon group, or optionally esterified carboxyl, and the other is an optionally substituted heterocyclic group, with the proviso that at

least one of A1, A2, and A3 is optionally substituted 3-pyridyl). These compns. are useful as preventive or therapeutic agents for sex hormone-dependent diseases such as prostatic hypertrophy, virilism, hypertrichosis, male alopecia, male early maturation, endometriosis, hysterosarcoma, uterine adenomyosis, mastopathy, and polycystic ovary syndrome. Thus, 2-bromo-1-(4-methylpyridin-3-yl)ethanone hydrobromide and 4-methylpyridine-3-thiocarboxamide were suspended in ethanol and refluxed for 3 h to give 4-methyl-3-[2-(4-methylpyridin-3-yl)-1,3-thiazol-4-yl]pyridine (II). II showed IC<sub>50</sub> of <10 nM against rat steroid C17,20 lyase. Pharmaceutical formulations, e.g. a coated tablet containing II, were prepared

IC ICM C07D417-04  
ICS C07D417-14; A61K031-4439; A61K031-4545; A61K031-4725; A61P043-00; A61P013-08; A61P015-00; A61P017-14; A61P035-00

CC 28-7 (Heterocyclic Compounds (More Than One Hetero Atom))  
Section cross-reference(s): 1, 63

IT 25021-37-8P 71562-73-7P 93209-48-4P 181632-82-6P 222629-41-6P  
435271-34-4P 435271-35-5P 435271-36-6P 435271-37-7P 435271-38-8P  
435271-39-9P 435271-40-2P 435271-41-3P 435271-42-4P 435271-43-5P  
435271-44-6P 435271-45-7P 435271-46-8P 435271-47-9P 435271-48-0P  
435271-49-1P 435271-50-4P 435271-51-5P 435271-52-6P 435271-53-7P  
435271-54-8P 435271-55-9P 435271-56-0P 435271-57-1P 435271-58-2P  
435271-59-3P 435271-60-6P 435271-61-7P 435271-62-8P 435271-63-9P  
435271-64-0P 435271-65-1P 435271-66-2P 435271-67-3P 435271-68-4P  
435271-69-5P 435271-70-8P 435271-71-9P 435271-72-0P 435271-73-1P  
435271-74-2P 435271-75-3P 435271-76-4P 435271-77-5P 435271-78-6P  
435271-79-7P 435271-80-0P 435271-81-1P 435271-82-2P 435271-83-3P  
435271-84-4P 435271-85-5P 435271-86-6P 435271-87-7P 435271-88-8P  
435271-89-9P 435271-90-2P 435271-91-3P 435271-92-4P 435271-93-5P  
435271-94-6P 435271-95-7P 435271-96-8P 435271-97-9P 435271-98-0P  
435271-99-1P 435272-00-7P 435272-01-8P 435272-02-9P 435272-03-0P  
435272-04-1P 435272-05-2P 435272-06-3P 435272-07-4P  
435272-08-5P 435272-09-6P 435272-10-9P 435272-11-0P 435272-12-1P  
435272-13-2P 435272-14-3P 435272-15-4P 435272-16-5P 435272-17-6P  
435272-18-7P 435272-19-8P 435272-20-1P 435272-21-2P 435272-22-3P  
435272-23-4P 435272-24-5P 435272-25-6P 435272-26-7P 435272-27-8P,  
4-[3-[4-(4-Chlorophenyl)-1,3-thiazol-2-yl]pyridin-4-yl]morpholine  
435272-28-9P 435272-29-0P 435272-30-3P, 2-[3-[4-(4-Chlorophenyl)-1,3-thiazol-2-yl]pyridin-4-yl]propan-2-ol 435272-31-4P, 3-[4-(4-Chlorophenyl)-1,3-thiazol-2-yl]-N,N-dimethylisonicotinamide 435272-32-5P  
435272-33-6P 435272-34-7P 435272-35-8P, 3-[5-Chloro-4-(4-chlorophenyl)-1,3-thiazol-2-yl]-4-methylpyridine 435272-36-9P 435272-37-0P  
435272-38-1P, 3-[5-Fluoro-4-(4-methylphenyl)-1,3-thiazol-2-yl]-4-methylpyridine 435272-39-2P, 4-[2-(4-Methylpyridin-3-yl)-1,3-thiazol-4-yl]benzenesulfonamide 435272-40-5P, 4-[2-[4-(Trifluoromethyl)pyridin-3-yl]-1,3-thiazol-4-yl]benzenesulfonamide 435272-41-6P,  
4-[2-[4-(Trifluoromethyl)pyridin-3-yl]-1,3-thiazol-4-yl]aniline  
435272-42-7P, 3-[2-[4-(Trifluoromethyl)pyridin-3-yl]-1,3-thiazol-4-yl]aniline 435272-43-8P, N-(4-[2-[4-(Trifluoromethyl)pyridin-3-yl]-1,3-thiazol-4-yl]phenyl)acetamide 435272-44-9P, N-(4-[2-[4-(Trifluoromethyl)pyridin-3-yl]-1,3-thiazol-4-yl]phenyl)methanesulfonamide hydrochloride 435272-45-0P, N-(3-[2-[4-(Trifluoromethyl)pyridin-3-yl]-1,3-thiazol-4-yl]phenyl)methanesulfonamide hydrochloride 435272-46-1P,  
4-[2-[4-(Trifluoromethyl)pyridin-3-yl]-1,3-thiazol-4-yl]benzoic acid  
435272-47-2P, 4-[2-(4-Methylpyridin-3-yl)-1,3-thiazol-4-yl]benzoic acid  
435272-48-3P, 4-[2-[4-(Trifluoromethyl)pyridin-3-yl]-1,3-thiazol-4-yl]benzamide 435272-49-4P, 4-[2-(4-Methylpyridin-3-yl)-1,3-thiazol-4-yl]benzamide 435272-50-7P, 3-[4-(4-Methylpyridin-3-yl)-1,3-thiazol-2-yl]benzamide 435272-51-8P, N-Methyl-3-[4-(4-methylpyridin-3-yl)-1,3-thiazol-2-yl]benzamide 435272-52-9P, N,N-Dimethyl-3-[4-(4-methylpyridin-

3-yl)-1,3-thiazol-2-yl]benzamide 435272-53-0P, 4-[4-(4-Methylpyridin-3-yl)-1,3-thiazol-2-yl]benzamide 435272-54-1P, N-Methyl-4-[4-(4-methylpyridin-3-yl)-1,3-thiazol-2-yl]benzamide 435272-55-2P, N,4-Dimethyl-3-[4-(4-methylpyridin-3-yl)-1,3-thiazol-2-yl]benzamide 435272-56-3P, N,N,4-Trimethyl-3-[4-(4-methylpyridin-3-yl)-1,3-thiazol-2-yl]benzamide 435272-57-4P, 4-Methyl-3-[2-[2-methyl-5-(pyrrolidin-1-yl)carbonyl]phenyl]-1,3-thiazol-4-yl]pyridine 435272-58-5P, 4-Fluoro-N-methyl-3-[4-(4-methylpyridin-3-yl)-1,3-thiazol-2-yl]benzamide 435272-59-6P, 2-Chloro-N-methyl-5-[4-(4-methylpyridin-3-yl)-1,3-thiazol-2-yl]benzamide 435272-60-9P, N-[3-[4-(4-Methylpyridin-3-yl)-1,3-thiazol-2-yl]phenyl]acetamide 435272-61-0P, N-[4-[4-(4-Methylpyridin-3-yl)-1,3-thiazol-2-yl]phenyl]acetamide 435272-62-1P, 4-Methyl-3-[4-(4-methylpyridin-3-yl)-1,3-thiazol-2-yl]phenyl]formamide 435272-63-2P, N-[4-Methyl-3-[4-(4-methylpyridin-3-yl)-1,3-thiazol-2-yl]phenyl]acetamide 435272-64-3P, 4-Methyl-3-[2-(2-pyridyl)-1,3-thiazol-4-yl]pyridine 435272-65-4P, 4-Methyl-3-[2-(3-pyridyl)-1,3-thiazol-4-yl]pyridine 435272-66-5P, 4-Methyl-3-[2-(4-pyridyl)-1,3-thiazol-4-yl]pyridine 435272-67-6P, 5-[4-(4-Methylpyridin-3-yl)-1,3-thiazol-2-yl]nicotinamide 435272-68-7P, N-Methyl-5-[4-(4-methylpyridin-3-yl)-1,3-thiazol-2-yl]nicotinamide 435272-69-8P, N-Ethyl-5-[4-(4-methylpyridin-3-yl)-1,3-thiazol-2-yl]nicotinamide 435272-70-1P, N-Methyl-6-[4-(4-methylpyridin-3-yl)-1,3-thiazol-2-yl]pyridine-2-carboxamide 435272-71-2P, N-Methyl-6-[4-(4-methylpyridin-3-yl)-1,3-thiazol-2-yl]nicotinamide 435272-72-3P, 4-[4-(4-Methylpyridin-3-yl)-1,3-thiazol-2-yl]isoindolin-1-one 435272-73-4P, 2-Methyl-4-[4-(4-methylpyridin-3-yl)-1,3-thiazol-2-yl]isoindolin-1-one 435272-74-5P, 5-[4-(4-Methylpyridin-3-yl)-1,3-thiazol-2-yl]pyridin-2(1H)-one 435272-75-6P, 3-[4-(4-Methylpyridin-3-yl)-1,3-thiazol-2-yl]isoquinoline 435272-76-7P, 1-[4-(4-Methylpyridin-3-yl)-1,3-thiazol-2-yl]isoquinoline 435272-77-8P, 2,4-Dimethoxy-5-[4-(4-methylpyridin-3-yl)-1,3-thiazol-2-yl]pyrimidine 435272-78-9P, 3-[5-Methyl-4-(4-methylpyridin-3-yl)-1,3-thiazol-2-yl]benzamide 435272-79-0P, 3-[5-Isopropyl-4-(4-methylpyridin-3-yl)-1,3-thiazol-2-yl]benzamide 435272-80-3P, 3-[5-Chloro-4-(4-methylpyridin-3-yl)-1,3-thiazol-2-yl]-N,N-dimethylbenzamide 435272-81-4P, 3-[5-Methyl-4-(4-methylpyridin-3-yl)-1,3-thiazol-2-yl]benzenesulfonamide 435272-82-5P, 3-[2-[4-Methylpyridin-3-yl]-1,3-thiazol-4-yl]benzamide 435272-83-6P, 3-[2-[4-(Trifluoromethyl)pyridin-3-yl]-1,3-thiazol-4-yl]benzamide 435272-84-7P, 2-Fluoro-5-[2-[4-(trifluoromethyl)pyridin-3-yl]-1,3-thiazol-4-yl]benzamide 435272-85-8P, 2-Fluoro-N-methyl-5-[2-[4-(trifluoromethyl)pyridin-3-yl]-1,3-thiazol-4-yl]benzamide 435272-86-9P, 2-Fluoro-N,N-dimethyl-5-[2-[4-(trifluoromethyl)pyridin-3-yl]-1,3-thiazol-4-yl]benzamide 435272-87-0P, N-Ethyl-2-fluoro-5-[2-[4-(trifluoromethyl)pyridin-3-yl]-1,3-thiazol-4-yl]benzamide 435272-88-1P, 3-[4-(4-(Ethylpyridin-3-yl)-1,3-thiazol-2-yl]benzamide 435272-89-2P, 3-[4-(4-(Ethylpyridin-3-yl)-1,3-thiazol-2-yl]-N-methylbenzamide 435272-90-5P, 3-[4-(4-(Ethylpyridin-3-yl)-1,3-thiazol-2-yl]-N,N-dimethylbenzamide 435272-91-6P, 3-[4-(4-(Isopropylpyridin-3-yl)-1,3-thiazol-2-yl]benzamide 435272-92-7P, 3-[4-(4-(Isopropylpyridin-3-yl)-1,3-thiazol-2-yl]-N,4-dimethylbenzamide 435272-94-9P, 3-[4-(4-(Isopropylpyridin-3-yl)-1,3-thiazol-2-yl]-N,N-dimethylbenzamide hemifumarate 435272-95-0P, 3-[4-(4-(Ethylpyridin-3-yl)-1,3-thiazol-2-yl]benzenesulfonamide 435272-96-1P, 4-[4-(4-(Ethylpyridin-3-yl)-1,3-thiazol-2-yl]benzenesulfonamide 435273-00-0P, 3-[4-(3-Bromo-4-fluorophenyl)-1,3-thiazol-2-yl]-4-(trifluoromethyl)pyridine 435273-01-1P, Ethyl 2-fluoro-5-[2-[4-trifluoromethyl)pyridin-3-yl]-1,3-thiazol-4-yl]benzoic acid 435273-03-3P, 4-Methyl-3-[2-(4-methylpyridin-3-yl)-1,3-thiazol-4-yl]pyridine 435273-04-4P, 4-Methyl-3-[4-(pyridin-4-yl)-1,3-thiazol-2-yl]pyridine 435273-05-5P, N-Methyl-3-[2-(4-methylpyridin-3-yl)-1,3-thiazol-4-yl]benzamide 435273-06-6P, N,N-Dimethyl-3-[2-(4-methylpyridin-3-yl)-1,3-thiazol-4-yl]benzamide

435273-07-7P, N-Ethyl-3-[2-(4-methylpyridin-3-yl)-1,3-thiazol-4-yl]benzamide 435273-08-8P, 3-[4-[3-(1-Azetidinylcarbonyl)phenyl]-1,3-thiazol-2-yl]-4-methylpyridine

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of substituted pyridylthiazole derivs. as steroid C17,20 lyase inhibitors for treatment and prevention of sex hormone-dependent diseases)


IT 435272-05-2P 435272-60-9P, N-[3-[4-(4-Methylpyridin-3-yl)-1,3-thiazol-2-yl]phenyl]acetamide 435272-63-2P, N-[4-Methyl-3-[4-(4-methylpyridin-3-yl)-1,3-thiazol-2-yl]phenyl]acetamide

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of substituted pyridylthiazole derivs. as steroid C17,20 lyase inhibitors for treatment and prevention of sex hormone-dependent diseases)

RN 435272-05-2 CAPLUS


CN Acetamide, N-[3-[2-[4-(trifluoromethyl)-3-pyridinyl]-4-thiazolyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 435272-60-9 CAPLUS

CN Acetamide, N-[3-[4-(4-methyl-3-pyridinyl)-2-thiazolyl]phenyl]- (9CI) (CA INDEX NAME)



RN 435272-63-2 CAPLUS

CN Acetamide, N-[4-methyl-3-[4-(4-methyl-3-pyridinyl)-2-thiazolyl]phenyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 78 THERE ARE 78 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L54 ANSWER 12 OF 23 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2000:772628 CAPLUS

DOCUMENT NUMBER: 133:321879

TITLE: Preparation of 5-pyridyl-1,3-azole compounds as antagonists of adenosine A3 receptor, process for producing the same and use thereof

INVENTOR(S): Ohkawa, Shigenori; Kanzaki, Naoyuki; Miwatashi, Seiji

PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan

SOURCE: PCT Int. Appl., 152 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000064894	A1	20001102	WO 2000-JP2575	20000420
W:	AE, AG, AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CR, CU, CZ, DM, DZ, EE, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MA, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ZA			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
CA 2370264	AA	20001102	CA 2000-2370264	20000420
EP 1180518	A1	20020220	EP 2000-917375	20000420
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
BR 2000009952	A	20020326	BR 2000-9952	20000420
NZ 515215	A	20030725	NZ 2000-515215	20000420
AU 765473	B2	20030918	AU 2000-38401	20000420
RU 2237062	C2	20040927	RU 2001-131556	20000420
JP 2001114779	A2	20010424	JP 2000-126289	20000421
JP 3333774	B2	20021015		
JP 2002363179	A2	20021218	JP 2002-164744	20000421
TW 220900	B1	20040911	TW 2000-89122035	20001020
NO 2001005156	A	20011218	NO 2001-5156	20011022
NO 320588	B1	20051227		
ZA 2001008996	A	20030131	ZA 2001-8996	20011031
PRIORITY APPLN. INFO.:			JP 1999-116686	A 19990423
			JP 1999-224650	A 19990806
			WO 2000-JP2575	W 20000420
			JP 2000-126289	A3 20000421

OTHER SOURCE(S): MARPAT 133:321879

GI




- AB Optionally N-oxidized compds. represented by general formula (I) salts thereof [wherein R1 represents hydrogen, hydrocarbyl, a heterocycle, amino or acyl; R2 represents an aromatic group; R3 represents hydrogen, pyridyl or aromatic hydrocarbyl; X represents oxygen or optionally oxidized sulfur; Y represents a bond, oxygen, optionally oxidized sulfur or NR4 (wherein R4 represents hydrogen, hydrocarbyl, or acyl); and Z represents a bond or a divalent chain hydrocarbyl] are prepared. These compds. are usable as preventives or remedies for diseases in association with adenosine A3 receptor because of having excellent adenosine A3 receptor antagonism thereof. Moreover, the compds. I or salts thereof exhibit excellent effects of inhibiting p38 MAP kinase and inhibiting TNF- $\alpha$  and, therefore, are also usable as preventives or remedies for diseases in association with p38 MAP kinase or TNF- $\alpha$ . Above diseases include asthma, allergies, brain edema, cerebral vascular disorders, head injuries, inflammation, Addison's disease, autoimmune hemolytic anemia, Crohn's disease, psoriasis, rheumatism, spinal cord injury, multiple sclerosis, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, diabetes, arthritis, septicemia, ulcerative colitis, chronic pneumonia, silicosis, lung sarcoidosis, pulmonary tuberculosis, cachexia, arteriosclerosis, Creutzfeldt-Jakob disease, virus infection, atopic dermatitis, systemic lupus erythematosus, AIDS encephalopathy, meningitis, angina pectoris, myocardial infarction, ischemic heart failure, hepatitis, transplant, dialysis hypotension, and frequent disseminated intravascular coagulation. Thus, bromination of 2-(2-benzoylamino-4-pyridyl)-1-(4-methoxyphenyl)ethanone with Br in AcOH at room temperature for 1 h followed by cyclocondensation of the bromination product with thiourea in the presence of Et3N in MeCN at 80° for 5 h gave N-[4-[2-amino-4-(4-methoxyphenyl)-1,3-thiazol-5-yl]-2-pyridyl]benzamide (II). II showed IC50 of 0.020  $\mu$ M against p38 MAP kinase and 0.014  $\mu$ M for inhibiting the production of TNF- $\alpha$  in THP-1 cells.
- IC ICM C07D417-04  
ICS C07D417-14; A61K031-4439; A61P043-00; A61P029-00; A61P031-12; A61P003-10; A61P001-00; A61P009-00; A61P007-00
- CC 28-7 (Heterocyclic Compounds (More Than One Hetero Atom))  
Section cross-reference(s): 1, 7
- IT 303162-57-4P 303162-71-2P 303162-72-3P 303162-74-5P 303162-75-6P  
303162-76-7P **303162-77-8P** 303162-78-9P 303162-79-0P  
303162-80-3P 303162-85-8P 303162-86-9P 303162-87-0P 303162-88-1P  
303162-89-2P 303162-90-5P **303162-91-6P 303162-92-7P**  
303162-93-8P 303162-94-9P 303162-95-0P 303162-96-1P 303163-15-7P  
303163-17-9P 303163-18-0P  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(preparation of pyridylazole compds. as antagonists of adenosine A3 receptor and inhibitors of TNF- $\alpha$  and p38 MAP kinase for therapeutics)
- IT **303162-77-8P 303162-91-6P 303162-92-7P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of pyridylazole compds. as antagonists of adenosine A3 receptor and inhibitors of TNF- $\alpha$  and p38 MAP kinase for therapeutics)


RN 303162-77-8 CAPLUS

CN Benzeneacetamide, N-[4-[2-(2-chlorophenyl)-4-(3-methylphenyl)-5-thiazolyl]-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 303162-91-6 CAPLUS

CN Benzenamide, N-[4-[2-(2-chlorophenyl)-4-(3-methylphenyl)-5-thiazolyl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 303162-92-7 CAPLUS

CN Benzenepropanamide, N-[4-[2-(2-chlorophenyl)-4-(3-methylphenyl)-5-thiazolyl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L54 ANSWER 13 OF 23 USPATFULL on STN

ACCESSION NUMBER: 2005:286541 USPATFULL

TITLE: Compositions and methods for treating hepatitis C  
virus (HCV) infection

INVENTOR(S): Holsztynska, Elzbieta J., Half Moon Bay, CA, UNITED  
STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005249805	A1	20051110
APPLICATION INFO.:	US 2004-17531	A1	20041218 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-531543P	20031219 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	DORSEY & WHITNEY LLP, 555 CALIFORNIA STREET, SUITE 1000, SUITE 1000, SAN FRANCISCO, CA, 94104, US	
NUMBER OF CLAIMS:	36	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	32 Drawing Page(s)	
LINE COUNT:	2498	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Provided are compositions and methods for protecting a compound comprising a haloalkylamide moiety from metabolic transformation by hydrolases. In one aspect, the disclosure is directed to increasing the bioavailability and tissue delivery of a anti-HCV compound comprising a haloalkylamide moiety by protecting the compound from inactivation by carboxylesterases. Specific approaches for limiting metabolic transformation include use of carboxylesterase inhibitors to inhibit metabolism of the compound, or use of orally administered compositions designed to deliver the compound to the small intestine or large intestine. Further provided are methods of treating or preventing HCV infection in a subject.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 667931-30-8

(as antiviral agent; treatment of hepatitis C virus infection with antiviral haloalkylamide agents and inhibitors for protecting the antiviral agent from inactivation by hydrolases)

RN 667931-30-8 USPATFULL

CN Acetamide, 2,2-dichloro-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]- (9CI) (CA INDEX NAME)





L54 ANSWER 14 OF 23 USPATFULL on STN

ACCESSION NUMBER: 2005:150748 USPATFULL

TITLE: Synergistically effective combinations of dihaloacetamide compounds and interferon or ribavirin against HCV infections

INVENTOR(S): Lu, Henry, Foster City, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005129659	A1	20050616
APPLICATION INFO.:	US 2004-993212	A1	20041119 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-523405P	20031119 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	DORSEY & WHITNEY LLP, INTELLECTUAL PROPERTY DEPARTMENT, 50 SOUTH SIXTH STREET, MINNEAPOLIS, MN, 55402-1498, US	
NUMBER OF CLAIMS:	17	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	4 Drawing Page(s)	
LINE COUNT:	960	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to anti-HCV dihaloacetamide compounds in synergistic combination with an interferon and/or ribavirin and pharmaceutical compositions thereof for inhibition of the replication of HCV virus. The present invention also relates to the use of the compositions to inhibit HCV replication and/or proliferation and to treat or prevent HCV infections.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 667931-30-8

(synergistically effective combinations of dihaloacetamide compds. and interferon or ribavirin against HCV infections)

RN 667931-30-8 USPATFULL

CN Acetamide, 2,2-dichloro-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]- (9CI) (CA INDEX NAME)



L54 ANSWER 15 OF 23 USPATFULL on STN

ACCESSION NUMBER: 2005:99595 USPATFULL

TITLE: Heteroaryl substituted pyrrole modulators of metabotropic glutamate receptor-5

INVENTOR(S): Cosford, Nicholas D.P., San Diego, CA, UNITED STATES  
Huang, Dehua, San Diego, CA, UNITED STATES  
Smith, Nicholas D, San Diego, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005085514	A1	20050421
APPLICATION INFO.:	US 2003-499393	A1	20021217 (10)
	WO 2002-US40486		20021217

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-343262P	20011221 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	MERCK AND CO., INC, P O BOX 2000, RAHWAY, NJ, 07065-0907, US	
NUMBER OF CLAIMS:	32	
EXEMPLARY CLAIM:	1	
LINE COUNT:	2635	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Pyrrole compounds substituted directly, or by a bridge, with a heteroaryl moiety containing N adjacent to the point of connection of the heteroaryl, are mGluR5 modulators useful in the treatment of psychiatric and mood disorders such as, for example, schizophrenia, anxiety, depression, bipolar disorder and panic, as well as in the treatment of pain, circadian rhythm disorders, and other diseases.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 507270-04-4P, N-[3-(5-Pyridin-2-yl-2H-tetrazol-2-yl)phenyl]acetamide

(preparation of diaryl substituted tetrazole modulators of metabotropic glutamate receptor-5)

RN 507270-04-4 USPATFULL

CN Acetamide, N-[3-[5-(2-pyridinyl)-2H-tetrazol-2-yl]phenyl]- (9CI) (CA INDEX NAME)



L54 ANSWER 16 OF 23 USPATFULL on STN  
 ACCESSION NUMBER: 2005:87910 USPATFULL  
 TITLE: Heterocyclic compounds for treating hepatitis C virus  
 INVENTOR(S): Vourloumis, Dionisios, San Diego, CA, UNITED STATES  
 Takahashi, Masayuki, San Diego, CA, UNITED STATES  
 Winters, Geoffrey C., Coquitlam, CANADA  
 Zhou, Jinglan, San Diego, CA, UNITED STATES  
 Duchene, Russell, San Diego, CA, UNITED STATES  
 PATENT ASSIGNEE(S): Anadys Pharmaceuticals, Inc., San Diego, CA (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005075375	A1	20050407
APPLICATION INFO.:	US 2004-845587	A1	20040514 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-470200P	20030514 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	CONNOLLY BOVE LODGE & HUTZ LLP, SUITE 800, 1990 M STREET NW, WASHINGTON, DC, 20036-3425	
NUMBER OF CLAIMS:	8	
EXEMPLARY CLAIM:	1	
LINE COUNT:	8178	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention is directed to heterocyclic compounds and pharmaceutical compositions of the same for treating Hepatitis C virus.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 814259-16-0P

(preparation of disubstituted pyrazoles, oxadiazoles and triazoles for treating hepatitis C virus)

RN 814259-16-0 USPATFULL

CN Carbamic acid, [4-hydroxy-3-[3-(3-methyl-2-pyridinyl)-1,2,4-oxadiazol-5-yl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




IT 814259-25-1P 814259-41-1P 814259-49-9P

(preparation of disubstituted pyrazoles, oxadiazoles and triazoles for treating hepatitis C virus)


RN 814259-25-1 USPTAFULL

CN Acetamide, N-[4-hydroxy-3-[3-(3-methyl-2-pyridinyl)-1,2,4-oxadiazol-5-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 814259-41-1 USPTAFULL

CN Benzamide, N-[4-hydroxy-3-[3-(3-methyl-2-pyridinyl)-1,2,4-oxadiazol-5-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 814259-49-9 USPTAFULL

CN Carbamic acid, [2-hydroxy-3-[3-(3-methyl-2-pyridinyl)-1,2,4-oxadiazol-5-yl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



L54 ANSWER 17 OF 23 USPTAFULL on STN

ACCESSION NUMBER: 2005:31526 USPTAFULL

TITLE: Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5

INVENTOR(S) : Cosford, Nicholas D.P., San Diego, CA, UNITED STATES  
 Chen, Chixu, San Diego, CA, UNITED STATES  
 Eastman, Brian W., San Diego, CA, UNITED STATES  
 Huang, Dehua, San Diego, CA, UNITED STATES  
 Munoz, Benito, San Diego, CA, UNITED STATES  
 Prasit, Petpiboon, San Diego, CA, UNITED STATES  
 Smith, Nicholas D., San Diego, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005026963	A1	20050203
APPLICATION INFO.:	US 2004-497122	A1	20040526 (10)
	WO 2002-US40147		20021213

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-341382P	20011218 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	MERCK AND CO INC, P O BOX 2000, RAHWAY, NJ, 070650907	
NUMBER OF CLAIMS:	44	
EXEMPLARY CLAIM:	1	
LINE COUNT:	4944	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


AB Pyrazole compounds substituted directly, or by a bridge, with a heteroaryl moiety containing N adjacent to the point of connection of the heteroaryl, are mGluR5 modulators useful in the treatment of psychiatric and mood disorders such as, for example, schizophrenia, anxiety, depression, bipolar disorder and panic, as well as in the treatment of pain, circadian rhythm disorders, and other diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 507270-04-4P, N-[3-(5-Pyridin-2-yl-2H-tetrazol-2-yl)phenyl]acetamide  
(preparation of diaryl substituted tetrazole modulators of metabotropic glutamate receptor-5)

RN 507270-04-4 USPATFULL

CN Acetamide, N-[3-[5-(2-pyridinyl)-2H-tetrazol-2-yl]phenyl]- (9CI) (CA INDEX NAME)



L54 ANSWER 18 OF 23 USPATFULL on STN

ACCESSION NUMBER: 2005:24036 USPATFULL

TITLE: Heteroaryl substituted triazole modulators of metabotropic glutamate receptor-5

INVENTOR(S): Cosford, Nicholas D.P., San Diego, CA, UNITED STATES  
Prasit, Petpiboon, San Diego, CA, UNITED STATES  
Roppe, Jeffrey R., Temecula, CA, UNITED STATES  
Smith, Nicholas D., San Diego, CA, UNITED STATES  
Tehrani, Lida R., San Diego, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005020585	A1	20050127
APPLICATION INFO.:	US 2004-499391	A1	20040617 (10)
	WO 2002-US41720		20021213

NUMBER	DATE


PRIORITY INFORMATION: US 2001-341582P 20011218 (60)  
 DOCUMENT TYPE: Utility  
 FILE SEGMENT: APPLICATION  
 LEGAL REPRESENTATIVE: MERCK AND CO INC, P O BOX 2000, RAHWAY, NJ, 070650907  
 NUMBER OF CLAIMS: 26  
 EXEMPLARY CLAIM: 1  
 LINE COUNT: 2022

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Triazole compounds substituted directly, or by a bridge, with a heteroaryl moiety containing N adjacent to the point of connection of the heteroaryl which are metabotropic glutamate receptor--subtype 5 ("mGluR5") modulators useful in the treatment of psychiatric and mood disorders such as, for example, schizophrenia, anxiety, depression, bipolar disorder and panic, as well as in the treatment of pain, Parkinson's disease, cognitive dysfunction, epilepsy, circadian rhythm disorders, drug addiction, drug abuse, drug withdrawal and other diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 507270-04-4P, N-[3-(5-Pyridin-2-yl-2H-tetrazol-2-yl)phenyl]acetamide  
 (preparation of diaryl substituted tetrazole modulators of metabotropic glutamate receptor-5)  
 RN 507270-04-4 USPATFULL  
 CN Acetamide, N-[3-[5-(2-pyridinyl)-2H-tetrazol-2-yl]phenyl]- (9CI) (CA INDEX NAME)



L54 ANSWER 19 OF 23 USPATFULL on STN  
 ACCESSION NUMBER: 2005:11742 USPATFULL  
 TITLE: Methods of identifying HCV NS5B polymerase inhibitors and their uses  
 INVENTOR(S): Lu, Henry, Foster City, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005009877	A1	20050113
APPLICATION INFO.:	US 2004-847822	A1	20040517 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-471444P	20030515 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	DORSEY & WHITNEY LLP, INTELLECTUAL PROPERTY DEPARTMENT, 4 EMBARCADERO CENTER, SUITE 3400, SAN FRANCISCO, CA, 94111	
NUMBER OF CLAIMS:	50	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	26 Drawing Page(s)	
LINE COUNT:	2407	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a variety of screening methods, utilizing both biochemical and cellular assays as well as in silicon assays, for use in the discovery of agents active in the treating or preventing Hepatitis C virus (HCV) infections. The invention also relates to methods of inhibiting an HCV NS5B polymerase and to the treatment and/or prevention of HCV infections with compounds having specified binding properties.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 667931-24-0 667931-30-8 667931-46-6

(methods of identifying hepatitis C virus gene NS5B polymerase inhibitors and their uses)


RN 667931-24-0 USPATFULL

CN Acetamide, 2,2-dichloro-N-[2-[3-[2-fluoro-6-(trifluoromethyl)phenyl]-5-isoxazolyl]-4-pyridinyl]- (9CI) (CA INDEX NAME)




RN 667931-30-8 USPATFULL

CN Acetamide, 2,2-dichloro-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]- (9CI) (CA INDEX NAME)



RN 667931-46-6 USPATFULL

CN Acetamide, 2,2-dichloro-N-[2-[3-[2-(4-morpholinyl)-6-(trifluoromethyl)phenyl]-5-isoxazolyl]-4-pyridinyl]- (9CI) (CA INDEX NAME)



L54 ANSWER 20 OF 23 USPATFULL on STN

ACCESSION NUMBER: 2004:328092 USPATFULL

TITLE: Heteroaryl substituted imidazole modulators of metabotropic glutamate receptor-5

INVENTOR(S): Cosford, Nicholas D.P., San Diego, CA, UNITED STATES

Huang, Dehua, San Diego, CA, UNITED STATES

Smith, Nicholas D., San Diego, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004259917	A1	20041223
APPLICATION INFO.:	US 2004-499392	A1	20040617 (10)
	WO 2002-US40237		20021216

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-341963P	20011219 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	MERCK AND CO INC, P O BOX 2000, RAHWAY, NJ, 070650907	
NUMBER OF CLAIMS:	28	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1795	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Imidazole compounds substituted directly, or by a bridge, with a heteroaryl moiety containing N adjacent to the point of connection of the heteroaryl, are mGluR5 modulators useful in the treatment of psychiatric and mood disorders such as, for example, schizophrenia, anxiety, depression, bipolar disorder and panic, as well as in the treatment of pain, circadian rhythm disorders, and other diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT **507270-04-4P**, N-[3-(5-Pyridin-2-yl-2H-tetrazol-2-yl)phenyl]acetamide

(preparation of diaryl substituted tetrazole modulators of metabotropic glutamate receptor-5)

RN 507270-04-4 USPATFULL

CN Acetamide, N-[3-[5-(2-pyridinyl)-2H-tetrazol-2-yl]phenyl]- (9CI) (CA INDEX NAME)





L54 ANSWER 21 OF 23 USPATFULL on STN

ACCESSION NUMBER: 2004:240480 USPATFULL

TITLE: Heteroaryl substituted tetrazole modulators of metabotropic glutamate receptor-5

INVENTOR(S): Cosford, Nicholas D P, San Diego, CA, UNITED STATES  
 Chen, Chixu, San Diego, CA, UNITED STATES  
 Reger, Thomas S, San Diego, CA, UNITED STATES  
 Roppe, Jeffrey R, Temecula, CA, UNITED STATES  
 Smith, Nicholas D, San Diego, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004186295	A1	20040923
APPLICATION INFO.:	US 2004-491613	A1	20040402 (10)
	WO 2002-US31294		20021001

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-327132P	20011004 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	MERCK AND CO INC, P O BOX 2000, RAHWAY, NJ, 070650907	
NUMBER OF CLAIMS:	45	
EXEMPLARY CLAIM:	1	
LINE COUNT:	4657	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


AB Tetrazole compounds substituted directly, or by a bridge, with a heteroaryl moiety containing N adjacent to the point of connection of the heteroaryl, are mGluR5 modulators useful in the treatment of psychiatric and mood disorders such as, for example, schizophrenia, anxiety, depression, and panic, as well as in the treatment of pain and other diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 507270-04-4P, N-[3-(5-Pyridin-2-yl-2H-tetrazol-2-yl)phenyl]acetamide  
 (preparation of diaryl substituted tetrazole modulators of metabotropic glutamate receptor-5)

RN 507270-04-4 USPATFULL

CN Acetamide, N-[3-[5-(2-pyridinyl)-2H-tetrazol-2-yl]phenyl]- (9CI) (CA INDEX NAME)



L54 ANSWER 22 OF 23 USPATFULL on STN

ACCESSION NUMBER: 2004:127571 USPATFULL

TITLE: Concomitant drugs

INVENTOR(S): Ohkawa, Shinegori, Takatsuki-shi, JAPAN  
Naruo, Kenichi, Sanda-shi, JAPAN  
Miwatashi, Seiji, Ikeda-shi, JAPAN

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004097555	A1	20040520
APPLICATION INFO.:	US 2003-451839	A1	20030625 (10)
	WO 2001-JP11353		20011225

	NUMBER	DATE
PRIORITY INFORMATION:	JP 2000-396220	20001226
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Mark Chao, Takeda Pharmaceuticals North America Inc, Intellectual Property Department, Suite 500 475 Half Day Road, Lincolnshire, IL, 60069	
NUMBER OF CLAIMS:	12	
EXEMPLARY CLAIM:	1	
LINE COUNT:	8688	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


AB The present invention relates to a pharmaceutical agent containing one or more kinds of a p38 MAP kinase inhibitor and/or a TNF- $\alpha$  production inhibitor and one or more kinds of drugs selected from the group consisting of (1) a non-steroidal antiinflammatory drug, (2) a disease-modifying anti-rheumatic drug, (3) an anti-cytokine drug, (4) an immunomodulator, (5) a steroid and (6) a c-Jun N-terminal kinase inhibitor in combination. This combination agent is useful as a prophylactic or therapeutic agent of the diseases such as rheumatism, arthritis and the like, and other diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 303162-77-8P 303162-91-6P 303162-92-7P  
(combination drugs containing p38MAP kinase inhibitors and/or TNF- $\alpha$  production inhibitors with other specified agents)


RN 303162-77-8 USPATFULL

CN Benzeneacetamide, N-[4-[2-(2-chlorophenyl)-4-(3-methylphenyl)-5-thiazolyl]-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 303162-91-6 USPATFULL

CN Benzamide, N-[4-[2-(2-chlorophenyl)-4-(3-methylphenyl)-5-thiazolyl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 303162-92-7 USPATFULL

CN Benzenepropanamide, N-[4-[(2-(2-chlorophenyl)-4-(3-methylphenyl)-5-thiazolyl]-2-pyridinyl)]- (9CI) (CA INDEX NAME)



L54 ANSWER 23 OF 23 USPATFULL on STN

ACCESSION NUMBER: 2004:95421 USPATFULL

TITLE: Substituted thiazole derivatives bearing 3-pyridyl groups, process for preparing the same and use thereof  
Kuroda, Noritaka, Toyono-gun, JAPANINVENTOR(S): Nara, Yoshi, Suita-shi, JAPAN  
Hashiguchi, Shohei, Toyonaka-shi, JAPAN  
Tasaka, Akihiro, Suita-shi, JAPAN  
Kusaka, Masami, Kobe-shi, JAPAN  
Yamaoka, Masuo, Kobe-shi, JAPAN  
Kaku, Tomohiro, Nishinomiya-shi, JAPAN

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004072876	A1	20040415
APPLICATION INFO.:	US 2003-433910	A1	20030604 (10)
	WO 2001-JP10723		20011207

	NUMBER	DATE
PRIORITY INFORMATION:	JP 2000-373868	20001208
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	TAKEDA PHARMACEUTICALS NORTH AMERICA, INC, INTELLECTUAL PROPERTY DEPARTMENT, 475 HALF DAY ROAD, SUITE 500, LINCOLNSHIRE, IL, 60069	

NUMBER OF CLAIMS: 60  
 EXEMPLARY CLAIM: 1  
 LINE COUNT: 5677

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides a pharmaceutical composition having a steroid C.sub.17,20-lyase inhibitory activity, which is useful as a prophylactic or therapeutic agent of prostatism, tumor such as breast cancer and the like, more particularly, a steroid C.sub.17,20-lyase inhibitor containing a compound represented by the formula: ##STR1##


wherein A.sup.1 is an aromatic hydrocarbon group optionally having substituents or a heterocyclic group optionally having substituents, one of A.sup.2 and A.sup.3 is a hydrogen atom, a halogen atom, a C.sub.1-4 aliphatic hydrocarbon group optionally having substituents or an optionally esterified carboxyl group, the other of A.sup.2 and A.sup.3 is an aromatic hydrocarbon group optionally having substituents or a heterocyclic group optionally having substituents, and at least one of A.sup.1, A.sup.2 and A.sup.3 is a 3-pyridyl group optionally having substituents, or a salt thereof or a prodrug thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 435272-05-2P 435272-60-9P, N-[3-[4-(4-Methylpyridin-3-yl)-1,3-thiazol-2-yl]phenyl]acetamide 435272-63-2P, N-[4-Methyl-3-[4-(4-methylpyridin-3-yl)-1,3-thiazol-2-yl]phenyl]acetamide (preparation of substituted pyridylthiazole derivs. as steroid C17,20 lyase inhibitors for treatment and prevention of sex hormone-dependent diseases)

RN 435272-05-2 USPATFULL


CN Acetamide, N-[3-[2-[4-(trifluoromethyl)-3-pyridinyl]-4-thiazolyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 435272-60-9 USPATFULL

CN Acetamide, N-[3-[4-(4-methyl-3-pyridinyl)-2-thiazolyl]phenyl]- (9CI) (CA INDEX NAME)



RN 435272-63-2 USPATFULL

CN    Acetamide, N-[4-methyl-3-[4-(4-methyl-3-pyridinyl)-2-thiazolyl]phenyl]-  
      (9CI)    (CA INDEX NAME)



=>

**This Page Blank (uspto)**

**this Page Blank (uspto)**